CD3 reconstitution in engineered iPSC and immune effector cells

Abstract

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

Description

RELATED APPLICATION

[0001] This application claims priority to U.S. Provisional Application Serial No. 62 / 832,622, filed April 11, 2019, which is hereby incorporated by reference in its entirety. FIELD OF THE INVENTION

[0002] The present disclosure is broadly concerned with the field of off-the-shelf immunocellular products. More particularly, the present disclosure is concerned with the strategies for developing multifunctional effector cells capable of delivering therapeutically relevant properties in vivo. The cell products developed under the present disclosure address critical limitations of patient-sourced cell therapies. REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0003] This application incorporates by reference a Computer Readable Form (CRF) of a Sequence Listing in ASCII text format submitted with this application, entitled entitled 056932-518001WO_SEQUENCE_LISTING_ST25.TXT, was created on April 2, 2020, and is 76,442 bytes in size. BACKGROUND OF THE INVENTION

[0004] The field of adoptive cell therapy is currently focused on using patient- and donor-sourced cells, which makes it particularly difficult to achieve consistent manufacturing of cancer immunotherapies and to deliver therapies to all patients who may benefit. There is also the need to improve the efficacy and persistence of adoptively transferred lymphocytes to promote favorable patient outcome. Lymphocytes such as T cells and natural killer (NK) cells are potent anti-tumor effectors that play an important role in innate and adaptive immunity. However, the use of these immune cells for adoptive cell therapies remain to be challenging and have unmet needs for improvement. Therefore, there are significant opportunities remain to harness the full potential of T and NK cells, or other lymphocytes in adoptive immunotherapy. SUMMARY OF THE INVENTION

[0005] There is a need for functionally improved effector cells that address issues ranging from response rate, cell exhaustion, loss of transfused cells (survival and / or persistence), tumor 2020271523   29 Jun 2026 escape through target loss or lineage switch, tumor targeting precision, off-target toxicity, off-tumor effect, to efficacy against solid tumors, i.e., tumor microenvironment and related immune suppression, recruiting, trafficking and infiltration.

[0006] The present invention provides methods and compositions to generate derivative non-pluripotent cells differentiated from a single cell derived iPSC (induced pluripotent stem cell) clonal line, which iPSC line comprises one or several genetic modifications in its genome. Said one or several genetic modifications include DNA insertion, deletion, and substitution, and which modifications are retained and remain functional in subsequently derived cells after differentiation, expansion, passaging and / or transplantation. [0006a]       In a first aspect, the present invention provides a cell or a population thereof, wherein (i) the cell is an induced pluripotent stem cell (iPSC), a clonal iPSC, or a clonal iPS cell line cell, or a derivative cell obtained from differentiating said iPSC; (ii) the cell lacks expression of an endogenous TCR (TCRneg); (iii) the cell comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex that lacks antigen recognition activity (cs-CD3) when expressed; (iv) expression of the one or more exogenous protein in the cell or a T cell derived therefrom induces formation of the cs-CD3 comprising (a) a CD3Z endodomain, and (b) one or more of a CD3c ectodomain, a CD35 ectodomain, or a CD3y ectodomain; (v) the one or more exogenous protein comprises: (a) a nb-rTCR, wherein the nb-rTCR comprises a non-binding recombinant TCR characterized by (1) a tgTRAC that is a transgenic TCRa constant region lacking a TCRa variable region, or (2) a tgTRBC that is a transgenic TCRP constant region lacking a TCRP variable region; (b) a p-rTCR, wherein the p-rTCR is a recombinant pre-TCR; comprising extracellular and intracellular domains of a pre-TCRa; (c) a nb-rTCR-CD3, wherein the nb-rTCR-CD3 is a non-binding recombinant TCR comprising a fusion protein comprising: (1) a tgTRAC that is a transgenic TCRa constant region or a tgTRBC that is a transgenic TCRP constant region; (2) the CD3a ectodomain; and (3) the CD36 ectodomain or the CD3y ectodomain; or (d) a ccCD3, wherein the ccCD3 is a CD3 chimeric chain comprising a fusion between (1) the CD3c ectodomain; (2) the CD36 ectodomain or the CD3y ectodomain; and (3) the CD3Z endodomain; and 2020271523   29 Jun 2026 (vi) the derivative cell comprises a derivative T cell or a progenitor thereof. [0006b]     In a second aspect, the present invention provides a clonal master cell bank comprising the clonal iPSC cell line cells as recited in the first aspect. [0006c]     In a third aspect, the present invention provides a composition comprising the cell or population thereof of the first aspect. [0006d]     In a fourth aspect, the present invention provides a composition for therapeutic use comprising the derivative cell of the first aspect, and one or more therapeutic agents.

[0007] The iPSC derived non-pluripotent cells of the present application also include, but not limited to, CD34 cells, hemogenic endothelium cells, HSCs (hematopoietic stem and progenitor cells), hematopoietic multipotent progenitor cells, T cell progenitors, NK cell progenitors, T cells, NKT cells, NK cells, and B cells. The iPSC derived non-pluripotent cells of the present application comprise one or several genetic modifications in their genome through differentiation from an iPSC comprising the same genetic modifications. The engineered clonal iPSC differentiation strategy for obtaining genetically engineered iPSC-derived cells requires that the developmental potential of the iPSC in a directed differentiation is not adversely impacted by the engineered modality in the iPSC, and also that the engineered modality functions as intended in the derivative cell. Further, this strategy overcomes the present barrier in engineering primary lymphocytes, such as T cells or NK cells obtained from peripheral blood, umbilical cord blood or any other donor tissues, as such cells are difficult to engineer, with engineering of such cells often lacking reproducibility and uniformity, resulting in cells exhibiting poor cell persistence with high cell death and low cell expansion. Moreover, this strategy avoids production of a heterogenous effector cell population otherwise obtained using primary cell sources which are heterogenous to start with.

[0008] Some aspects of the present invention provide genome-engineered iPSCs obtained using a method comprising (I), (II) or (III), reflecting a strategy of genomic engineering subsequently to, simultaneously with, and prior to the reprogramming process, respectively:

[0009] (I): genetically engineering iPSCs by one or both of (i) and (ii), in any order: (i) introducing into iPSCs one or more construct(s) to allow targeted integration at selected site(s); (ii) (a) introducing into iPSCs one or more double stranded break(s) at selected site(s) using one or more endonuclease capable of selected site recognition; and (b) culturing the iPSCs of step (I)(ii)(a) to allow endogenous DNA repair to generate targeted in / dels at the selected site(s), simultaneously or sequentially; thereby obtaining genome-engineered iPSCs capable of differentiation into partially or fully differentiated cells.

[00010] (II): genetically engineering reprogramming non-pluripotent cells to obtain the genome-engineered iPSCs comprising: (i) contacting non-pluripotent cells with one or more reprogramming factors, and optionally a small molecule composition comprising a TGFP receptor / ALK inhibitor, a MEK inhibitor, a GSK3 inhibitor and / or a ROCK inhibitor to initiate reprogramming of the non-pluripotent cells; and (ii) introducing into the reprogramming non-pluripotent cells of step (II)(i) one or both of (a) and (b), in any order: (a) one or more construct(s) to allow targeted integration at selected site(s); (b) one or more double stranded break(s) at a selected site using at least one endonuclease capable of selected site recognition, then the cells of step (II)(ii)(b) are cultured to allow endogenous DNA repair to generate targeted in / dels at the selected site(s); as such the obtained genome-engineered iPSCs comprise at least one functional targeted genomic editing, and said genome-engineered iPSCs are capable of differentiation into partially or fully differentiated cells.

[00011] (III): genetically engineering non-pluripotent cells for reprogramming to obtain genome-engineered iPSCs comprising (i) and (ii): (i) introducing into non-pluripotent cells one or both of (a) and (b), in any order: (a) one or more construct(s) to allow targeted integration at selected site(s); (b) one or more double stranded break(s) at a selected site using at least one endonuclease capable of selected site recognition, wherein the cells of step (III)(i)(b) are cultured to allow endogenous DNA repair to generate targeted in / dels at the selected sites; and (ii) contacting the cells of step (III)(i) with one or more reprogramming factors, and optionally a small molecule composition comprising a TGFP receptor / ALK inhibitor, a MEK inhibitor, a GSK3 inhibitor and / or a ROCK inhibitor, to obtain genome-engineered iPSCs comprising targeted editing at selected sites; thereby obtaining genome-engineered iPSCs comprising at least one functional targeted genomic editing, and said genome-engineered iPSCs are capable of being differentiated into partially differentiated cells or fully-differentiated cells.

[00012] In one embodiment of the above method, the at least one targeted genomic editing at one or more selected sites comprises insertion of one or more exogenous polynucleotides encoding safety switch proteins, targeting modalities, receptors, signaling molecules, transcription factors, pharmaceutically active proteins and peptides, drug target candidates, or proteins promoting engraftment, trafficking, homing, viability, self-renewal, persistence, and / or survival of the genome-engineered iPSCs or derivative cells therefrom. In some embodiments, the exogenous polynucleotides for insertion are operatively linked to (1) one or more exogenous promoters comprising CMV, EFla, PGK, CAG, UBC, or other constitutive, inducible, temporal-, tissue-, or cell type- specific promoters; or (2) one or more endogenous promoters comprised in the selected sites comprising AAVS1, CCR5, ROSA26, collagen, HTRP, Hll, beta-2 microglobulin, CD38, GAPDH, TCR or RUNX1, or other locus meeting the criteria of a genome safe harbor. In some embodiments, the genome-engineered iPSCs generated using the above method comprise one or more different exogenous polynucleotides encoding protein comprising caspase, thymidine kinase, cytosine deaminase, modified EGFR, or B-cell CD20, wherein when the genome-engineered iPSCs comprise two or more suicide genes, the suicide genes are integrated in different safe harbor locus comprising AAVS1, CCR5, ROSA26, collagen, HTRP, Hll, beta-2 microglobulin, CD38, GAPDH, TCR or RUNX1. In one embodiment, the exogenous polynucleotide encodes a partial or full length peptide of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and / or respective receptors thereof. In some embodiments, the partial or full peptide of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and / or respective receptors thereof encoded by the exogenous polynucleotide is in a form of fusion protein.

[00013] In some other embodiments, the genome-engineered iPSCs generated using the method provided herein comprise in / del at one or more endogenous genes associated with targeting modality, receptors, signaling molecules, transcription factors, drug target candidates, immune response regulation and modulation, or proteins suppressing engraftment, trafficking, homing, viability, self-renewal, persistence, and / or survival of the iPSCs or derivative cells therefrom. In some embodiments, the endogenous gene for disruption comprises at least one of CD38, B2M, TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region.

[00014] In yet some other embodiments, the genome-engineered iPSCs generated using the method provided herein comprise a caspase encoding exogenous polynucleotide at AAVS1 locus, and a thymidine kinase encoding exogenous polynucleotide at Hll locus.

[00015] In still some other embodiments, approach (I), (II) and / or (III) further comprises: contacting the genome-engineered iPSCs with a small molecule composition comprising a MEK inhibitor, a GSK3 inhibitor and a ROCK inhibitor, to maintain the pluripotency of the genomic-engineered iPSCs. In one embodiments, the obtained genome engineered iPSCs comprising at least one targeted genomic editing are functional, are differentiation potent, and are capable of differentiating into non-pluripotent cells comprising the same functional genomic editing.

[00016] The present invention also provides the followings.

[00017] One aspect of the present application provides a cell or a population thereof, wherein the cell is an induced pluripotent cell (iPSC), a clonal iPSC, or a clonal iPS cell line cell, or a derivative cell obtained from differentiating any of the above said iPSC; and wherein any of the above said cell comprises at least TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed. In some embodiments of the obtained derivative cell from iPSC differentiation, the derivative cell is a hematopoietic cell, including, but not limited to, CD34 cells, hemogenic endothelium cells, HSCs (hematopoietic stem and progenitor cells), hematopoietic multipotent progenitor cells, T cell progenitors, NK cell progenitors, T cells, NKT cells, NK cells, and B cells; which the derivative hematopoietic cell (i.e., derivative CD34 cell, derivative hemogenic endothelium cells, derivative hematopoietic stem and progenitor cell, derivative hematopoietic multipotent progenitor cell, derivative T cell progenitor, derivative NK cell progenitor, derivative T cell, derivative NKT cell, derivative NK cell, or derivative B cell) comprises longer telomeres in comparison to its native counterpart cell obtained from peripheral blood, umbilical cord blood, or any other donor tissues. In some embodiments of the obtained derivative cell from iPSC differentiation, the derivative cell is a T cell progenitor or a T cell. In some embodiments of the obtained derivative cell from iPSC differentiation, the derivative cell is an NK cell progenitor or an NK cell.

[00018] In some embodiments of said iPSC and its derivative cell comprising TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, the cell further comprises one or more of the following genomic editing: (i) B2M negative or low; (ii) CIITA negative or low; (iii) introduced expression of HLA-G or non-cleavable HLA-G; (iv) a high affinity non-cleavable CD 16 (hnCD16) or a variant thereof; (v) a chimeric antigen receptor (CAR), (vi) a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof; (vii) CD38 negative; (viii) at least one of the genotypes listed in Table 1; (ix) deletion or reduced expression in at least one of TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; and (x) introduced or increased expression in at least one of HLA-E, 41BBL, CD4, CD8, CD 16, CD47, CD113, CD131, CD137, CD80, PDL1, A2aR, CAR, Fc receptor, an engager, and a surface triggering receptor for coupling with bi- or multi- specific or universal engager.

[00019] In some embodiments of said iPSC and its derivative cell comprising at least TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and optional additional genomic editing as described above and throughout this application, the cell may comprise (i) one or more exogenous polynucleotides integrated in one safe harbor locus; or (ii) two or more exogenous polynucleotides integrated in different safe harbor loci. In some embodiments, the safe harbor locus comprises at least one of AAVS1, CCR5, ROSA26, collagen, HTRP, Hll, beta-2 microglobulin, CD38, GAPDH, TCR or RUNX1. In one particular embodiment, the safe harbor locus is Hl 1. In one particular embodiment, the safe harbor locus TCR is a constant region of TCR alpha or TCR beta. In some embodiments, the insertion of one or more exogenous polynucleotides at the safe harbor locus resulting in disruption or knock-out of the endogenous gene at the safe harbor, for example, insertion at B2M, CD38 or TCR alpha / beta resulting in knockout of B2M, CD38 or TCR alpha / beta gene.

[00020] In some embodiments of the cell or population thereof, the cell comprising TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and one or more of the additional genomic editing above is, in some embodiments, a derivative T cell, and in some other embodiments, a derivative NK cell, obtained from an iPSC comprising said genomic editing, and the derivative T or NK cell has at least one of the following characteristics including, but not limited to: (i) improved persistency and / or survival; (ii) increased resistance to native (i.e., recipient) immune cells; (iii) increased cytotoxicity; (iv) improved tumor penetration; (v) enhanced or acquired ADCC; (vi) enhanced ability in migrating, and / or activating or recruiting bystander immune cells, to tumor sites; (vii) enhanced ability to reduce tumor immunosuppression; (viii) improved ability in rescuing tumor antigen escape; and (ix) reduced fratricide, when compared to its native counterpart, primary T or NK cell, obtained from peripheral blood, umbilical cord blood, or any other donor tissues. When compared to TCRneg T or NK cell (primary or derivative), which are cell surface CD3 negative, the derivative T or NK cell comprising both TCRnegand one or more exogenous protein enabling a surface presented CD3 complex or a subunit or a subdomain thereof further has at least one of the following phenotypic and functional characteristics including, but not limited to: cell surface presented a full or partial endogenous or exogenous cell surface CD3 complex, and the capability of responding to molecules that bind to CD3 related cell surface triggering receptor, which molecules include, but are not limited to, CD3 binding antibodies or functional variants thereof, scFV, and / or various CD3 engagers.

[00021] In one embodiment of the cell or population thereof, the cell comprising TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed further comprises a high affinity non-cleavable CD 16 or a variant thereof (hnCD16). Some embodiments of the high affinity non-cleavable CD 16 or a variant thereof (hnCD16) comprises at least any one of the followings: (a) Fl 76 V and S197P in ectodomain domain of CD 16; (b) a full or partial ectodomain originated from CD64; (c) a non-native (or non-CD16) transmembrane domain; (d) a non-native (or non-CD16) intracellular domain; (e) a non-native (or non-CD16) signaling domain; (f) a non-native stimulatory domain; and (g) transmembrane, signaling, and stimulatory domains that are not originated from CD 16, and are originated from a same or different polypeptide. In some embodiments, the non-native transmembrane domain is derived from CD3D, CD3E, CD3G, CD3y, CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, 0X40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL 12, U.K KIR2DL4, KiR2DS L XKp30, NKp44, NKp46, XKG2C, NKG2D, or f cell receptor (TCR) polypeptide. In some embodiments, the non-native stimulatory domain is derived from CD27, CD28, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D polypeptide. In some other embodiments, the non-native signaling domain is derived from CD3i; 2B4, DAP10, DAP12, DNAM1, CD137 (41BB), IL21, IL7, IL12, U J A NKp30, NKp44, NKp46, NKG2C, or NKG2D polypeptide. In some particular embodiments of a hnCD16 or a variant thereof, the non-native transmembrane domain is derived from NKG2D, the non-native stimulatory domain is derived from 2B4, and the non-native signaling domain is derived from CD3(^ or DAP 10.

[00022] In one embodiment of the cell or population thereof, the cell comprising TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed further comprises at least one chimeric antigen receptor (CAR), and wherein the CAR could be any one or more of the followings: (i) T cell specific or NK cell specific; (ii) bi-specific antigen binding CAR; (iii) a switchable CAR; (iv) a dimerized CAR; (v) a split CAR; (vi) a multi-chain CAR; (vii) an inducible CAR; (viii) co-expressed with another CAR; (ix) co-expressed with a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof, optionally in separate constructs or in a bi- or poly- cistronic construct; (xi) co-expressed with a checkpoint inhibitor, optionally in separate constructs or in a bi- or poly- cistronic construct; (xii) is specific to CD 19 or BCMA; and / or (xiii) is specific to any one of ADGRE2, carbonic anhydrase IX (CAIX), CCRI, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CDS, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell, epithelial glycoprotein2 (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine-protein kinases erb-B2,3,4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), ICAM-1, Integrin B7, Interleukin-13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A (CAI9.9), Lewis Y (LeY), LI cell adhesion molecule (LI-CAM), LILRB2, melanoma antigen family A 1 (MAGE-A1), MICA / B, Mucin 1 (Muc-1), Mucin 16 (Muc-16), Mesothelin (MSLN), NKCSI, NKG2D ligands, c-Met, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), PRAME, prostate stem cell antigen (PSCA), PRAME prostatespecific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), TIM-3, TRBCI, TRBC2, vascular endothelial growth factor R2 (VEGF- R2), Wilms tumor protein (WT-1), and a pathogen antigen. In some embodiments, any one of the above CAR may be inserted at a constant region of a TCR locus, such as TCRa or TCRp. In some embodiments, the CAR inserted at TRAC or TRBC locus may be driven by a respective endogenous promoter of TCR. In some embodiments, the insertion of the CAR at TRAC or TRBC locus leads to TCR negative or knockout. In some embodiments, the TCR negative cell is also CD3 negative.

[00023] In some of the embodiments, in which a checkpoint inhibitor is co-expressed with a CAR, the checkpoint inhibitor is an antagonist to one or more checkpoint molecules comprising PD-1, PDL-1, TIM-3, TIGIT, LAG-3, CTLA-4, 2B4, 4-1BB, 4-1BBL, A2aR, BATE, BTLA, CD39, CD47, CD73, CD94, CD96, CD160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxpl, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2, Rara (retinoic acid receptor alpha), TLR3, VISTA, NKG2A / HLA-E, or inhibitory KIR. The checkpoint inhibitor co-expressed with the CAR could be an antibody, or humanized or Fc modified variants or fragments and functional equivalents and biosimilars thereof, specific to any of the above checkpoint molecules.

[00024] In one embodiment of the cell or population thereof, the cell comprising TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed further comprises a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof, and wherein the exogenous cytokine or a receptor thereof may comprise at least one of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and respective receptor thereof; or may comprise at least one of: (i) co-expression of IL15 and IL15Ra by using a selfcleaving peptide; (ii) a fusion protein of IL 15 and IL15Ra; (iii) an IL15 / IL15Ra fusion protein with intracellular domain of IL15Ra truncated (IL 15 A); (iv) a fusion protein of IL 15 and membrane bound Sushi domain of IL15Ra; (v) a fusion protein of IL15 and IL15RP; (vi) a fusion protein of IL15 and common receptor yC, wherein the common receptor yC is native or modified; and (vii) a homodimer of IL15RP; wherein any one of (i)-(vii) can be co-expressed with a CAR in separate constructs or in a bi- or poly- cistronic construct. In some embodiments, the partial or full peptide of a cell surface exogenous cytokine or a receptor is transiently expressed in the cell provided herein. In one embodiment, the cell or population thereof comprises a polynucleotide encoding an IL15A comprising an amino acid sequence of at least 75%, 80%, 85%, 90%, 95% or 99% identity to SEQ ID NOs: 17, 19 or 21.

[00025] In one embodiment of the cell or population thereof, the cell comprising TCRneg, one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and an IL15 or a variant including those embodiments (i)-(vii) as disclosed above may further comprise one or more of B2M negative or low; CIITA negative or low; introduced expression of HLA-G or non-cleavable HLA-G; a high affinity non-cleavable CD 16 or a variant thereof (hnCD16); a chimeric antigen receptor (CAR), a partial or full length peptide of a cell surface expressed an additional exogenous cytokine or a receptor thereof, wherein the cytokine is not IL15; at least one of the genotypes listed in Table 1; deletion or reduced expression in at least one of TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; and introduced or increased expression in at least one of HLA-E, 41 BBL, CD4, CD8, CD 16, CD47, CD 113, CD131, CD 137, CD80, PDL1, A2AR, CAR, Fc receptor, an engager, and surface triggering receptor for coupling with bi- or multi- specific or universal engagers. In an embodiment of a cell or population thereof comprising both an IL15A and a CAR, the IL15A can be co-expressed with a CAR in separate constructs or in a bi- or polycistronic construct.

[00026] In one embodiment of the cell or population thereof, the cell comprising TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed is a derivative NK or a derivative T cell, wherein the derivative NK or the derivative T cell is capable of reducing tumor immunosuppression in the presence of one or more checkpoint inhibitors. In some embodiments, the presence of the one or more checkpoint inhibitors is through administer the inhibitor(s) to a subject before, during or after receiving said cell. In some other embodiments, the presence of the one or more checkpoint inhibitors is through expressing the inhibitor by said cell by introducing the checkpoint inhibitor expression to said cell using a polynucleotide encoding the selected inhibitor. In some embodiments, the checkpoint inhibitors are antagonists to one or more checkpoint molecules comprising PD-1, PDL-1, TIM-3, TIGIT, LAG-3, CTLA-4, 2B4, 4-1BB, 4-1BBL, A2aR, BATE, BTLA, CD39, CD47, CD73, CD94, CD96, CD160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxpl, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2, Rara (retinoic acid receptor alpha), TLR3, VISTA, NKG2A / HLA-E, or inhibitory KIR. In some other embodiments, the checkpoint inhibitors comprise either (a) one or more of atezolizumab, avelumab, durvalumab, ipilimumab, IPH4102, IPH43, IPH33, lirimumab, monalizumab, nivolumab, pembrolizumab, and their derivatives or functional equivalents; or (b) at least one of atezolizumab, nivolumab, and pembrolizumab.

[00027] Another aspect of the present application provides a composition comprising any of the cells or populations thereof as described above, and throughout this application. In some embodiments, the iPSC or iPSC derived cells (also called “derivative cells” herein) may comprise any one of the genotypes listed in Table 1 of this application. In some embodiments, the TCRneg iPSC or derivative cell therefrom comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed. In some embodiments, the TCRneg iPSC or derivative cell therefrom comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed; and a hnCD16. In some embodiments, the TCRneg iPSC or derivative cell therefrom comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed; hnCD16; and an IL 15 or variant thereof. In some embodiments, the TCRneg iPSC or derivative cell therefrom comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed; a hnCD16; and a CAR. In some embodiments, the TCRnegiPSC or derivative cell therefrom comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed; a hnCD16; an IL15 or variant thereof; and a CAR. In some embodiments, the TCRneg iPSC or derivative cell therefrom comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed; a hnCD16; CD38 negative; a CAR; and a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof as provided above and throughout this application. In some other embodiments, the CAR is specific to any one of ADGRE2, carbonic anhydrase IX (CAIX), CCRI, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CDS, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell (e.g., a cell surface antigen), epithelial glycoprotein2 (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine-protein kinases erb- B2,3,4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), ICAM-1, Integrin B7, Interleukin-13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9), Lewis Y (LeY), LI cell adhesion molecule (Ll-CAM), LILRB2, melanoma antigen family A 1 (MAGE-A1), MICA / B, Mucin 1 (Muc-1), Mucin 16 (Muc-16), Mesothelin (MSLN), NKCSI, NKG2D ligands, c-Met, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), PRAME, prostate stem cell antigen (PSCA), PRAME prostate-specific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), TIM-3, TRBCI, TRBC2, vascular endothelial growth factor R2 (VEGF- R2), Wilms tumor protein (WT-1), and various pathogen antigen known in the art. In yet some embodiments of cells comprising TCRneg, the cell comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed; a hnCD16; and a CAR, wherein the CAR is specific to CD19 or CD269 (BCMA). In some embodiments of cells comprising TCRneg, the cell comprises a surface CD3 complex, or a subunit or a subdomain thereof, when expressed in the cell; a hnCD16; an IL15 or variant thereof; and a CAR, wherein the CAR is specific to CD 19 or CD269 (BCMA). In some other embodiments of cells comprising TCRneg, the cell comprises a surface CD3 complex, or a subunit or a subdomain thereof, when expressed in the cell; a hnCD16; an IL15 or variant thereof; CD38 negative; and a CAR, wherein the CAR is specific to CD 19 or CD269 (BCMA).

[00028] Accordingly, a further aspect of the present application provides a composition for therapeutic use, which comprises, in addition to any of the derivative cell as provided herein, one or more therapeutic agents. In some embodiments of the composition for therapeutic use, the therapeutic agents comprise a peptide, a cytokine, a checkpoint inhibitor, a mitogen, a growth factor, a small RNA, a dsRNA (double stranded RNA), mononuclear blood cells, feeder cells, feeder cell components or replacement factors thereof, a vector comprising one or more polynucleic acids of interest, an antibody, a chemotherapeutic agent or a radioactive moiety, or an immunomodulatory drug (IMiD). In some embodiments of the composition for therapeutic use, the checkpoint inhibitor used with the provided cells comprises one or more antagonists checkpoint molecules comprising PD-1, PDL-1, TIM-3, TIGIT, LAG-3, CTLA-4, 2B4, 4-1BB, 4-1BBL, A2aR, BATE, BTLA, CD39, CD47, CD73, CD94, CD96, CD160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxpl, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2, Rara (retinoic acid receptor alpha), TLR3, VISTA, NKG2A / HLA-E, or inhibitory KIR. In some embodiments of the composition for therapeutic use, the checkpoint inhibitor used with the provided cells comprises one or more of atezolizumab, avelumab, durvalumab, ipilimumab, IPH4102, IPH43, IPH33, lirimumab, monalizumab, nivolumab, pembrolizumab, and their derivatives or functional equivalents. In some other embodiments of the composition for therapeutic use, the checkpoint inhibitor used with the provided cells comprises at least one of atezolizumab, nivolumab, and pembrolizumab. In some embodiments of the composition for therapeutic use, the therapeutic agents comprise one or more of venetoclax, azacitidine, and pomalidomide.

[00029] In some embodiments of the composition for therapeutic use, the antibody used with the provided cells comprises any one of the anti-CD20, anti-CD22, anti-HER2, anti-CD52, anti-EGFR, anti-CD123, anti-GD2, anti-PDLl, and / or anti-CD38 antibody. In some embodiments of the composition for therapeutic use, the antibody used with the provided cells comprises one or more of rituximab, veltuzumab, ofatumumab, ublituximab, ocaratuzumab, obinutuzumab, ibritumomab, ocrelizumab, inotuzumab, moxetumomab, epratuzumab, trastuzumab, pertuzumab, alemtuzumab, certuximab, dinutuximab, avelumab, daratumumab, isatuximab, MOR202, 7G3, CSL362, elotuzumab, and their humanized or Fc modified variants or fragments and their functional equivalents and biosimilars. In still some other embodiments of the composition for therapeutic use, the antibody used with the provided cells comprises daratumumab.

[00030] The present application also provides a therapeutic use of the cell or therapeutic composition as described herein by introducing the composition to a subject suitable for adoptive cell therapy. In some embodiments, the subject suitable for and in need of the adoptive cell therapy has an autoimmune disorder; a hematological malignancy; a solid tumor; cancer, or a virus infection.

[00031] A further aspect of the present application provides a method of manufacturing the derivative cell as described herein, and the method comprises differentiating an TCRneg iPSC which comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and optionally one or more of: (i) B2M negative or low; (ii) CIITA negative or low; (iii) introduced expression of HLA-G or non-cleavable HLA-G; (iv) a high affinity non-cleavable CD 16 (hnCD16) or a variant thereof; (v) a chimeric antigen receptor (CAR); (vi) a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof; (vii) CD38 negative; (viii) at least one of the genotypes listed in Table 1; (ix) deletion or reduced expression in at least one of TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; and (x) introduced or increased expression in at least one of HLA-E, 41BBL, CD4, CD8, CD16, CD47, CD113, CD131, CD137, CD80, PDL1, A2AR, CAR, Fc receptor, an engager, and surface triggering receptor for coupling with bi- or multi- specific or universal engagers.

[00032] In some embodiments of the manufacturing method, the method further comprises genomically engineering a clonal iPSC (1) to knock out endogenous TCR; and (2) to introduce to the cell one or more polynucleotides encoding at least one exogenous protein comprising tgTRAC, tgTRBC, tgTCRa, tgTCRp, tgpTCRa, tgCD3(s-8)-TRAC, tgCD3(s-y)-TRBC, tgCD3(s-y)-TRAC, tgCD3(s-8)-TRBC, tgCD3(s-yK, tgCD3(s-8H, tgCD3(s- y / 8)-28£ tgCD3(s- y / 6)-BB^, and / or tgCD3(s- y / 6)-(28-BB)^ to provide a surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3), when expressed in the cell, and optionally, to knock out B2M and CIITA, or to introduce expression of HLA-G or non-cleavable HLA-G, a high affinity non-cleavable CD 16 or a variant thereof, a CAR, and / or a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof; and the CAR and the partial or full peptide of a cell surface expressed exogenous cytokine or a receptor thereof are co-expressed in separate constructs or in a bi- or poly- cistronic construct. In some embodiments of the manufacturing method, the genomic engineering of an iPSC comprises targeted editing. In some embodiments, the targeted editing comprises deletion, insertion, or in / del. In some embodiments, the targeted deletion / knockout and the targeted insertion are carried out simultaneously, wherein the insertion is at the location where the deletion is conducted. In some embodiments, the targeted deletion / knockout and the targeted insertion are carried out consecutively, in any order, wherein the insertion and the deletion may or may not be at the same location. In some embodiments, the targeted editing tool comprises CRISPR, ZFN, TALEN, homing nuclease, homology recombination, or any other functional variation of these methods and composition.

[00033] The present application further provides the targeted editing tool mediated editing of clonal iPSCs, thereby producing edited clonal iPSCs that lack endogenous TCRa or TCRP and comprise introduced one or more polynucleotides encoding at least one exogenous protein comprising tgTRAC, tgTRBC, tgTCRa, tgTCRp, tgpTCRa, tgCD3(s-6)-TRAC, tgCD3(s-y)-TRBC, tgCD3(s-y)-TRAC, tgCD3(s-8)-TRBC, tgCD3(s-yH, tgCD3(s-8)<, tgCD3(s- y / 8)-28£ tgCD3(s- y / 6)-BB^, and / or tgCD3(s- y / 6)-(28-BB)^ to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3), when expressed in the cell, or at least one of the genotypes listed in Table 1. In some embodiments of the genome targeting tool mediated editing, the obtained TCR knockout is through targeted disruption of the endogenous TCRa constant region (TRAC). In some embodiments of the genome targeting tool mediated editing, the obtained TCR knockout is through targeted disruption of the endogenous TCRP constant region (TRBC). In some embodiments of the genome targeting tool mediated editing above, the editing further comprises an insertion of a CAR at the endogenous TRAC or TRBC locus, and / or wherein the CAR is driven by an endogenous promoter of TCRa or TCRP, and / or wherein the TCR is knocked out by the CAR insertion. In some embodiments of the genome targeting tool mediated editing above, the editing further comprises an insertion at the endogenous TRAC locus a polynucleotide encoding an exogenous protein comprising tgTRAC, tgTCRa, tgpTCRa, tgCD3(s-6)-TRAC, tgCD3(s-y)-TRAC, tgCD3(s-yH, tgCD3(e-5)<, tgCD3(s- y / 6)-28^, tgCD3(s- y / 6)-BB^, or tgCD3(s- y / 6)-(28-BB)^ to provide a surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3), when expressed in the cell. In some embodiments of the genome targeting tool mediated editing above, the editing further comprises an insertion at the endogenous TRBC locus a polynucleotide encoding an exogenous protein comprising tgTRBC, tgTCRp, tgCD3(s-y)-TRBC, tgCD3(s-8)-TRBC, tgCD3(e-y)<, tgCD3(s-8)-£, tgCD3(s- y / 8)-28£, tgCD3(s- y / 6)-BB^, and / or tgCD3 (a- y / 6)-(28-BB)^to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3), when expressed in the cell.

[00034] In one embodiment of the cell or a population thereof as provided, the cell is an induced pluripotent cell (iPSC), a clonal iPSC, or a clonal iPS cell line cell, or a derivative cell obtained from differentiating said iPSC; and the cell is TCRneg, and comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed. In some embodiments, the cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) is associated with a non-binding recombinant TCR (nb-rTCR); a defined recombinant TCR (d-rTCR); a recombinant pre-TCR (p-rTCR); or is anchored to a non-binding recombinant TCR (nb-rTCR-CD3); or is a CD3 chimeric chain (ccCD3). In one embodiment, the nb-rTCR comprises one or both of a tgTRAC and a tgTRBC. In one embodiment, the d-rTCR comprises a tgTCRa, and optionally, a tgTCRp, wherein each of the tgTCRa and the tgTCRp comprises a respective defined variable region. In one embodiment, the p-rTCR comprises a tgpTCRa, and optionally a tgTRBC or a tgTCRp, wherein the tgTCRp comprises a defined variable region. In one embodiment, the nb-rTCR-CD3 comprises one or more of fusion proteins: (1) a tgCD3(a-6)- TRAC; (2) a tgCD3(s-y)-TRBC; (3) a tgCD3(s-y)-TRAC; and / or (4) a tgCD3(s-8)-TRBC, wherein the fusion protein comprises full or partial length of ectodomains of CD3s, CD36, CD3y, and / or a full or partial length of TRAC or TRBC. In one embodiment, the ccCD3 comprises at least one of fusion proteins: tgCD3(s-y)-^, tgCD3(s-6)-^, tgCD3(s- y / 6)-28^, tgCD3(s- y / 6)-BB^, and tgCD3(s-y / 6)-(28-BB)^, wherein the fusion protein comprising full or partial length of ectodomains of CD3s, CD36 and / or CD3y protein, further comprises a cytoplasmic domain comprising a full or partial length endodomain of CD(j protein, and optionally one or both of a CD28 signaling domain and a 4IBB signaling domain. In yet another embodiment, the nb-rTCR-CD3 comprising fusion protein tgCD3(s-6)-TRAC further comprises tgTRBC or tgTCRp. In yet another embodiment, the nb-rTCR-CD3 comprising fusion protein tgCD3(s-y)-TRBC further comprises tgTRAC or tgTCRa. Or in yet another embodiment, the d-rTCR comprising a tgTCRa and a tgTCRp comprises TCRa and TCRP of an invariant NKT cell.

[00035] In view of the above embodiments, the cell as provided, in some aspects, comprises one of the recombinant TCRs: nb-rTCR, d-rTCR, or the p-rTCR, which recombinant TCR complexes with endogenous CD3 subunits, thereby enabling cell surface presentation of endogenous CD3 subunits and signaling thereof. In some other embodiments, the cell comprises a nb-rTCR-CD3 or a ccCD3, thereby enabling cell surface presentation of exogenous CD3 subunits and signaling thereof.

[00036] One aspect of the present application provides a clonal master cell bank comprising the clonal iPSC cell line cells as described herein. Another aspect of the present application provides a composition comprising the cell or population thereof, including various embodiments of the iPSCs and derivative cells differentiated from said iPSCs as described herein. In some embodiments, the composition comprising said derivative cell is suitable for therapeutic use. In some embodiments of the composition for therapeutic use, the compostion further comprises one or more therapeutic agents in addition to the derivative cell as desired. In some embodiments, said therapeutic agents comprise a peptide, a cytokine, a checkpoint inhibitor, a mitogen, a growth factor, a small RNA, a dsRNA (double stranded RNA), mononuclear blood cells, feeder cells, feeder cell components or replacement factors thereof, a vector comprising one or more polynucleic acids of interest, an antibody, a chemotherapeutic agent or a radioactive moiety, or an immunomodulatory drug (IMiD).

[00037] Additional aspect of the present application provides therapeutic use of said therapeutic composition in various embodiments by introducing the composition to a subject suitable for adoptive cell therapy, wherein the subject has an autoimmune disorder; a hematological malignancy; a solid tumor; cancer, or a virus infection.

[00038] A further aspect of the present application provide a method of manufacturing a derivative effector cell by differentiating a TCRneg iPSC, which iPSC comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and optionally the iPSC further comprises one or more of: (i) B2M negative or low; (ii) CIITA negative or low; (iii) introduced expression of HLA-G or non-cleavable HLA-G; (iv) a high affinity non-cleavable CD 16 (hnCD16) or a variant thereof; (v) a chimeric antigen receptor (CAR); (vi) a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof; (vii) at least one of the genotypes listed in Table 1; (viii) deletion or reduced expression in at least one of CD38, TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; and (ix) introduced or increased expression in at least one of HLA-E, 41BBL, CD3, CD4, CD8, CD16, CD47, CD113, CD131, CD137, CD80, PDL1, A2aR, CAR, TCR, Fc receptor, an engager, and surface triggering receptor for coupling with bi- or multi- specific or universal engagers. In some embodiments of the method of manufacturing cells of the present application, the method further comprises a step of providing a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) by knocking out TCR of a clonal iPSC to obtain the genomically engineered TCRneg iPSC by, and knocking in, simultaneously or subsequently, one or more polynucleotide encoding one or more exogenous protein; or by reprogramming an invariant NKT cell to iPSC to provide a clonal iPSC comprising iTCRaP but not T cell-TCR; and an optional step of genomically engineering the TCR negative cell by knocking out B2M and CIITA, or introducing expression of HLA-G or non-cleavable HLA-G, a high affinity non-cleavable CD 16 or a variant thereof, a CAR, and / or a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof, and said CAR and the partial or full peptide of a cell surface expressed exogenous cytokine or a receptor thereof are co-expressed in separate constructs or in a bi-cistronic construct.

[00039] In one embodiment of the method of manufacturing the cells, the step of knocking in one or more polynucleotide encoding one or more exogenous protein to provide cs-CD3, further comprises introducing to the iPSC one of: (i) one or both of a tgTRAC and a tgTRBC encoding polynucleotide, to provide a nb-rTCR when expressed; (ii) a tgTCRa, and optionally a tgTCRp, encoding polynucleotide, to provide a d-rTCR when expressed, wherein each of the tgTCRa and the tgTCRp comprises a respective defined variable region; (iii) a tgpTCRa, and optionally a tgTRBC or a tgTCRp, encoding polynucleotide, to provide a p-rTCR, wherein the tgTCRp comprises a defined variable region; (iv) one or more polynucleotides encoding one or more of fusion proteins: (1) tgCD3(s-6)-TRAC, (2) tgCD3(s-y)-TRBC, (3) tgCD3(s-y)-TRAC, and / or (4) tgCD3(s-6)-TRBC, to provide a nb-rTCR-CD3; wherein the fusion protein comprises full or partial length of ectodomains of CD3s, CD36, CD3y, and / or a full or partial length of TRAC or TRBC; or (v) one or more polynucleotides encoding one or more of fusion proteins: (1) tgCD3(s-y)-£, (2) tgCD3(s-8)-£, (3) tgCD3(s- y / 8)-28£, (4) tgCD3(s- y / 8)-BB£ and (5) tgCD3(s-y / 6)-(28-BB)^, to provide ccCD3; wherein the fusion protein comprising full or partial length of ectodomains of CD3s, CD36 and / or CD3y protein, further comprises a cytoplasmic domain comprising a full or partial length endodomain of CD(j protein, and optionally one or both of a CD28 signaling domain and a 4 IBB signaling domain. In some embodiments of the manufacturing method for the cell as described, the step of introducing to the iPSC one or more polynucleotides encoding fusion protein tgCD3(s-6)-TRAC, further comprises introducing a polynucleotide encoding tgTRBC or tgTCRP, to provide the nb-rTCR-CD3. In some embodiments, the step of introducing to the iPSC one or more polynucleotides encoding fusion protein tgCD3(s-y)-TRBC further comprises tgTRAC or tgTCRa, to provide the nb-rTCR-CD3. In some embodiments, the step of introducing to the iPSC one or more polynucleotides encoding fusion protein tgCD3(s-y)-TRBC further comprises tgTRAC or tgTCRa, to provide the nb-rTCR-CD3. In some other embodiments, the step of introducing to the iPSC the polynucleotide encoding tgTCRa, and optionally, the polynucleotide encoding tgTCRP, to provide the d-rTCR, the tgTCRa and the tgTCRP respectively comprise a TCRa and a TCRP of an invariant NKT cell.

[00040] In the various embodiments of the manufacturing method of the cell as provided, the genomic engineering is targeted editing, which comprises deletion and / or insertion. Such targeted editing may be carried out by CRISPR, ZFN, TALEN, homing nuclease, homology recombination, or any other functional variation of these tools. One aspect of the present invention provides CRISPR mediated editing of clonal iPSCs of various embodiments as provided herein, thereby obtaining edited iPSCs that are TCRneg and comprise one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, wherein the edited clonal iPSCs comprise at least one of the genotypes listed in Table 1. In some embodiments, the CRISPR mediated editing further comprises an insertion of a CAR at a TRAC or a TRBC locus, and / or wherein the CAR is driven by an endogenous promoter of TCR, and / or wherein the TCR is knocked out by the CAR insertion.

[00041] Still another aspect of the present application provides a method of combinational treatment, and the method comprises providing to a subject under the treatment effector cells comprising TCRneg, and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and a selected multi-specific engager, wherein the effector cells comprise the derivative cells as provided. In some embodiments, the selected multi-specific engager in said method is at least one of (i) a T cell engager; (ii) an NK cell engager; (iii) a bispecific T cell engager (BiTE); (iv) a bispecific killer cell engager (BiKE); (v) a tri-specific killer cell engager (TriKE); (vi) a CD3 engager; or (vii) a CD 16 engager. In some embodiments, the selected multispecific engager is a CD3 engager, wherein the CD3 engager comprises a first variable segment that binds to a cs-CD3 and a second variable segment that binds to an antigen comprising at least one of (i) ADGRE2, carbonic anhydrase IX (CAIX), CCRI, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CDS, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell, epithelial glycoprotein2 (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine-protein kinases erb- B2,3,4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), ICAM-1, Integrin B7, Interleukin-13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A(CA19.9), Lewis Y (LeY), LI cell adhesion molecule (Ll-CAM), LILRB2, melanoma antigen family A 1 (MAGE-A1), MICA / B, Mucin 1 (Muc-1), Mucin 16 (Muc-16), Mesothelin (MSLN), NKCSI, NKG2D ligands, c-Met, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), PRAME, prostate stem cell antigen (PSCA), PRAME prostate-specific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), TIM-3, TRBCI, TRBC2, vascular endothelial growth factor R2 (VEGF- R2), Wilms tumor protein (WT-1), and / or a pathogen antigen; or(ii) BCMA, CD19, CD20, CD33, CD38, CD52, CD123, CEA, EGFR, EpCAM, GD2, GPA33, HER2, MICA / B, PDL1, and / or PSMA; or (iii) CD19, CD33, CD123, CEA, EpCAM, GPA33, HER2, and / or PSMA. In some embodiments, the CD3 engager comprises at least one of blinatumomab, catumaxomab, ertumaxomab, RO6958688, AFM11, MT110 / AMG 110, MT111 / AMG211 / MEDI-565, AMG330, MT112 / BAY2010112, MOR209 / ES414, MGD006 / S80880, MGD007, and / or FBTA05. In some embodiments, the CD3 engager is administered to the subject simultaneously or subsequently with the effector cells. In some embodiments, the effector cells comprise derivative hematopoietic cells comprising derivative NK cells or derivative T cells, wherein the derivative NK cells or derivative T cells comprise a CD38 knockout, a high affinity non-cleavable CD 16 or a variant thereof, and optionally comprise: (i) B2M and CIITA knockout; (ii) introduced expression of HLA-G or non-cleavable HLA-G, a CAR, and / or a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof; wherein the CAR and a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof is co-expressed in separate constructs or in a bi-cistronic construct; and / or (iii) at least one of the genotypes listed in Table 1.

[00042] Still another aspect of this application provides a method of reducing or preventing allorej ection by recipient T cells against effector cells in an adoptive cell treatment, wherein the method comprises providing to a subject under the treatment (i) an anti-CD3 agent, and (ii) effector cells comprising TCRneg, and a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) preloaded with a CD3 engager, wherein the effector cells comprise the derivative cells provided herein. In some embodiments, said anti-CD3 agent is CD3 antibody or a CD3-CAR, wherein the CD3-CAR is comprised in a NK cell; and wherein the anti-CD3 agent deactivates recipient T cells, thereby reducing or preventing allorejection. In some embodiments, said CD3 engager comprising a first variable segment that binds to a cs-CD3 of the effector cell, comprises a second variable segment that binds to an antigen related to an autoimmune disorder; a hematological malignancy; a solid tumor; cancer, or a virus infection. In some embodiments of the the CD3 engager comprising a second variable segment that binds to an antigen, and the antigen comprises at least one of: (i) ADGRE2, carbonic anhydrase IX (CAIX), CCRI, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CDS, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell, epithelial glycoprotein2 (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine-protein kinases erb- B2,3,4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), ICAM-1, Integrin B7, Interleukin-13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9), Lewis Y (LeY), LI cell adhesion molecule (Ll-CAM), LILRB2, melanoma antigen family A 1 (MAGE-A1), MICA / B, Mucin 1 (Muc-1), Mucin 16 (Muc-16), Mesothelin (MSLN), NKCSI, NKG2D ligands, c-Met, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), PRAME, prostate stem cell antigen (PSCA), PRAME prostatespecific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), TIM-3, TRBCI, TRBC2, vascular endothelial growth factor R2 (VEGF- R2), Wilms tumor protein (WT-1), and / or a pathogen antigen; or (ii) BCMA, CD 19, CD20, CD33, CD38, CD52, CD 123, CEA, EGFR, EpCAM, GD2, GPA33, HER2, MICA / B, PDL1, and / or PSMA; or (iii) CD19, CD33, CD 123, CEA, EpCAM, GPA33, HER2, and / or PSMA. In yet some other embodiment, the CD3 engager comprises at least one of: blinatumomab, catumaxomab, ertumaxomab, RO6958688, AFM11, MT110 / AMG 110, MT111 / AMG211 / MEDI-565, AMG330, MT112 / BAY2010112, MOR209 / ES414, MGD006 / S80880, MGD007, and / or FBTA05.

[00043] Various objects and advantages of the compositions and methods as provided herein will become apparent from the following description taken in conjunction with the accompanying drawings wherein are set forth, by way of illustration and example, certain embodiments of this invention. BRIEF DESCRIPTION OF THE DRAWINGS

[00044] FIGS. 1A-C show illustrative designs for generating cell surface presented CD3 complex, or a subunit or a subdomain thereof (cs-CD3) associated with recombinant TCR complex, or subunits thereof upon disruption of endogenous TCR in a cell: (1) nb-rTCR (nonbinding recombinant TCR); (2) d-rTCR (defined recombinant TCR); (3) p-rTCR (recombinant pre-TCRa, with optional non-binding TCRP); (4) nb-rTCR-CD3 (non-binding recombinant TCR anchored CD3); and (5) ccCD3 (CD3 chimeric chain).

[00045] FIG. 2 is a graphic representation of several construct designs for cell surface expressed cytokine in iPSC derived cells. IL15 is used as an illustrative example, which can be replaced with other desirable cytokines.

[00046] FIG. 3 shows reprogramming and engineering of aPT Cells into single cell-derived TRAC-targeted CAR TiPSC clones. A: Phase contrast images of cultures at different stages as indicated. B: Flow cytometry profiles of aPT cells before reprogramming (left panel), reprogrammed and engineered cell pool before sorting and a clonal TiPSC clone (right panel).

[00047] FIG. 4 is a graphic representation of flow cytometry of mature TCRneg iPSC-derived NK cells that demonstrates stepwise engineering of hnCD16 expression, B2M knockout (indicated as “B2M”; loss of HLA-A2 expression), HLA-G expression, and IL-15 / IL-15ra (LNGFR) construct expression.

[00048] FIG. 5 is a graphic representation of telomere length determined by flow cytometry, and the mature derivative NK cells from iPSC maintain longer telomeres compared to adult peripheral blood NK cells.

[00049] FIG. 6 shows that iNK cells transduced with full-length IL15 / IL15Ra fusion construct (filled circles; positive control), or a truncated IL15 / IL15Ra fusion construct without cytoplasmic signaling domain (open circles) had a survival advantage compared to non transduced or GFP transduced cells in the same cultures independent of exogenous soluble IL2. A: in the presence of exogenous IL2; B: without the presence of exogenous IL2.

[00050] FIG. 7 shows exemplary constructs for transducing invariant NKT TCRa with or without TCRp.

[00051] FIGS. 8A-B show that CD3 is not expressed by invariant NKT TCR transduced iPSCs or iPSC derived iCD34 progenitor cells.

[00052] FIGS. 9A-C show that invariant NKT TCR supports surface expression of CD3 in TCR deficient iPSC derived T cells. FIG. 9A-B show flow cytometry results at various time points for CD3 and TCR expression. FIG. 9C shows MFI of CD3 on day 25 after iCD34 differentiation.

[00053] FIG. 10 shows that iPSC-derived T cells comprising NKT TCRa with or without NKT TCRP aggregate upon stimulation with cell surface CD3 binding using tetramers.

[00054] FIG. 11 shows that iPSC-derived T cells comprising NKT TCRa with or without NKT TCRP have increased CD25 expressing upon CD3 tetramer stimulation.

[00055] FIGS. 12A-B show that iPSC-derived T cells comprising NKT TCRa with or without NKT TCRP have enhanced cytotoxicity in the presence of CD3 binding BiTEs. FIG. 12A shows representative FACS plots demonstrating the enhanced killing of target cell in the presence of CD19xCD3 and CD20xCD3 BiTEs at 10:1 effector to target ratio. FIG. 12B shows the percentage of specific cytotoxicity for iPSC-derived effector cells comprising NKT TCRa with or without NKT TCRp. DETAILED DESCRIPTION OF THE INVENTION

[00056] Genomic modification of iPSCs (induced pluripotent stem cells) includes polynucleotide insertion, deletion and substitution. Exogenous gene expression in genome-engineered iPSCs often encounters problems such as gene silencing or reduced gene expression after prolonged clonal expansion of the original genome-engineered iPSCs, after cell differentiation, and in dedifferentiated cell types from the cells derived from the genome-engineered iPSCs. On the other hand, direct engineering of primary immune cells such as T or NK cells isolated from peripheral blood, umbilical cord blood, or any other donor tissues is challenging, and presents a hurdle to the preparation and delivery of engineered immune cells for adoptive cell therapy. The present invention provides an efficient, reliable, and targeted approach for stably integrating one or more exogenous genes, including suicide genes and other functional modalities, which provide improved therapeutic properties relating to engraftment, trafficking, homing, migration, cytotoxicity, viability, maintenance, expansion, longevity, self-renewal, persistence, and / or survival, into derivative cells differentiated from iPSC, including but not limited to HSCs (hematopoietic stem and progenitor cell), T cell progenitor cells, NK cell progenitor cells, T cells, NKT cells, NK cells.

[00057] Definitions

[00058] Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[00059] It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[00060] As used herein, the articles “a,” “an,” and “the” are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[00061] The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives.

[00062] The term “and / or” should be understood to mean either one, or both of the alternatives.

[00063] As used herein, the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% compared to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. In one embodiment, the term “about” or “approximately” refers a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length ± 15%, ± 10%, ± 9%, ± 8%, ± 7%, ± 6%, ± 5%, ± 4%, ± 3%, ± 2%, or ± 1% about a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

[00064] As used herein, the term “substantially” or “essentially” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or higher compared to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. In one embodiment, the terms “essentially the same” or “substantially the same” refer a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that is about the same as a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

[00065] As used herein, the terms “substantially free of’ and “essentially free of’ are used interchangeably, and when used to describe a composition, such as a cell population or culture media, refer to a composition that is free of a specified substance or its source thereof, such as, 95% free, 96% free, 97% free, 98% free, 99% free of the specified substance or its source thereof, or is undetectable as measured by conventional means. The term “free of’ or “essentially free of’ a certain ingredient or substance in a composition also means that no such ingredient or substance is (1) included in the composition at any concentration, or (2) included in the composition functionally inert, but at a low concentration. Similar meaning can be applied to the term “absence of,” where referring to the absence of a particular substance or its source thereof of a composition.

[00066] Throughout this specification, unless the context requires otherwise, the words “comprise,” “comprises” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. In particular embodiments, the terms “include,” “has,” “contains,” and “comprise” are used synonymously.

[00067] By “consisting of’ is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of’ indicates that the listed elements are required or mandatory, and that no other elements may be present.

[00068] By “consisting essentially of’ is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of’ indicates that the listed elements are required or mandatory, but that no other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

[00069] Reference throughout this specification to “one embodiment,” “an embodiment,” “a particular embodiment,” “a related embodiment,” “a certain embodiment,” “an additional embodiment,” or “a further embodiment” or combinations thereof means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[00070] The term “ex vivo” refers generally to activities that take place outside an organism, such as experimentation or measurements done in or on living tissue in an artificial environment outside the organism, preferably with minimum alteration of the natural conditions. In particular embodiments, “ex vivo” procedures involve living cells or tissues taken from an organism and cultured in a laboratory apparatus, usually under sterile conditions, and typically for a few hours or up to about 24 hours, but including up to 48 or 72 hours or longer, depending on the circumstances. In certain embodiments, such tissues or cells can be collected and frozen, and later thawed for ex vivo treatment. Tissue culture experiments or procedures lasting longer than a few days using living cells or tissue are typically considered to be “in vitro” though in certain embodiments, this term can be used interchangeably with ex vivo.

[00071] The term “in vivo” refers generally to activities that take place inside an organism.

[00072] As used herein, the terms "reprogramming" or "dedifferentiation" or "increasing cell potency" or "increasing developmental potency" refers to a method of increasing the potency of a cell or dedifferentiating the cell to a less differentiated state. For example, a cell that has an increased cell potency has more developmental plasticity (i.e., can differentiate into more cell types) compared to the same cell in the non-reprogrammed state. In other words, a reprogrammed cell is one that is in a less differentiated state than the same cell in a non-reprogrammed state.

[00073] As used herein, the term "differentiation" is the process by which an unspecialized ("uncommitted") or less specialized cell acquires the features of a specialized cell such as, for example, a blood cell or a muscle cell. A differentiated or differentiation- induced cell is one that has taken on a more specialized ("committed") position within the lineage of a cell. The term "committed", when applied to the process of differentiation, refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type. As used herein, the term "pluripotent" refers to the ability of a cell to form all lineages of the body or soma (i.e., the embryo proper). For example, embryonic stem cells are a type of pluripotent stem cells that are able to form cells from each of the three germs layers, the ectoderm, the mesoderm, and the endoderm. Pluripotency is a continuum of developmental potencies ranging from the incompletely or partially pluripotent cell (e.g., an epiblast stem cell or EpiSC), which is unable to give rise to a complete organism to the more primitive, more pluripotent cell, which is able to give rise to a complete organism (e.g., an embryonic stem cell).

[00074] As used herein, the term "induced pluripotent stem cells" or, iPSCs, means that the stem cells are produced in vitro, using reprogramming factor and / or small molecule chemical driven methods, from differentiated adult, neonatal or fetal cells that have been induced or changed, i.e., reprogrammed into cells capable of differentiating into tissues of all three germ or dermal layers: mesoderm, endoderm, and ectoderm. The iPSCs produced do not refer to cells as they are found in nature.

[00075] As used herein, the term "embryonic stem cell" refers to naturally occurring pluripotent stem cells of the inner cell mass of the embryonic blastocyst. Embryonic stem cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. They do not contribute to the extra-embryonic membranes or the placenta, i.e., are not totipotent.

[00076] As used herein, the term "multipotent stem cell" refers to a cell that has the developmental potential to differentiate into cells of one or more germ layers (ectoderm, mesoderm and endoderm), but not all three. Thus, a multipotent cell can also be termed a "partially differentiated cell." Multipotent cells are well known in the art, and examples of multipotent cells include adult stem cells, such as for example, hematopoietic stem cells and neural stem cells. "Multipotent" indicates that a cell may form many types of cells in a given lineage, but not cells of other lineages. For example, a multipotent hematopoietic cell can form the many different types of blood cells (red, white, platelets, etc.), but it cannot form neurons. Accordingly, the term "multipotency" refers to a state of a cell with a degree of developmental potential that is less than totipotent and pluripotent.

[00077] Pluripotency can be determined, in part, by assessing pluripotency characteristics of the cells. Pluripotency characteristics include, but are not limited to: (i) pluripotent stem cell morphology; (ii) the potential for unlimited self-renewal; (iii) expression of pluripotent stem cell markers including, but not limited to SSEA1 (mouse only), SSEA3 / 4, SSEA5, TRA1-60 / 81, TRA1-85, TRA2-54, GCTM-2, TG343, TG30, CD9, CD29, CD133 / prominin, CD140a, CD56, CD73, CD90, CD105, OCT4, NANOG, SOX2, CD30 and / or CD50; (iv) ability to differentiate to all three somatic lineages (ectoderm, mesoderm and endoderm); (v) teratoma formation consisting of the three somatic lineages; and (vi) formation of embryoid bodies consisting of cells from the three somatic lineages.

[00078] Two types of pluripotency have previously been described: the “primed” or “metastable” state of pluripotency akin to the epiblast stem cells (Epi SC) of the late blastocyst, and the “Naive” or “Ground” state of pluripotency akin to the inner cell mass of the early / preimplantation blastocyst. While both pluripotent states exhibit the characteristics as described above, the naive or ground state further exhibits: (i) pre-inactivation or reactivation of the X-chromosome in female cells; (ii) improved clonality and survival during single-cell culturing; (iii) global reduction in DNA methylation; (iv) reduction of H3K27me3 repressive chromatin mark deposition on developmental regulatory gene promoters; and (v) reduced expression of differentiation markers relative to primed state pluripotent cells. Standard methodologies of cellular reprogramming in which exogenous pluripotency genes are introduced to a somatic cell, expressed, and then either silenced or removed from the resulting pluripotent cells are generally seen to have characteristics of the primed-state of pluripotency. Under standard pluripotent cell culture conditions such cells remain in the primed state unless the exogenous transgene expression is maintained, wherein characteristics of the ground-state are observed.

[00079] As used herein, the term “pluripotent stem cell morphology” refers to the classical morphological features of an embryonic stem cell. Normal embryonic stem cell morphology is characterized by being round and small in shape, with a high nucleus-to-cytoplasm ratio, the notable presence of nucleoli, and typical inter-cell spacing.

[00080] As used herein, the term "subject" refers to any animal, preferably a human patient, livestock, or other domesticated animal.

[00081] A “pluripotency factor,” or “reprogramming factor,” refers to an agent capable of increasing the developmental potency of a cell, either alone or in combination with other agents. Pluripotency factors include, without limitation, polynucleotides, polypeptides, and small molecules capable of increasing the developmental potency of a cell. Exemplary pluripotency factors include, for example, transcription factors and small molecule reprogramming agents.

[00082] "Culture" or "cell culture" refers to the maintenance, growth and / or differentiation of cells in an in vitro environment. "Cell culture media," "culture media" (singular "medium" in each case), "supplement" and "media supplement" refer to nutritive compositions that cultivate cell cultures.

[00083] "Cultivate," or “maintain,” refers to the sustaining, propagating (growing) and / or differentiating of cells outside of tissue or the body, for example in a sterile plastic (or coated plastic) cell culture dish or flask. "Cultivation," or “maintaining,” may utilize a culture medium as a source of nutrients, hormones and / or other factors helpful to propagate and / or sustain the cells.

[00084] As used herein, the term “mesoderm” refers to one of the three germinal layers that appears during early embryogenesis and which gives rise to various specialized cell types including blood cells of the circulatory system, muscles, the heart, the dermis, skeleton, and other supportive and connective tissues.

[00085] As used herein, the term “definitive hemogenic endothelium” (HE) or “pluripotent stem cell-derived definitive hemogenic endothelium” (iHE) refers to a subset of endothelial cells that give rise to hematopoietic stem and progenitor cells in a process called endothelial-to-hematopoietic transition. The development of hematopoietic cells in the embryo proceeds sequentially from lateral plate mesoderm through the hemangioblast to the definitive hemogenic endothelium and hematopoietic progenitors.

[00086] The term “hematopoietic stem and progenitor cells,” “hematopoietic stem cells,” “hematopoietic progenitor cells,” or “hematopoietic precursor cells” refers to cells which are committed to a hematopoietic lineage but are capable of further hematopoietic differentiation and include, multipotent hematopoietic stem cells (hematoblasts), myeloid progenitors, megakaryocyte progenitors, erythrocyte progenitors, and lymphoid progenitors. Hematopoietic stem and progenitor cells (HSCs) are multipotent stem cells that give rise to all the blood cell types including myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes / platelets, dendritic cells), and lymphoid lineages (T cells, B cells, NK cells). The term “definitive hematopoietic stem cell” as used herein, refers to CD34+ hematopoietic cells capable of giving rise to both mature myeloid and lymphoid cell types including T cells, NK cells and B cells. Hematopoietic cells also include various subsets of primitive hematopoietic cells that give rise to primitive erythrocytes, megakarocytes and macrophages.

[00087] As used herein, the terms “T lymphocyte” and “T cell” are used interchangeably and refer to a principal type of white blood cell that completes maturation in the thymus and that has various roles in the immune system, including the identification of specific foreign antigens in the body and the activation and deactivation of other immune cells. AT cell can be any T cell, such as a cultured T cell, e.g., a primary T cell, or a T cell from a cultured T cell line, e.g., Jurkat, SupTl, etc., or a T cell obtained from a mammal. The T cell can be CD3+ cells. The T cell can be any type of T cell and can be of any developmental stage, including but not limited to, CD4+ / CD8+ double positive T cells, CD4+ helper T cells (e.g., Thl and Th2 cells), CD8+ T cells (e.g., cytotoxic T cells), peripheral blood mononuclear cells (PBMCs), peripheral blood leukocytes (PBLs), tumor infiltrating lymphocytes (TILs), memory T cells, naive T cells, regulator T cells, gamma delta T cells (y5 T cells), and the like. Additional types of helper T cells include cells such as Th3 (Treg), Thl 7, Th9, or Tfh cells. Additional types of memory T cells include cells such as central memory T cells (Tcm cells), effector memory T cells (Tern cells and TEMRA cells). The T cell can also refer to a genetically engineered T cell, such as a T cell modified to express a T cell receptor (TCR) or a chimeric antigen receptor (CAR). The T cell can also be differentiated from a stem cell or progenitor cell.

[00088] “CD4+ T cells” refers to a subset of T cells that express CD4 on their surface and are associated with cell-mediated immune response. They are characterized by the secretion profiles following stimulation, which may include secretion of cytokines such as IFN-gamma, TNF-alpha, IL2, IL4 and IL10. “CD4” are 55-kD glycoproteins originally defined as differentiation antigens on T-lymphocytes, but also found on other cells including monocytes / macrophages. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MHC (major histocompatibility complex) class Il-restricted immune responses. On T-lymphocytes they define the helper / inducer subset.

[00089] “CD8+ T cells” refers to a subset of T cells which express CD8 on their surface, are MHC class I-restricted, and function as cytotoxic T cells. “CD8” molecules are differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in major histocompatibility complex class I-restricted interactions.

[00090] As used herein, the term “NK cell” or “Natural Killer cell” refer to a subset of peripheral blood lymphocytes defined by the expression of CD56 or CD 16 and the absence of the T cell receptor (CD3). As used herein, the terms “adaptive NK cell” and “memory NK cell” are interchangeable and refer to a subset of NK cells that are phenotypically CD3- and CD56+, expressing at least one of NKG2C and CD57, and optionally, CD16, but lack expression of one or more of the following: PLZF, SYK, FceRy, and EAT-2. In some embodiments, isolated subpopulations of CD56+ NK cells comprise expression of CD 16, NKG2C, CD57, NKG2D, NCR ligands, NKp30, NKp40, NKp46, activating and inhibitory KIRs, NKG2A and / or DNAM-1. CD56+ can be dim or bright expression.

[00091] As used herein, the term "NKT cells" or “natural killer T cells” refers to CD Id-restricted T cells, which express a T cell receptor (TCR). Unlike conventional T cells that detect peptide antigens presented by conventional major histocompatibility (MHC) molecules, NKT cells recognize lipid antigens presented by CD Id, a non-classical MHC molecule. Two types of NKT cells are recognized. Invariant or type I NKT cells express a very limited TCR repertoire - a canonical a-chain (Va24-Jal8 in humans) associated with a limited spectrum of P chains (Vpil in humans). The second population of NKT cells, called non-classical or non-invariant type II NKT cells, display a more heterogeneous TCR aP usage. Type I NKT cells are considered suitable for immunotherapy. Adaptive or invariant (type I) NKT cells can be identified with the expression of at least one or more of the following markers, TCR Va24-Jal8, Vbll, CDld, CD3, CD4, CD8, aGalCer, CD 161 and CD56.

[00092] As used herein, the term “isolated” or the like refers to a cell, or a population of cells, which has been separated from its original environment, i.e., the environment of the isolated cells is substantially free of at least one component as found in the environment in which the “un-isolated” reference cells exist. The term includes a cell that is removed from some or all components as it is found in its natural environment, for example, isolated from a tissue or biopsy sample. The term also includes a cell that is removed from at least one, some or all components as the cell is found in non-naturally occurring environments, for example, isolated form a cell culture or cell suspension. Therefore, an isolated cell is partly or completely separated from at least one component, including other substances, cells or cell populations, as it is found in nature or as it is grown, stored or subsisted in non-naturally occurring environments. Specific examples of isolated cells include partially pure cell compositions, substantially pure cell compositions and cells cultured in a medium that is non-naturally occurring. Isolated cells may be obtained from separating the desired cells, or populations thereof, from other substances or cells in the environment, or from removing one or more other cell populations or subpopulations from the environment.

[00093] As used herein, the term “purify” or the like refers to increasing purity. For example, the purity can be increased to at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%.

[00094] As used herein, the term “encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or a mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNAand mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.

[00095] A “construct” refers to a macromolecule or complex of molecules comprising a polynucleotide to be delivered to a host cell, either in vitro or in vivo. A “vector,” as used herein refers to any nucleic acid construct capable of directing the delivery or transfer of a foreign genetic material to target cells, where it can be replicated and / or expressed. The term “vector” as used herein comprises the construct to be delivered. A vector can be a linear or a circular molecule. A vector can be integrating or non-integrating. The major types of vectors include, but are not limited to, plasmids, episomal vector, viral vectors, cosmids, and artificial chromosomes. Viral vectors include, but are not limited to, adenovirus vector, adeno-associated virus vector, retrovirus vector, lentivirus vector, Sendai virus vector, and the like.

[00096] By “integration” it is meant that one or more nucleotides of a construct is stably inserted into the cellular genome, i.e., covalently linked to the nucleic acid sequence within the cell's chromosomal DNA. By “targeted integration” it is meant that the nucleotide(s) of a construct is inserted into the cell's chromosomal or mitochondrial DNA at a pre-selected site or “integration site”. The term “integration” as used herein further refers to a process involving insertion of one or more exogenous sequences or nucleotides of the construct, with or without deletion of an endogenous sequence or nucleotide at the integration site. In the case, where there is a deletion at the insertion site, “integration” may further comprise replacement of the endogenous sequence or a nucleotide that is deleted with the one or more inserted nucleotides.

[00097] As used herein, the term “exogenous” is intended to mean that the referenced molecule or the referenced activity is introduced into, or non-native to, the host cell. The molecule can be introduced, for example, by introduction of an encoding nucleic acid into the host genetic material such as by integration into a host chromosome or as non-chromosomal genetic material such as a plasmid. Therefore, the term as it is used in reference to expression of an encoding nucleic acid refers to introduction of the encoding nucleic acid in an expressible form into the cell. The term “endogenous” refers to a referenced molecule or activity that is present in the host cell. Similarly, the term when used in reference to expression of an encoding nucleic acid refers to expression of an encoding nucleic acid contained within the cell and not exogenously introduced.

[00098] As used herein, a “gene of interest” or “a polynucleotide sequence of interest” is a DNA sequence that is transcribed into RNA and in some instances translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. A gene or polynucleotide of interest can include, but is not limited to, prokaryotic sequences, cDNAfrom eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and synthetic DNA sequences. For example, a gene of interest may encode an miRNA, an shRNA, a native polypeptide (i.e. a polypeptide found in nature) or fragment thereof; a variant polypeptide (i.e. a mutant of the native polypeptide having less than 100% sequence identity with the native polypeptide) or fragment thereof; an engineered polypeptide or peptide fragment, a therapeutic peptide or polypeptide, an imaging marker, a selectable marker, and the like.

[00099] As used herein, the term “polynucleotide” refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or analogs thereof. The sequence of a polynucleotide is composed of four nucleotide bases: adenine (A); cytosine (C); guanine (G); thymine (T); and uracil (U) for thymine when the polynucleotide is RNA. A polynucleotide can include a gene or gene fragment (for example, a probe, primer, EST or SAGE tag), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. Polynucleotide also refers to both double- and single-stranded molecules. [000100] As used herein, the term “peptide,” “polypeptide,” and “protein” are used interchangeably and refer to a molecule having amino acid residues covalently linked by peptide bonds. A polypeptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids of a polypeptide. As used herein, the terms refer to both short chains, which are also commonly referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as polypeptides or proteins. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural polypeptides, recombinant polypeptides, synthetic polypeptides, or a combination thereof. [000101] As used herein, the term “subunit” as used herein refers to each separate polypeptide chain of a protein complex, where each separate polypeptide chain can form a stable folded structure by itself. Many protein molecules are composed of more than one subunit, where the amino acid sequences can either be identical for each subunit, or similar, or completely different. For example, CD3 complex is composed of CD3a, CD3s, CD36, CD3y, and CD3(^ subunits, which form the CD3s / CD3y, CD3s / CD36, and CD3iy CD3(^ dimers. Within a single subunit, contiguous portions of the polypeptide chain frequently fold into compact, local, semiindependent units that are called “domains”. Many protein domains may further comprise independent “structural subunits”, also called subdomains, contributing to a common function of the domain. As such, the term “subdomain” as used herein refers to a protein domain inside of a larger domain, for example, a binding domain within an ectodomain of a cell surface receptor; or a stimulatory domain or a signaling domain of an endodomain of a cell surface receptor. [000102] “Operably-linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably-linked with a coding sequence or functional RNA when it is capable of affecting the expression of that coding sequence or functional RNA (i.e., the coding sequence or functional RNA is under the transcriptional control of the promoter). Coding sequences can be operably-linked to regulatory sequences in sense or antisense orientation. [000103] As used herein, the term “genetic imprint” refers to genetic or epigenetic information that contributes to preferential therapeutic attributes in a source cell or an iPSC, and is retainable in the source cell derived iPSCs, and / or the iPSC-derived hematopoietic lineage cells. As used herein, “a source cell” is a non-pluripotent cell that may be used for generating iPSCs through reprogramming, and the source cell derived iPSCs may be further differentiated to specific cell types including any hematopoietic lineage cells. The source cell derived iPSCs, and differentiated cells therefrom are sometimes collectively called “derived” or “derivative” cells depending on the context. For example, derivative effector cells, or derivative NK cells or derivative T cells, as used throughout this application are cells differentiated from an iPSC, as compared to their primary counterpart obtained from natural / native sources such as peripheral blood, umbilical cord blood, or other donor tissues. As used herein, the genetic imprint(s) conferring a preferential therapeutic attribute is incorporated into the iPSCs either through reprogramming a selected source cell that is donor-, disease-, or treatment response- specific, or through introducing genetically modified modalities to iPSC using genomic editing. In the aspect of a source cell obtained from a specifically selected donor, disease or treatment context, the genetic imprint contributing to preferential therapeutic attributes may include any context specific genetic or epigenetic modifications which manifest a retainable phenotype, i.e. a preferential therapeutic attribute, that is passed on to iPSC-derived cells of the selected source cell, irrespective of the underlying molecular events being identified or not. Donor-, disease-, or treatment response- specific source cells may comprise genetic imprints that are retainable in iPSCs and derived hematopoietic lineage cells, which genetic imprints include but are not limited to, prearranged monospecific TCR, for example, from a viral specific T cell or invariant natural killer T (iNKT) cell; trackable and desirable genetic polymorphisms, for example, homozygous for a point mutation that encodes for the high-affinity CD 16 receptor in selected donors; and predetermined HLA requirements, i.e., selected HLA-matched donor cells exhibiting a haplotype with increased population. As used herein, preferential therapeutic attributes include improved engraftment, trafficking, homing, viability, self-renewal, persistence, immune response regulation and modulation, survival, and cytotoxicity of a derived cell. A preferential therapeutic attribute may also relate to antigen targeting receptor expression; HLA presentation or lack thereof; resistance to tumor microenvironment; induction of bystander immune cells and immune modulations; improved on-target specificity with reduced off-tumor effect; resistance to treatment such as chemotherapy. [000104] The term “enhanced therapeutic property” as used herein, refers to a therapeutic property of a cell that is enhanced as compared to a typical immune cell of the same general cell type. For example, an NK cell with an “enhanced therapeutic property” will possess an enhanced, improved, and / or augmented therapeutic property as compared to a typical, unmodified, and / or naturally occurring NK cell. Therapeutic properties of an immune cell may include, but are not limited to, cell engraftment, trafficking, homing, viability, self-renewal, persistence, immune response regulation and modulation, survival, and cytotoxicity. Therapeutic properties of an immune cell are also manifested by antigen targeting receptor expression; HLA presentation or lack thereof; resistance to tumor microenvironment; induction of bystander immune cells and immune modulations; improved on-target specificity with reduced off-tumor effect; resistance to treatment such as chemotherapy. [000105] As used herein, the term “engager” refers to a molecule, e.g. a fusion polypeptide, which is capable of forming a link between an immune cell, e.g. a T cell, a NK cell, a NKT cell, a B cell, a macrophage, a neutrophil, and a tumor cell; and activating the immune cell. Examples of engagers include, but are not limited to, bi-specific T cell engagers (BiTEs), bi-specific killer cell engagers (BiKEs), tri-specific killer cell engagers, or multi- specific killer cell engagers, or universal engagers compatible with multiple immune cell types. [000106] As used herein, the term “surface triggering receptor” refers to a receptor capable of triggering or initiating an immune response, e.g. a cytotoxic response. Surface triggering receptors may be engineered, and may be expressed on effector cells, e.g. a T cell, aNK cell, a NKT cell, a B cell, a macrophage, a neutrophil. In some embodiments, the surface triggering receptor facilitates bi- or multi- specific antibody engagement between the effector cells and specific target cell e.g. a tumor cell, independent of the effector cell’s natural receptors and cell types. Using this approach, one may generate iPSCs comprising a universal surface triggering receptor, and then differentiate such iPSCs into populations of various effector cell types that express the universal surface triggering receptor. By “universal”, it is meant that the surface triggering receptor can be expressed in, and activate, any effector cells irrespective of the cell type, and all effector cells expressing the universal receptor can be coupled or linked to the engagers having the same epitope recognizable by the surface triggering receptor, regardless of the engager’s tumor binding specificities. In some embodiments, engagers having the same tumor targeting specificity are used to couple with the universal surface triggering receptor. In some embodiments, engagers having different tumor targeting specificity are used to couple with the universal surface triggering receptor. As such, one or multiple effector cell types can be engaged to kill one specific type of tumor cells in some case, and to kill two or more types of tumors in some other cases. A surface triggering receptor generally comprises a co-stimulatory domain for effector cell activation and an anti-epitope that is specific to the epitope of an engager. Abi-specific engager is specific to the anti-epitope of a surface triggering receptor on one end, and is specific to a tumor antigen on the other end. [000107] As used herein, the term ‘‘safety switch protein” refers to an engineered protein designed to prevent potential toxicity or otherwise adverse effects of a cell therapy. In some instances, the safety switch protein expression is conditionally controlled to address safety concerns for transplanted engineered cells that have permanently incorporated the gene encoding the safety switch protein into its genome. This conditional regulation could be variable and might include control through a small molecule-mediated post-translational activation and tissuespecific and / or temporal transcriptional regulation. The safety switch could mediate induction of apoptosis, inhibition of protein synthesis, DNA replication, growth arrest, transcriptional and post-transcriptional genetic regulation and / or antibody-mediated depletion. In some instance, the safety switch protein is activated by an exogenous molecule, e.g. a prodrug, that when activated, triggers apoptosis and / or cell death of a therapeutic cell. Examples of safety switch proteins, include, but are not limited to suicide genes such as caspase 9 (or caspase 3 or 7), thymidine kinase, cytosine deaminase, B-cell CD20, modified EGFR, and any combination thereof. In this strategy, a prodrug that is administered in the event of an adverse event is activated by the suicide-gene product and kills the transduced cell. [000108] As used herein, the term “pharmaceutically active proteins or peptides” refer to proteins or peptides that are capable of achieving a biological and / or pharmaceutical effect on an organism. A pharmaceutically active protein has healing curative or palliative properties against a disease and may be administered to ameliorate relieve, alleviate, reverse or lessen the severity of a disease. A pharmaceutically active protein also has prophylactic properties and is used to prevent the onset of a disease or to lessen the severity of such disease or pathological condition when it does emerge. Pharmaceutically active proteins include an entire protein or peptide or pharmaceutically active fragments thereof. It also includes pharmaceutically active analogs of the protein or peptide or analogs of fragments of the protein or peptide. The term pharmaceutically active protein also refers to a plurality of proteins or peptides that act cooperatively or synergistically to provide a therapeutic benefit. Examples of pharmaceutically active proteins or peptides include, but are not limited to, receptors, binding proteins, transcription and translation factors, tumor growth suppressing proteins, antibodies or fragments thereof, growth factors, and / or cytokines. [000109] As used herein, the term “signaling molecule” refers to any molecule that modulates, participates in, inhibits, activates, reduces, or increases, the cellular signal transduction. Signal transduction refers to the transmission of a molecular signal in the form of chemical modification by recruitment of protein complexes along a pathway that ultimately triggers a biochemical event in the cell. Signal transduction pathways are well known in the art, and include, but are not limited to, G protein coupled receptor signaling, tyrosine kinase receptor signaling, integrin signaling, toll gate signaling, ligand-gated ion channel signaling, ERK / MAPK signaling pathway, Wnt signaling pathway, cAMP-dependent pathway, and IP3 / DAG signaling pathway. [000110] As used herein, the term “targeting modality” refers to a molecule, e.g., a polypeptide, that is genetically incorporated into a cell to promote antigen and / or epitope specificity that includes but not limited to i) antigen specificity as it related to a unique chimeric antigen receptor (CAR) or T cell receptor (TCR), ii) engager specificity as it related to monoclonal antibodies or bispecific engager, iii) targeting of transformed cell, iv) targeting of cancer stem cell, and v) other targeting strategies in the absence of a specific antigen or surface molecule. [000111] As used herein, the term “specific” or “specificity” can be used to refer to the ability of a molecule, e.g., a receptor or an engager, to selectively bind to a target molecule, in contrast to non-specific or non-selective binding. [000112] The term “adoptive cell therapy” as used herein refers to a cell-based immunotherapy that, as used herein, relates to the transfusion of autologous or allogenic lymphocytes, identified as T or B cells, genetically modified or not, that have been expanded ex vivo prior to said transfusion. [000113] A "therapeutically sufficient amount", as used herein, includes within its meaning a non-toxic but sufficient and / or effective amount of the particular therapeutic and / or pharmaceutical composition to which it is referring to provide a desired therapeutic effect. The exact amount required will vary from subject to subject depending on factors such as the patient's general health, the patient's age and the stage and severity of the condition. In particular embodiments, a therapeutically sufficient amount is sufficient and / or effective to ameliorate, reduce, and / or improve at least one symptom associated with a disease or condition of the subject being treated. [000114] Differentiation of pluripotent stem cells requires a change in the culture system, such as changing the stimuli agents in the culture medium or the physical state of the cells. The most conventional strategy utilizes the formation of embryoid bodies (EBs) as a common and critical intermediate to initiate the lineage-specific differentiation. “Embryoid bodies” are threedimensional clusters that have been shown to mimic embryo development as they give rise to numerous lineages within their three-dimensional area. Through the differentiation process, typically few hours to days, simple EBs (for example, aggregated pluripotent stem cells elicited to differentiate) continue maturation and develop into a cystic EB at which time, typically days to few weeks, they are further processed to continue differentiation. EB formation is initiated by bringing pluripotent stem cells into close proximity with one another in three-dimensional multilayered clusters of cells, typically this is achieved by one of several methods including allowing pluripotent cells to sediment in liquid droplets, sedimenting cells into “U” bottomed well-plates or by mechanical agitation. To promote EB development, the pluripotent stem cell aggregates require further differentiation cues, as aggregates maintained in pluripotent culture maintenance medium do not form proper EBs. As such, the pluripotent stem cell aggregates need to be transferred to differentiation medium that provides eliciting cues towards the lineage of choice. EB-based culture of pluripotent stem cells typically results in generation of differentiated cell populations (ectoderm, mesoderm and endoderm germ layers) with modest proliferation within the EB cell cluster. Although proven to facilitate cell differentiation, EBs, however, give rise to heterogeneous cells in variable differentiation state because of the inconsistent exposure of the cells in the three-dimensional structure to differentiation cues from the environment. In addition, EBs are laborious to create and maintain. Moreover, cell differentiation through EB is accompanied with modest cell expansion, which also contributes to low differentiation efficiency. [000115] In comparison, “aggregate formation,” as distinct from “EB formation,” can be used to expand the populations of pluripotent stem cell derived cells. For example, during aggregate-based pluripotent stem cell expansion, culture media are selected to maintain proliferation and pluripotency. Cells proliferation generally increases the size of the aggregates forming larger aggregates, these aggregates can be routinely mechanically or enzymatically dissociated into smaller aggregates to maintain cell proliferation within the culture and increase numbers of cells. As distinct from EB culture, cells cultured within aggregates in maintenance culture maintain markers of pluripotency. The pluripotent stem cell aggregates require further differentiation cues to induce differentiation. [000116] As used herein, “monolayer differentiation” is a term referring to a differentiation method distinct from differentiation through three-dimensional multilayered clusters of cells, i.e., “EB formation.” Monolayer differentiation, among other advantages disclosed herein, avoids the need for EB formation for differentiation initiation. Because monolayer culturing does not mimic embryo development such as EB formation, differentiation towards specific lineages are deemed as minimal as compared to all three germ layer differentiation in EB. [000117] As used herein, a "dissociated" cell refers to a cell that has been substantially separated or purified away from other cells or from a surface (e.g., a culture plate surface). For example, cells can be dissociated from an animal or tissue by mechanical or enzymatic methods. Alternatively, cells that aggregate in vitro can be dissociated from each other, such as by dissociation into a suspension of clusters, single cells or a mixture of single cells and clusters, enzymatically or mechanically. In yet another alternative embodiment, adherent cells are dissociated from a culture plate or other surface. Dissociation thus can involve breaking cell interactions with extracellular matrix (ECM) and substrates (e.g., culture surfaces), or breaking the ECM between cells. [000118] As used herein, “feeder cells” or “feeders” are terms describing cells of one type that are co-cultured with cells of a second type to provide an environment in which the cells of the second type can grow, expand, or differentiate, as the feeder cells provide stimulation, growth factors and nutrients for the support of the second cell type. The feeder cells are optionally from a different species as the cells they are supporting. For example, certain types of human cells, including stem cells, can be supported by primary cultures of mouse embryonic fibroblasts, or immortalized mouse embryonic fibroblasts. In another example, peripheral blood derived cells or transformed leukemia cells support the expansion and maturation of natural killer cells. The feeder cells may typically be inactivated when being co-cultured with other cells by irradiation or treatment with an anti-mitotic agent such as mitomycin to prevent them from outgrowing the cells they are supporting. Feeder cells may include endothelial cells, stromal cells (for example, epithelial cells or fibroblasts), and leukemic cells. Without limiting the foregoing, one specific feeder cell type may be a human feeder, such as a human skin fibroblast. Another feeder cell type may be mouse embryonic fibroblasts (MEF). In general, various feeder cells can be used in part to maintain pluripotency, direct differentiation towards a certain lineage, enhance proliferation capacity and promote maturation to a specialized cell type, such as an effector cell. [000119] As used herein, a “feeder-free” (FF) environment refers to an environment such as a culture condition, cell culture or culture media which is essentially free of feeder or stromal cells, and / or which has not been pre-conditioned by the cultivation of feeder cells. “Pre-conditioned” medium refers to a medium harvested after feeder cells have been cultivated within the medium for a period of time, such as for at least one day. Pre-conditioned medium contains many mediator substances, including growth factors and cytokines secreted by the feeder cells cultivated in the medium. In some embodiments, a feeder-free environment is free of both feeder or stromal cells and is also not pre-conditioned by the cultivation of feeder cells. [000120] “Functional” as used in the context of genomic editing or modification of iPSC, and derived non-pluripotent cells differentiated therefrom, or genomic editing or modification of non-pluripotent cells and derived iPSCs reprogrammed therefrom, refers to (1) at the gene levelsuccessful knocked-in, knocked-out, knocked-down gene expression, transgenic or controlled gene expression such as inducible or temporal expression at a desired cell development stage, which is achieved through direct genomic editing or modification, or through “passing-on” via differentiation from or reprogramming of a starting cell that is initially genomically engineered; or (2) at the cell level—successful removal, adding, or altering a cell function / characteristics via (i) gene expression modification obtained in said cell through direct genomic editing, (ii) gene expression modification maintained in said cell through “passing-on” via differentiation from or reprogramming of a starting cell that is initially genomically engineered; (iii) down-stream gene regulation in said cell as a result of gene expression modification that only appears in an earlier development stage of said cell, or only appears in the starting cell that gives rise to said cell via differentiation or reprogramming; or (iv) enhanced or newly attained cellular function or attribute displayed within the mature cellular product, initially derived from the genomic editing or modification conducted at the iPSC, progenitor or dedifferentiated cellular origin. [000121] “HLA deficient”, including HLA-class I deficient, or HLA-class II deficient, or both, refers to cells that either lack, or no longer maintain, or have reduced level of surface expression of a complete MHC complex comprising a HLA class I protein heterodimer and / or a HLA class II heterodimer, such that the diminished or reduced level is less than the level naturally detectable by other cells or by synthetic methods. [000122] “Modified HLA deficient iPSC,” as used herein, refers to HLA deficient iPSC that is further modified by introducing genes expressing proteins related but not limited to improved differentiation potential, antigen targeting, antigen presentation, antibody recognition, persistence, immune evasion, resistance to suppression, proliferation, co-stimulation, cytokine stimulation, cytokine production (autocrine or paracrine), chemotaxis, and cellular cytotoxicity, such as non-classical HLA class I proteins (e.g., HLA-E and HLA-G), chimeric antigen receptor (CAR), T cell receptor (TCR), CD16 Fc Receptor, BCLllb, NOTCH, RUNX1, IL15, 41BB, DAP10, DAP12, CD24, CD3z, 41BBL, CD47, CD113, and PDL1. The cells that are “modified HLA deficient” also include cells other than iPSCs. [000123] “Fc receptors,” abbreviated FcR, are classified based on the type of antibody that they recognize. For example, those that bind the most common class of antibody, IgG, are called Fc-gamma receptors (FcyR), those that bind IgA are called Fc-alpha receptors (FcaR) and those that bind IgE are called Fc-epsilon receptors (FcsR). The classes of FcR's are also distinguished by the cells that express them (macrophages, granulocytes, natural killer cells, T and B cells) and the signaling properties of each receptor. Fc-gamma receptors (FcyR) includes several members, FcyRI (CD64), FcyRIIA (CD32), FcyRIIB (CD32), FcyRIIIA (CD 16a), FcyRIIIB (CD 16b), which differ in their antibody affinities due to their different molecular structure. [000124]    “Chimeric Fc Receptor,” abbreviated as CFcR, are terms used to describe engineered Fc receptors having their native transmembrane and / or intracellular signaling domains modified, or replaced, with non-native transmembrane and / or intracellular signaling domains. In some embodiments of the chimeric Fc receptor, in addition to having one of, or both, transmembrane and signaling domains being non-native, one or more stimulatory domains can be introduced to the intracellular portion of the engineered Fc receptor to enhance cell activation, expansion and function upon triggering of the receptor. Unlike chimeric antigen receptor (CAR) which contains antigen binding domain to target antigen, the chimeric Fc receptor binds to an Fc fragment, or the Fc region of an antibody, or the Fc region comprised in an engager or a binding molecule and activating the cell function with or without bringing the targeted cell close in vicinity. For example, a Fey receptor can be engineered to comprise selected transmembrane, stimulatory, and / or signaling domains in the intracellular region that respond to the binding of IgG at the extracellular domain, thereby generating a CFcR. In one example, a CFcR is produced by engineering CD 16, a Fey receptor, by replacing its transmembrane domain and / or intracellular domain. To further improve the binding affinity of the CD 16 based CFcR, the extracellular domain of CD64 or the high-affinity variants of CD 16 (Fl76V, for example) can be incorporated. In some embodiments of the CFcR where high affinity CD 16 extracellular domain is involved, the proteolytic cleavage site comprising a serine at position 197 is eliminated or is replaced such at the extracellular domain of the receptor is non-cleavable, i.e., not subject to shedding, thereby obtaining a hnCD16 based CFcR. [000125] CD 16, a FcyR receptor, has been identified to have two isoforms, Fc receptors FcyRIIIa (CD16a) and FcyRIIIb (CD16b). CD16a is a transmembrane protein expressed by NK cells, which binds monomeric IgG attached to target cells to activate NK cells and facilitate antibody-dependent cell-mediated cytotoxicity (ADCC). “High affinity CD 16,” “non-cleavable CD 16,” or “high affinity non-cleavable CD 16 (hnCD16),” as used herein, refers to a natural or non-natural variant of CD 16. The wildtype CD 16 has low affinity and is subject to ectodomain shedding, a proteolytic cleavage process that regulates the cells surface density of various cell surface molecules on leukocytes upon NK cell activation. F176V and F158V are exemplary CD 16 polymorphic variants having high affinity. A CD 16 variant having the cleavage site (position 195-198) in the membrane-proximal region (position 189-212) altered or eliminated is not subject to shedding. The cleavage site and the membrane-proximal region are described in detail in WO2015148926, the complete disclosures of which are incorporated herein by reference. The CD 16 S197P variant is an engineered non-cleavable version of CD 16. A CD 16 variant comprising both F158V and S197P has high affinity and is non-cleavable. Another exemplary high affinity and non-cleavable CD16 (hnCD16) variant is an engineered CD16 comprising an ectodomain originated from one or more of the 3 exons of the CD64 ectodomain. I. Cells and Compositions Useful for Adoptive Cell Therapies with Enhanced Properties [000126] Provided herein is a strategy to systematically engineer the regulatory circuitry of a clonal iPSC without impacting the differentiation potency of the iPSC and cell development biology of the iPSC and its derivative cells, while enhancing the therapeutic properties of the derivative cells differentiated from iPSC. The iPSC-derived cells are functionally improved and suitable for adoptive cell therapies following a combination of selective modalities being introduced to the cells at the level of iPSC through genomic engineering. It was unclear, prior to this invention, whether altered iPSCs comprising one or more provided genetic editing still have the capacity to enter cell development, and / or to mature and generate functional differentiated cells while retaining modulated activities. Unanticipated failures during directed cell differentiation from iPSCs have been attributed to aspects including, but not limited to, development stage specific gene expression or lack thereof, requirements for HLA complex presentation, protein shedding of introduced surface expressing modalities, and need for reconfiguration of differentiation protocols enabling phenotypic and / or functional change in the cell. The present application has shown that the one or more selected genomic modifications as provided herein does not negatively impact iPSC differentiation potency, and the functional effector cells derived from the engineered iPSC have enhanced and / or acquired therapeutic properties attributable to the individual or combined genomic modifications retained in the effector cells following the iPSC differentiation. 1. CD3 surface presentation in the absence of endogenous TCR [000127] Alpha-beta T cell receptors (aPTCR) are antigen specific receptors essential to the immune response and are present on the cell surface of aP T lymphocytes. Binding of TCRaP to peptide-major histocompatibility complex (pMHC) initiates TCR-CD3 intracellular activation, recruitment of numerous signaling molecules, and branching and integrating signaling pathways, leading to mobilization of transcription factors that are critical for gene expression and T cell growth and function acquisition. Although NKT cells are a subset of T cells that also express an aP TCR, differ from conventional aP T cells, NKT cells’ TCR is composed of a canonical invariant TCR a chain (Va24-Jal8 in humans) and TCR P chains that use limited VP segments (Vpil in humans), which is limited in diversity and recognizes a limited number of lipid antigens presented by CD Id. [000128] Disrupting the constant region of TCR alpha or TCR beta (TRAC or TRBC), either through direct editing of a T cell or through iPSC editing as a source for obtaining modified derivative T cell, is one of the approaches to produce a TCRneg T cell. For example, an insertion of, at a pre-selected position in TRAC or TRBC, a 2A sequence either operatively linked to an endogenous promoter of the TRAC or TRBC or to an exogenous promoter can lead to TRAC or TRBC disruption (or truncation in this example) and a TCR negative cell (TCRneg). In a particular embodiment, the TCRneg cell is an iPSC. In another embodiment, the TCRneg cell is an NK lineage cell. As used herein, the term “TCR negative” or “TCRneg” refers to the lack of endogenous TCR expression, either due to TCR gene expression disruption (such as in T lineage cells: primary or iPSC-derived T lineage cells) or due to natural absence of TCR gene expression despite the existence of TCR locus in the genome (for example, iPSCs, or NK linage cells: primary or iPSC-derived NK lineage cells). The subsequent directed differentiation of clonally selected engineered iPSC to hematopoietic cells make it possible to generate iPSC derived immune effector cells, and / or a homogenous population thereof, without TCR expression. [000129] In some embodiments, the targeted truncation or disruption using self-cleaving peptide such as 2A could optionally take place concomitantly with integration of one or more exogenous genes of interest at the location of truncation or disruption, and the expression of the integrated gene(s) could be driven by an operatively linked exogenous promoter or by endogenous promoter of TCR alpha or TCR beta upon integration, which leads to TRAC or TRBC knockout, and thus TCR negative while expressing one or more exogenous genes inserted at the TRAC or TRBC locus. [000130] iPSC-derived TCR negative T cells (with or without exogenous gene integration) obtained using this approach do not require HLA matching, have reduced alloreactivity and are able to prevent GvHD (Graft versus Host Disease) when used in allogeneic adoptive cell therapies. However, it has been found that TCR disruption also results in the elimination of the CD3 signaling complex from the T-cell surface despite the CD3 subunit gene expression in the cell. The lack of cell surface CD3 may alter the cells’ capacity for expansion and / or survival and reduce the cells’ functional potential due to incompatibility with technologies requiring cell surface CD3 recognition and binding, which include, but are not limited to: BiTE, BiKE, or TRiKE (or collectively called, engager) technology; CD3 / CD28 T cell activation bead technology; and anti-CD3 antibody or CD3-CAR stimulation technology. Further, when TCRneg iPSCs are used for directed T cell differentiation, there may also be impact on T cell development biology and T cell function maturation. However, overexpressing CD3 in cells that are TCR negative does not seem to restore the cell surface presentation of CD3 complex and / or CD3 signaling. As for cells that do not express TCR despite the existence of TCR genes, for example, NK or NK progenitor cells, the cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) as disclosed herein in a TCRneg NK cell can function as an acquired CD3 related cell surface triggering receptor for binding with molecules including, not limited to, antibodies or functional variants thereof, and / or bi- or multi- specific engagers recognizing CD3 receptor. To address the unresolved issues in the art, among other provided advantages described herein, the following designs, as shown in FIGS. 1A-C, are detailed in this application to reconstitute and / or provide the surface CD3 presentation when without endogenous TCR expression (TCRnegcell), whether due to loss of endogenous TCR gene expression via gene disruption (such as in derivative T lineage cells) or due to natural absence of TCR gene expression (such as in derivative NK linage cells). [000131] Design 1: Non-binding Recombinant TCR (nb-rTCR) [000132] As presented in FIG. 1 A, in this Design 1, while the endogenous TCRa in a cell is knocked out (TCRa' / _) using targeted genomic editing tools, leading to TCR negative (TCRneg), the knockout of TCRP (TCRP' / _) is optional; or vice versa, while the endogenous TCRP in a cell is knocked out (TCRP' / _) using targeted genomic editing tools, leading to TCR negative (TCRneg), the knockout of TCRa (TCRa' / _) is optional. In embodiments which comprises TCRa knockout, a polynucleotide encoding a full or partial length of the constant region of TCRa (transgenic TRAC, or tgTRAC) is introduced to the cell subsequently, or is integrated at TRAC upon targeted TRAC knockout, and the expression of the polynucleotide is driven by the endogenous promoter of TCRa or alternatively by an exogenous promoter that is operatively linked to the polynucleotide. In some embodiments, the polynucleotide encoding a full or partial length of the constant region of TCRa further comprises an appropriate N- terminal signal peptide coupled with the full or partial length of the constant region of TCRa. In the embodiment where the endogenous TCRP (TCRP' / _) is knocked out, a polynucleotide encoding a full or partial length of the constant region of TCRP, (tgTCRP, or tgTRBC) is introduced to the cell; and the expression of the tgTCRP or tgTRBC is driven by the endogenous promoter of TCRP or alternatively by an exogenous promoter. In some embodiments, the polynucleotide encoding a full or partial length of the constant region of TCRP further comprises an appropriate N- terminal signal peptide coupled with the full or partial length of the constant region of TCRP. In some embodiments, the exogenous promoter comprises a constitutive, inducible, temporal-, tissue-, or cell type- specific promoter. In some embodiments, the exogenous promoter comprises one of CMV, EFla, PGK, CAG, and UBC. In one embodiment, the exogenous promoter comprises at least CAG. [000133] In some embodiments, the polynucleotide encoding full or partial TCRa constant region (tgTRAC) comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 1. In some embodiments, the polynucleotide encoding TCRP comprising at least a full or partial constant region (tgTRBC) comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 2 or SEQ ID. 3. In some embodiments of the polynucleotide encoding an N- terminal signal peptide and a full or partial length of TCRa or TCRP constant region, the polynucleotide further comprises a linker peptide in-between the signal peptide and the sequence related to the TCR constant region. In some embodiments of the polynucleotide encoding an N- terminal signal peptide and a full length of TCRa or TCRP constant region, the polynucleotide further comprises a poly A tail at the C-terminal. In some embodiments of the polynucleotide encoding an N- terminal signal peptide and a partial length of TCRa or TCRP constant region, the integration of the polynucleotide is at a site within endogenous constant region (for example, an exon) and is in-frame, i.e., in-frame with the remaining endogenous sequence of TCRa or TCRP constant region downstream of the integration site, such that a full length transgenic / chimeric TRAC or TRBC is formed with a part of its sequence being exogenous / transgenic and another part being endogenous. In some embodiments of Design 1, at least one of the endogenous TCRa and TCRP is engineered to essentially remove the respective variable region, while presenting to cell surface the respective transgenic constant region when expressed. In some embodiments, only one of the endogenous TCRa and TCRP is engineered to essentially remove the related variable region while presenting to cell surface a transgenic constant region and a wildtype TCR subunit (TCRa or TCRP). In some embodiments, both endogenous TCRa and TCRP are engineered as provided to remove the respective variable region, while presenting to cell surface both transgenic constant region when expressed. Exemplary N- terminal signal peptide includes MALPVTALLLPLALLLHA (SEQ ID NO. 4; CD8asp) or MDFQVQIFSFLLISASVIMSR (SEQ ID NO. 5; IgKsp), or any signal peptide sequence or functional variants thereof known in the art. Exemplary linker peptide includes DYKDDDDK (SEQ ID NO. 6; FLAG), or any linker peptide sequence or functional variants thereof known in the art. SEQ ID NO. 1: IQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFA CANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS (TRAC) SEQ ID NO. 2: DLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDS RYCLSSRLRNHFRCRVSATFWQNPQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVL SATILYEILLGKATLYAVLVSALVLMAMVKRKDF (TRBC1) SEQ ID NO. 3 DLKNVFPPKVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDS RYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVL SATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG (TRBC2) [000134] In this application, it is discovered that the transgenic constant region of either TCR subunits, tgTRAC or tgTRBC, while being capable of forming a recombinant TCR complex (rTCR) by associating with the other TCR subunit (endogenous / wildtype or transgenic; if transgenic, with or without its respective variable region) and endogenous CD3 subunits, does not enable peptide-MHC binding for lack of a TCRa or TCRP variable region that participates in the antigen recognition. The resulting cell regains the canonical TCR / CD3 signaling through the cell surface presented endogenous CD3 (cs-CD3) complex but does not have alloreactivity due to endogenous TCR knockout and a rTCR without TCRa variable region. As such, in view of Design 1, provided herein is a cell or a population thereof, wherein the cell is an iPSC, a clonal iPSC, a clonal iPS cell line cell, or a derivative cell obtained from differentiating said iPSC; and the cell comprises: a disruption at at least one of endogenous TCRa and TCRP constant regions such that the endogenous TCR is knocked out (TCRneg), and one or both exogenous polynucleotide encoding the constant region of TCRa (tgTRAC) and / or TCRP (tgTRBC) that is disrupted; wherein the tgTRAC and / or tgTRAB enables cell surface presentation of endogenous CD3 (cs-CD3) when expressed. The recombinant TCR complex comprising at least one of tgTRAC and tgTRBC does not bind antigen peptide presented by MHC for not having both variable regions (Va and VP) of the TCR subunits, and is thus termed as non-binding recombinant TCR (nb-rTCR). [000135] Design 2: Defined recombinant TCR (d-rTCR) [000136] As presented in FIG. 1 A, in this Design 2, both endogenous TCRa and endogenous TCRp are knocked out (TCRa' / _ and TCRP' / _; or TCRneg TCRpneg) in a cell using a genomic editing tool, leading to a TCRneg cell. Simultaneously with, or subsequently to, the TCR knockout, a first polynucleotide encoding a TCRa comprising a defined variable region of TCRa and a full or partial constant region (tgTCRa) and a second polynucleotide encoding a TCRP comprising a defined variable region of TCRP and a full or partial constant region (tgTCRP) are introduced to said TCRneg cell. A defined TCRa or TCRP variable region can be of any given specificity such that its sequence has been, or can be, identified. In some embodiments, one or both of the first and the second polynucleotides is driven by an endogenous promoter of TCRa and TCRP, respectively. In some other embodiments, one or both of the first and the second polynucleotides is driven by an exogenous promoter. In some embodiments, the second polynucleotide is driven by an endogenous promoter of TCRP, whereas in some other embodiments, the second polynucleotide is driven by an exogenous promoter. In some embodiments, the exogenous promoter comprises a constitutive, inducible, temporal-, tissue-, or cell type- specific promoter. In some embodiments, the exogenous promoter comprises one of CMV, EFla, PGK, CAG, and UBC. In one embodiment, the exogenous promoter comprises at least CAG. In some embodiments, the polynucleotide encoding a full or partial length of TCRa constant region and a given defined variable region comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 1. In some embodiments, the polynucleotide encoding a full or partial length of TCRP constant region and a given defined variable region comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 2 or SEQ ID NO. 3. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. In some embodiments of the polynucleotide encoding a full length of TCRa or TCRP constant region, the polynucleotide further comprises a polyAtail at the C’ terminal. In some embodiments of the polynucleotide encoding a partial length of TCRa or TCRP constant region, the integration of the polynucleotide is at a site within the endogenous constant region and is in frame with the remaining endogenous sequence of TCRa or TCRP constant region downstream of the integration site, such that a full length transgenic / chimeric TRAC or TRBC is formed with a part of its sequence being exogenous / transgenic and another part being endogenous. Sequences for TCRa or TCRP variable regions can be found, for example, in the Universal Protein Resource (UniProt) database, and some non-limiting defined TCRa or TCRP variable regions examples are listed in the following Table A and B, respectively. TABLE A: UniProt Sequence Entry No. Protein Names Gene Names A0A0B4J248 TCR alpha variable 1-1 TRAV1-1 A0A0B4J238 TCR alpha variable 1-2 TRAV1-2 A0A0B4J234 TCR alpha variable 2 TRAV2 A0A0B4J244 TCR alpha variable 3 TRAV3 A0A0B4J268 TCR alpha variable 4 TRAV4 A0A0B4J249 TCR alpha variable 5 TRAV5 A0A075B6T7 TCR alpha variable 6 TRAV6 A0A075B6U4 TCR alpha variable 7 TRAV7 A0A0A6YYK 1 TCR alpha variable 8-1 TRAV8-1 A0A0B4J237 TCR alpha variable 8-2 TRAV8-2 A0A0A6YYJ 7 TCR alpha variable 8-3 TRAV8-3 P01737 TCR alpha variable 8-4 TRAV8-4 A0A0B4J262 TCR alpha variable 8-6 TRAV8-6 A0A075B6U6 TCR alpha variable 8-7 TRAV8-7 A0A075B6T8 TCR alpha variable 9-1 TRAV9-1 A0A087WT0 2 TCR alpha variable 9-2 TRAV9-2 UniProt Sequence Entry No. Protein Names Gene Names A0A0A6YY K6 TCR alpha variable 16 TRAV16 A0A0B4J275 TCR alpha variable 17 TRAV17 A0A075B6X 5 TCR alpha variable 18 TRAV18 A0A0A6YY K7 TCR alpha variable 19 TRAV19 A0A0B4J274 TCR alpha variable 20 TRAV20 A0A0B4J279 TCR alpha variable 21 TRAV21 A0A0B4J277 TCR alpha variable 22 TRAV22 A0A075B6W 5 TCR alpha variable 23 / delta variable 6 TRAV23D V6 A0A0B4J272 TCR alpha variable 24 TRAV24 A0A0B4J276 TCR alpha variable 25 TRAV25 A0A087WT0 3 TCR alpha variable 26-1 TRAV26-1 A0A0B4J265 TCR alpha variable 26-2 TRAV26-2 A0A087WT0 1 TCR alpha variable 27 TRAV27 P04437 TCR alpha variable 29 / delta variable 5 TRAV29D V5 A0A087WSZ 9 TCR alpha variable 30 TRAV30 A0A0B4J273 TCR alpha variable 34 TRAV34 A0A0B4J240 TCR alpha variable 10 TRAV10 A0A0B4J245 TCR alpha variable 12-1 TRAV12-1 A0A075B6T6 TCR alpha variable 12-2 TRAV12-2 A0A0B4J271 TCR alpha variable 12-3 TRAV12-3 A0A0B4J241 TCR alpha variable 13-1 TRAV13-1 A0A0B4J235 TCR alpha variable 13-2 TRAV13-2 A0A0A6YYC 5 TCR alpha variable 14 / delta variable 4 TRAV14D V4 P0DPF4 TCR alpha variable 35 TRAV35 A0A075B6V 5 TCR alpha variable 36 / delta variable 7 TRAV36D V7 A0A0B4J264 TCR alpha variable 38-1 TRAV38-1 A0JD32 TCR alpha variable 38-2 / delta variable 8 TRAV38-2DV8 A0A0B4J263 TCR alpha variable 39 TRAV39 A0A0B4J280 TCR alpha variable 40 TRAV40 A0A0B4J266 TCR alpha variable 41 TRAV41 TABLE B: UniProt Sequence Entry No. Protein Names Gene Names A0A1B0GX6 8 TCR beta variable 2 TRBV2 A0A576 TCR beta variable 3-1 TRBV3-1 A0A577 TCR beta variable 4-1 TRBV4-1 A0A539 TCR beta variable 4-2 TRBV4-2 A0A589 TCR beta variable 4-3 TRBV4-3 A0A578 TCR beta variable 5-1 TRBV5-1 A0A0C4DH5 9 TCR beta variable 5-4 TRBV5-4 A0A597 TCR beta variable 5-5 TRBV5-5 A0A599 TCR beta variable 5-6 TRBV5-6 A0A5A2 TCR beta variable 5-8 TRBV5-8 A0A0K0K1D 8 TCR beta variable 6-1 TRBV6-1 A0A0J9YXY 3 TCR beta variable 6-2 TRBV6-2 P0DPF7 TCR beta variable 6-3 TRBV6-3 A0A1B0GX4 9 TCR beta variable 6-4 TRBV6-4 UniProt Sequence Entry No. Protein Names Gene Names A0A1B0GX5 1 TCR beta variable 7-8 TRBV7-8 P04435 TCR beta variable 7-9 TRBV7-9 A0A0B4J1U 6 TCR beta variable 9 TRBV9 A0A0K0K1A 3 TCR beta variable 10-1 TRBV10-1 A0A0K0K1G 8 TCR beta variable 10-2 TRBV10-2 A0A0K0K1G 6 TCR beta variable 10-3 TRBV10-3 A0A0K0K1C 0 TCR beta variable 11-1 TRBV11-1 A0A584 TCR beta variable 11-2 TRBV11-2 A0A5A6 TCR beta variable 11-3 TRBV11-3 P01733 TCR beta variable 12-3 TRBV12-3 A0A0B4J2E0 TCR beta variable 12-4 TRBV12-4 A0A1B0GX7 8 TCR beta variable 12-5 TRBV12-5 A0A0A6YY D4 TCR beta variable 13 TRBV13 A0A5B0 TCR beta variable 14 TRBV14 A0A0K0K1A 5 TCR beta variable 6-5 TRBV6-5 A0A0A6YYG 2 TCR beta variable 6-6 TRBV6-6 A0A0A6YYG 3 TCR beta variable 6-8 TRBV6-8 A0A0J9YX75 TCR beta variable 6-9 TRBV6-9 A0A1B0GXF 2 TCR beta variable 7-2 TRBV7-2 A0A1B0GX9 5 TCR beta variable 7-4 TRBV7-4 A0A1B0GX3 1 TCR beta variable 7-6 TRBV7-6 A0A0K0K1E 9 TCR beta variable 7-7 TRBV7-7 A0A087WV6 2 TCR beta variable 16 TRBV16 A0A087X0M 5 TCR beta variable 18 TRBV18 A0A075B6N 1 TCR beta variable 19 TRBV19 A0A075B6N 2 TCR beta variable 20-1 TRBV20-1 A0A075B6N 3 TCR beta variable 24-1 TRBV24-1 A0A075B6N 4 TCR beta variable 25-1 TRBV25-1 A0A0K0K1C 4 TCR beta variable 27 TRBV27 A0A5B6 TCR beta variable 28 TRBV28 [000137] Invariant NKT cells are a unique subset of T cells that express a canonical invariant TCRa chain (Va24-Jal8 in humans, or iTCRa) and TCRP chains that use limited V'P segments (Vpll in humans; or iTCRp), resulting in highly conserved TCR and CD Id-dependent antigen presentation. To utilize this property of the TCR of invariant NKT (iTCR or iTCRap), in some embodiments of Design 2, a defined TCR comprises either or both of TCRa and TCRP of invariant NKT cell (iTCRa or iTCRaP), such that a polynucleotide encoding a full or partial length of TCRa constant region and a given defined variable region comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 44; and a polynucleotide encoding a full or partial length of TCRP constant region and a given defined variable region comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 45. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. SEQ ID NO. 44 MKKHLTTFLVILWLYFYRGNGKNQVEQSPQSLIILEGKNCTLQCNYTVSPFSNLRWYKQDTGRGPVSLTIM TFSENTKSNGRYTATLDADTKQSSLHITASQLSDSASYICVVSDRGSTLGRLYFGRGTQLTVWPDIQNPDP AVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFN NSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS (iNKT TCR a chain of human Va24Jal8; the underlined portion is the variable region) SEQ ID NO. 45 MTIRLLCYMGFYFLGAGLMEADIYQTPRYLVIGTGKKITLECSQTMGHDKMYWYQQDPGMELHLIHYSYGV NSTEKGDLSSESTVSRIRTEHFPLTLESARPSHTSQYLCASEDLN KV F P P E VAV F E P S EAEIS HT QKAT LV CLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFY GLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMV KRKDF (iNKT TCR P chain of human Vpi 1; the underlined portion is the variable region) [000138] In this application, it is discovered that a transgenic TCRa (tgTCRa) having a constant region and a defined variable region, optionally with a transgenic TCRP (tgTCRP) having a constant region and a defined variable region is capable of forming a recombinant TCR complex (rTCR) by associating with the endogenous CD3 subunits including the CD3(^ chain, while having a defined, or no, peptide-MHC binding due to the specificity of the variable region of tgTCRa and tgTCRp. In addition to genetic engineering transgenic TCR subunits for defined recombinant TCR, other approaches to take advantage of the TCRa and TCRP of invariant NKT cells include reprogramming isolated NKT cells to iPSC, and differentiating the iPSC to a T cell, which derived T cell, as a result, comprises the TCRa and TCRP of invariant NKT cells (iTCRa, iTCRP; and iTCR, the complex), using the reprogramming and differentiating composition and method disclosed herein. The resulting cell, differentiated from genetically engineered iPSCs or iNKT reprogramed iPSCs, regains the canonical TCR / CD3 signaling through the cell surface presented endogenous CD3 (cs-CD3), while having no, or a known and defined MHC binding specificity. As such, in view of Design 2, provided herein is a cell or a population thereof, wherein the cell is an iPSC, a clonal iPSC, a clonal iPS cell line cell, or a derivative cell obtained from differentiating the iPSC; and the cell comprises: a disruption at each of an endogenous TCRa and an endogenous TCRP, an exogenous polynucleotide encoding a tgTCRa having a full or partial constant region and a defined variable region, and an exogenous polynucleotide encoding a tgTCRp having a full or partial constant region and a defined variable region; wherein an endogenous CD3 molecule is present at the cell surface (cs-CD3) when expressed. [000139] Design 3: Recombinant pre-TCRa with optional non-binding TCRP (p-rTCR) [000140] Pre-TCRa is a type I transmembrane receptor protein encoded by developmentally controlled gene in immature thymocytes, an early stage in T cell development. The pre-TCRa covalently associates with TCRP and with the CD3 subunits to form pre-TCR complex. Pre-TCRa, , among other structural and functional difference, has a relatively longer cytoplasmic tail as compared to TCRa chain. As presented in FIG. 1 A, in this Design 3, the TCR negative cell has at least the endogenous TCRa knocked out (TCRneg) using a genomic editing tool, with the knockout of the endogenous TCRP being optional. Simultaneously with or subsequently to the TCR knockout, a first polynucleotide encoding a full or a partial length of pre-TCRa (tgpTCRa) is introduced to said TCRneg cell. In some embodiments where said TCRneg cell further comprises TCRP knockout, a second polynucleotide encoding a full or partial TCRP constant region with or without a given defined variable region (tgTCRP or tgTRBC) is introduced to the TCRneg cell, wherein the cell is not an early stage, immature thymocytes. In some embodiments of the polynucleotide encoding a full length of TCRa or TCRP constant region, the polynucleotide further comprises a polyAtail at the C’ terminal. In some embodiments of the polynucleotide encoding a partial length of TCRa or TCRP constant region, the integration of the polynucleotide is at a site within endogenous constant region and is in frame with the remaining endogenous sequence of TCRa or TCRP constant region downstream of the integration site, such that a full length transgenic / chimeric TRAC or TRBC is formed with a part of its sequence being exogenous / transgenic and another part being endogenous. [000141] In some embodiments, the first polynucleotide encoding a full or a partial length of pre-TCRa (tgpTCRa) is operatively linked to endogenous promoter of TCRa upon integration. In some embodiments, the first polynucleotide encoding a full or a partial length of pre-TCRa (tgpTCRa) is driven by an exogenous promoter. In some embodiments, the second polynucleotide encoding a full or partial TCRP constant region with or without a given defined variable region is operatively linked to endogenous promoter of TCRP upon integration. In some embodiments, the second polynucleotide encoding a full or partial TCRP constant region with or without a given defined variable region is driven by an exogenous promoter. In some embodiments, the exogenous promoter comprises a constitutive, inducible, temporal-, tissue-, or cell type- specific promoter. In some embodiments, the exogenous promoter comprises one of CMV, EFla, PGK, CAG, and UBC. In one embodiment, the exogenous promoter comprises at least CAG. In some embodiments, the polynucleotide encoding tgpTCRa comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 23. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. In some embodiments, the polynucleotide encoding tgpTCRa comprises a partial length of SEQ ID NO. 23, which is represented herein as SEQ ID NO. 24. In some embodiments of the polynucleotide encoding tgpTCRa comprising a full or partial length of SEQ ID NO. 23 or any functional variants thereof, the encoded tgpTCRa further comprises a signal peptide known in the art. One non-limiting exemplary signal peptide comprises a peptide represented by SEQ ID NO. 22. SEQ ID NO. 22 MAGTWLLLLLALGCPALPTGVGG SEQ ID NO. 23 TPFPSLAPPIMLLVDGKQQMVVVCLVLDVAPPGLDSPIWFSAGNGSALDAFTYGPSPATDGTWTNLAHLSL PSEELASWEPLVCHTGPGAEGHSRSTQPMHLSGEASTARTCPQEPLRGGCGLLRAPERFLLAGTPGGALWL GVLRLLLFKLLLFDLLLTCSCLCDPAGPLPSPATTTRLRALGSHRLHPATETGGREATSSPRPQPRDRRWG DTPPGRKPGSPVWGEGSYLSSYPTCPAQAWCSRSALRAPSSSLGAFFAGDLPPPLQAGAA (tgpTCRa with TM) SEQ ID NO. 24 TPFPSLAPPIMLLVDGKQQMVVVCLVLDVAPPGLDSPIWFSAGNGSALDAFTYGPSPATDGTWTNLAHLSL PSEELASWEPLVCHTGPGAEGHSRSTQPMHLSGEASTARTCPQEPLRGGCGLLRAPERFLLAGTPGGALWL GVLRLLLFKLLLFDLLLTCSCLCDPAGPLPSPATTTRLRALGSHRLHPATETGGREATSSPRPQPRDRRWG DTPPGRKPGSPV (Truncated tgpTCRa with TM) [000142] In some embodiments, the polynucleotide encoding a TCRP comprising a full or partial constant region and a given defined variable region comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 2 or SEQ ID NO. 3. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. A defined TCRP variable region can be of any given specificity such that its sequence has been or can be identified. Non-limiting defined TCRP variable region are exemplified in Table B above, and that comprised in SEQ ID NO. 45 (the underlined portion). [000143] It was unknown previously whether an iPSC having a pre-TCRa expression controlled by a promoter (whether exogenous promoter or endogenous TCRa promoter) different from its native promoter (i.e., pre-TCRa promoter) still has the capacity to differentiate into a functional effector T cell. Here we tried to demonstrate that the cell development biology of iPSC comprising a transgenic pre-TCRa (tgpTCRa) controlled by a non-native promoter could be maintained to an extent that the directed differentiation to iPSC-derived T cell can be carried out to generate a functional T cell. This is surprising because normally the expression of an endogenous pre-TCR is developmentally regulated. Further, the T cells derived from tgpTCRa TCRneg iPSCs comprise an expressed surface recombinant pre-TCR complex (rpTCR) by associating with the endogenous CD3 subunits including CD3(^ chain, while having no peptide-MHC binding capability. Without being limited by theory, the transgenic pre-TCR / CD3 complex may have nonetheless driven the iPSC-derived T cell maturation through the canonical CD3 signaling via the cell surface presented endogenous CD3 (cs-CD3) complex. In view of the above, the scope of this application also includes various methods of upregulating and / or preventing downregulation of endogenous pre-TCRa. The over-expressed pre-TCRa in a cell that is not an early / immature thymocytes would associate with expressed endogenous TCRP and CD3 subunits to enable CD3 cell surface presentation while having no peptide-MHC binding capability. [000144] As such, in view of Design 3, provided herein is a cell or a population thereof, wherein the cell is an iPSC, a clonal iPSC, a clonal iPS cell line cell, or a derivative cell obtained from differentiating said iPSC; and the cell comprises: a disruption at least of an endogenous TCRa or TCRP such that the endogenous TCR is knocked out (TCRneg), and at least an exogenous polynucleotide encoding a peptide comprising a full or partial length of pre-TCRa; wherein the expression of the pre-TCRa, in the absence of TCRa, results in the reconstitution of cell surface CD3 complex (cs-CD3) in association with the endogenous or transgenic TCRP in the cells, but also contributes to the directed differentiation of iPSC into functional derivative effector cells including T cells. [000145] Design 4: Non-binding recombinant TCR anchored CD3 (nb-rTCR-CD3) [000146] As presented in FIG. IB, in this Design 4, one or both endogenous TCRa and endogenous TCRP are knocked out (TCRneg; TCRa' / _ and TCRP' / _) in a cell using a genomic editing tool. Simultaneously with, or subsequently to, the TCR knockout, exogenous polynucleotides are introduced to said TCRnegcell, which comprise: a first polynucleotide encoding a recombinant TCRa comprising a TCRa constant region, full or partial length ectodomains of CD3s and one of CD36 and CD3y; and / or a second polynucleotide encoding a recombinant TCRP comprising a TCRP constant region, full or partial length of ectodomains of CD3s and one of CD36 and CD3y that is not comprised in the recombinant TCRa; such that one heterodimer between CD3s and CD36 encoded by one polynucleotide, and / or another heterodimer between CD3s and CD3y encoded by another polynucleotide could form at cell surface. [000147] In some embodiments, the recombinant TCRa comprises a full or partial TCRa constant region at the C-terminal, fused with full or partial length of CD3s and CD36 ectodomains at the N-terminal(tgCD3(s-6)-TRAC). In some embodiments, the recombinant TCRa comprises a full or partial TCRa constant region at the C-terminal, fused with full or partial length of ectodomains of CD3s and CD3y at the N-terminal (tgCD3(s-y)-TRAC). In some embodiments, the recombinant TCRP comprises a full or partial TCRP constant region at the C-terminal, fused with full or partial length of ectodomains of CD3s and CD3y at the N-terminal (tgCD3(s-y)-TRBC). In some embodiments, the recombinant TCRP comprises a full or partial TCRP constant region at the C-terminal, fused with full or partial length of ectodomains of CD3s and CD36 at the N-terminal (tgCD3(s-6)-TRBC). In some embodiments of the polynucleotide encoding a full length of TCRa or TCRP constant region, the polynucleotide further comprises a polyAtail at the C-terminal. In some embodiments of the polynucleotide encoding a partial length of TCRa or TCRP constant region, the integration of the polynucleotide is at a site within the respective endogenous constant region and is in-frame with the remaining endogenous sequence of TCRa or TCRP constant region downstream of the integration site, such that a full length transgenic / chimeric TRAC or TRBC is formed with a part of its sequence being exogenous / transgenic and another part being endogenous. [000148] In some other embodiments, where both of the first and the second polynucleotide are introduced to a cell, the recombinant TCRa is encoded by the first polynucleotide comprising tgCD3(s-6)-TRAC, and the recombinant TCRP is encoded by the second polynucleotide comprising tgCD3(s-y)-TRBC; or the recombinant TCRa is encoded by the first polynucleotide comprising tgCD3(s-y)-TRAC, and the recombinant TCRP is encoded by the second polynucleotide comprising tgCD3(s-6)-TRBC. As such, in said embodiments, one heterodimer between CD3s and CD36 encoded by one polynucleotide and another heterodimer between CD3s and CD3y encoded by another polynucleotide could form at the cell surface. [000149] In some embodiments, where only one of the first and the second polynucleotides is introduced to a cell, the other TCR subunit is either wildtype / endogenous or is engineered to comprise only a constant region with its endogenous variable region removed with or without being replaced with a defined variable region: for example, tgTRAC or tgTRBC of Design 1 in FIG. 1A (without variable region), or tgTCRa or tgTCRP of Design 2 in FIG. 1A (with a defined variable region). As such, as shown in Design 4 of FIG. IB, in one embodiment where a first polynucleotide comprising tgCD3(s-6)-TRAC is introduced to a cell to provide a recombinant TCRa subunit, another polynucleotides comprising tgTRBC or tgTCRP is also introduced to the cell to provide a recombinant TCRP subunit; such that in this embodiment, one heterodimer between endogenous CD3s and endogenous CD3y, and another heterodimer between CD3s and CD36 encoded by the polynucleotide comprising tgCD3(s-6)-TRAC could be formed at cell surface. In yet another embodiment of Design 4 of FIG. IB, where a second polynucleotide comprising tgCD3(s-y)-TRBC is introduced to a cell to provide a recombinant TCRP subunit, another polynucleotide comprising tgTRAC or tgTCRa is also introduced to the cell to provide a recombinant TCRa subunit, such that one heterodimer between endogenous CD3s and endogenous CD36, and another heterodimer between CD3s and CD3y encoded by the polynucleotide comprising tgCD3(s-y)-TRBC could be formed at cell surface. [000150] In some embodiments, the first polynucleotide is driven by an endogenous promoter of TCRa, whereas in some other embodiments, the first polynucleotide is driven by an exogenous promoter. In some embodiments, the second polynucleotide is driven by an endogenous promoter of TCRP, whereas in some other embodiments, the second polynucleotide is driven by an exogenous promoter. In some embodiments, the exogenous promoter for either recombinant TCRa or recombinant TCRP comprises a constitutive, inducible, temporal-, tissue-, or cell type- specific promoter. In some embodiments, the exogenous promoter comprises one of CMV, EFla, PGK, CAG, and UBC. In one embodiment, the exogenous promoter comprises at least CAG. In some embodiments, the polynucleotide encoding a TCRa constant region comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 1. In some embodiments, the polynucleotide encoding a TCRP constant region comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 2 or SEQ ID NO. 3. In some embodiments, the polynucleotide encoding a full or partial length of CD3s ectodomain comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 25. In some embodiments, the polynucleotide encoding a full or partial length of CD36 ectodomain comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 26. In some embodiments, the polynucleotide encoding a full or partial length of CD3y ectodomain comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage inbetween, when compared to the exemplary sequence, SEQ ID NO. 27. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. In some embodiments of a polynucleotide encoding a full or partial length of CD3s, CD36, or CD3y ectodomain, the polynucleotide further comprises nucleic acids encoding a signal peptide. In some embodiments, the signal peptide comprises one of SEQ ID NO. 28, SEQ ID NO. 29, SEQ ID NO. 30, or any other signal peptide known in the art. In some embodiments of a polynucleotide encoding a full or partial length of CD3s ectodomain, the polynucleotide further comprises nucleic acids encoding a signal peptide of SEQ ID NO. 28. In some embodiments of a polynucleotide encoding a full or partial length of CD36 ectodomain, the polynucleotide further comprises nucleic acids encoding a signal peptide of SEQ ID NO. 29. In some embodiments of a polynucleotide encoding a full or partial length of CD3y ectodomain, the polynucleotide further comprises nucleic acids encoding a signal peptide of SEQ ID NO. 30. SEQ ID NO. 25 DGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQS GYYVCYPRGSKPEDANFYLYLRARVCENCMEMD (ecto- CD3s) SEQ ID NO. 26 FKIPIEELEDRVFVNCNTSITWVEGTVGTLLSDITRLDLGKRILDPRGIYRCNGTDIYKDKESTVQVHYRM CQSCVELDPATVA (ecto- CD36) SEQ ID NO. 27 QSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNK S KPLQVYY RMCQNCIELNAATIS (ecto-CD3y) SEQ ID NO. 28 MQSGTHWRVLGLCLLSVGVWGQ SEQ ID NO. 29 MEHSTFLSGLVLATLLSQVSP SEQ ID NO. 30 MEQGKGLAVLILAIILLQGTLA [000151]   In some embodiments of a polynucleotide encoding tgCD3(s-6)-TRAC fusion protein, the polynucleotide comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 31, wherein each of the two linker sequences (SEQ ID NO. 33 and SEQ ID NO. 34) comprised in SEQ ID NO. 31 may be replaced with any that is known in the art. In some embodiments of a polynucleotide encoding tgCD3(s-y)-TRBC fusion protein, the polynucleotide comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 32, wherein each of the two linker sequences (SEQ ID NO. 33 and SEQ ID NO. 34) comprised in SEQ ID NO. 32 may be replaced with any that is known in the art. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. In some embodiments of a recombinant TCRa or TCRP fusion protein, as provided herein, the fusion protein further comprises a signal peptide known in the art. One non-limiting exemplary signal peptide comprises a peptide represented by SEQ ID NO. 28. SEQ ID NO. 31 DGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQS GYYVCYPRGSKPEDANFYLYLRARVGSADDAKKDAAKKDDAKKDDAKKDGSFKIPIEELEDRVFVNCNTSI TWVEGTVGTLLSDITRLDLGKRILDPRGIYRCNGTDIYKDKESTVQVHYRMGGGGSGGGGSGGGGSIQNPD PAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAF NNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS (N’-CD3s-linker-CD35-G4S linker-TRAC-C’) SEQ ID NO. 32 DGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQS GYYVCYPRGSKPEDANFYLYLRARVGSADDAKKDAAKKDDAKKDDAKKDGSQSIKGNHLVKVYDYQEDGSV LLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMGGGGSGGGGS GGGGSDLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQP ALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSY QQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF (N’-CD3s-linker-CD3v-G4S linker-TRBC-C’) SEQ ID NO. 33 GSADDAKKDAAKKDDAKKDDAKKDGS SEQ ID NO. 34 GGGGSGGGGSGGGGS [000152] In this application, it is discovered that a TCRa or TCRP constant region fused with ectodomains of CD3s, and one of CD36 and CD3y is capable of associating with a transgenic TCRP or TCRa constant region with or without fused ectodomains of CD3s, and one of CD36 and CD3y, to form CD3s / CD36 and CD3s / CD3y heterodimers. The associated transgenic TCRa and TCRP subunits is capable of further associating with endogenous CD3(^ to support the cell surface expression of CD3 ectodomains (cs-CD3) and signaling transduction through the endogenous CD3(^, while having no peptide-MHC binding potential. As such, in view of Design 4, provided herein is a cell or a population thereof, wherein the cell is an iPSC, a clonal iPSC, a clonal iPS cell line cell, or a derivative cell obtained from differentiating said iPSC; and the cell comprises: a disruption at each of an endogenous TCRa constant region and an endogenous TCRP constant region, and at least one of a first exogenous polynucleotide encoding a tgTCRa comprising fused full or partial TCRa constant region, and full or partial ectodomains of CD3s and one of CD36 and CD3y (tgCD3(s-6 / y)-TRAC); and a second exogenous polynucleotide encoding a tgTCRP comprising fused full or partial TCRP constant region, and full or partial ectodomains of CD3s and one of CD36 and CD3y (tgCD3(s-y / 6)-TRBC); wherein the ectodomains of CD3 subunits are present at the cell surface (cs-CD3) when expressed; when only said first exogenous polynucleotide is comprised in the cell, the cell further comprises a tgTRBC or tgTCRP as provided herein; and when only said second exogenous polynucleotide is comprised in the cell, the cell further comprises a tgTRAC or tgTCRa as provided herein. [000153] Design 5: CD3 chimeric chain (ccCD3) [000154] As presented in FIG. IB, in this Design 5, a cell surface presented CD3 (cs-CD3) is in a form of a CD3 chimeric chain (ccCD3), which is constructed to comprise a full or partial length of CD3s ectodomain, a full or partial length of ectodomain of either CD3y or CD36, and a full or partial length of endodomain of CD3(^ comprising at least one ITAM (immunoreceptor tyrosine-based activation motif). Cells comprising a polynucleotide encoding said CD3 chimeric chain may further comprise disruption at either or both of endogenous TCRa and TCRp. When a genomic editing tool is used to generate TCRneg cells by targeted editing of TRAC and / or TRBC, simultaneously with or subsequently to the TCR knockout, at least one polynucleotide encoding 57 said CD3 chimeric chain is introduced to the cell. In some embodiments, the said polynucleotide is introduced to TRAC or TRBC, and is respectively driven by an endogenous promoter of TCRa or TCRP; whereas in some other embodiments, the introduced polynucleotide is driven by an exogenous promoter. In some embodiments, the exogenous promoter comprises a constitutive, inducible, temporal-, tissue-, or cell type- specific promoter. In some embodiments, the exogenous promoter comprises one of CMV, EFla, PGK, CAG, and UBC. In one embodiment, the exogenous promoter comprises at least CAG. [000155] In some embodiments, the CD3 chimeric chain comprises a full or partial length of CD3s ectodomain, a full or partial length of ectodomain of CD3y, and a full or partial length of endodomain of CD3(^ comprising at least one ITAM (tgCD3(s-y)-Q, wherein the CD3 chimeric chain is a fusion protein with either ectodomain at the N-terminal, and wherein the two ectodomains form a heterodimer. In some embodiments, the CD3 chimeric chain comprises a full or partial length of CD3s ectodomain, a full or partial length of ectodomain of CD36, and a full or partial length of endodomain of CD3(^ comprising at least one ITAM (tgCD3(s-6)-O, wherein the CD3 chimeric chain is a fusion protein with either ectodomain at N-terminal, and wherein the two ectodomains form a heterodimer. In some embodiments of the CD3 chimeric chain, the endodomain of CD3(^ comprises two ITAMs. In some embodiments of the CD3 chimeric chain, the endodomain of CD3(^ comprises all three ITAMs. [000156] In some embodiments, the polynucleotide encoding a full or partial length of CD3s ectodomain comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 25. In some embodiments, the polynucleotide encoding a full or partial length of CD36 ectodomain comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage inbetween, when compared to the exemplary sequence, SEQ ID NO. 26. In some embodiments, the polynucleotide encoding a full or partial length of CD3y ectodomain comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 27. In some embodiments of a polynucleotide encoding a full or partial length of CD3s, CD36, or CD3y ectodomain, the polynucleotide further comprises nucleic acids encoding a signal peptide. In some embodiments, the signal peptide comprises one of SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 30, or any other signal peptide known in the art. In some embodiments of a polynucleotide encoding a full or partial length of CD3s ectodomain, the polynucleotide further comprises nucleic acids encoding a signal peptide of SEQ ID NO. 28. In some embodiments of a polynucleotide encoding a full or partial length of CD36 ectodomain, the polynucleotide further comprises nucleic acids encoding a signal peptide of SEQ ID NO. 29. In some embodiments of a polynucleotide encoding a full or partial length of CD3y ectodomain, the polynucleotide further comprises nucleic acids encoding a signal peptide of SEQ ID NO. 30. In some embodiments, the polynucleotide encoding a full or partial length of CD3(^ endodomain comprises at least a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 35, which comprises CD3i; ITAMI, ITAM2, and ITAM3 (SEQ ID NOs. 36-38). In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. SEQ ID NO. 35 MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSADAPAYQQGQNQL YUEI^EGRREEYDVEDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQ GLSTATKDTYDALHMQKLP P R ( ITAMI ITAM2 ITAM3 ) SEQ ID NO. 36 APAYQQGQNQLYNELNLGRREEYDVLDKR SEQ ID NO. 37 PRRKNPQEGLYNELQKDKMAEAYSEIGM SEQ ID NO. 38 E RRRGKGH DGLY QGL S TAT KDT Y DAL HMQ [000157] In some embodiments of the CD3 chimeric chain, the endodomain of CD3(^ comprising at least one, two, or three ITAMs further comprises one or more signaling domains of 2B4, 4-1BB, CD16, CD2, CD28, CD28H, CD3i; DAP10, DAP12, DNAM1, FcERIy IL21R, IL-2Rp (IL-15Rp), IL-2Ry, IL-7R, KIR2DS2, NKG2D, NKp30, NKp44, NKp46, CD3i;iXX, CS1, or CD8 for signal transduction and / or co-stimulation. In one embodiment of the CD3 chimeric chain, the endodomain of CD3(^ comprising at least one, two, or three ITAMs further comprises at least a signaling domain of CD28 (tgCD3(s- y / 5)-28Q. In some embodiments of the CD3(^ endodomain comprising the signaling domain of CD28, the polynucleotide encoding a full or partial length of 28(^ endodomain comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 39, from which any one or two CD3(^ ITAMs may be removed. In some embodiments of the CD3 chimeric chain, the endodomain of CD3(^ comprising at least one, two, or three ITAMs further comprises a signaling domain of 4IBB (tgCD3(s- y / 6)-BBQ. In some embodiments of the CD3(^ endodomain comprising the signaling domain of 4IBB, the polynucleotide encoding a full or partial length of BB(^ endodomain comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 40, from which any one or two CD3(^ ITAMs may be removed. In some embodiments of the CD3 chimeric chain, the endodomain of CD3(^ comprising at least one, two, or three ITAMs further comprises a signaling domain of CD28 and a signaling domain of 4IBB (tgCD3(s- y / 6)-(28-BB)Q. In some embodiments of the CD3(^ endodomain comprising the signaling domain of both 28 and 4 IBB, the polynucleotide encoding a full or partial length of 28BB(^ endodomain comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 41, from which any one or two CD3(^ ITAMs may be removed. In one embodiment of the polynucleotide encoding tgCD3(s-y)-(28 / BB)^, the encoded polypeptide comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to the exemplary sequence, SEQ ID NO. 42; from which any one or two CD3(^ ITAMs may be removed, from which the linker sequence may be replaced with any other linker sequence known in the art, or from which the CD28 signaling domain may be replaced with, or enhanced by adding, the 4IBB signaling domain in yet some other embodiment. In one embodiment of tgCD3(s-6)-(28 / BB)^, the encoded polypeptide comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage inbetween, when compared to the exemplary sequence, SEQ ID NO. 43; from which any one or two CD3(^ ITAMs may be removed, from which the linker sequence may be replaced with any other linker sequence known in the art, or from which the CD28 signaling domain may be replaced by, or enhanced via further including, the 4IBB signaling domain in yet some other embodiment. In some other embodiments of the encoded CD3 chimeric chain tgCD3(s-y)-(28 / BB)(^ or tgCD3(s-6)-(28 / BB)^, the polypeptide further comprises a signal peptide of SEQ ID NO. 28, or any other signal peptide known in the art. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. SEQ ID NO. 39 RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRRE EYDVEDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY DALHMQKLPPR ( ITAMI ITAM2 ITAM3 ) SEQ ID NO. 40 KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRR EEYDVLDKRRGRDPEMGGKFRRKNPQEGLYNELQKDKMAEAYSEZGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQAEPPR ( ITAMI ITAM2 ITAM3 ) SEQ ID NO. 41 RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSKRGRKKLLYIFKQPFMRPVQTTQEEDGCSC RFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKWPQEGZY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQKLP P R ( ITAMI ITAM2 ITAM3 ) SEQ ID NO. 42 DGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQS GYYVCYPRGSKPE DAN FY LY L RARVGSADDAKKDAAKKDDAKKDDAKKDGSQSIKGNHLVKVYDYQEDGSV LLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMPJYEAIEVMYP PPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVWGGVLACYSLLVTVAFIIFWVRSKRSRLLHSD YMNMTPRRPGPTRKHYQP YAPPRDFAAYRSRVE F S RS ADAPAYQQGQNQLYNELNLGRREEYDVLDKRRG R DPEMGGEPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQKLP P R (CD3&-ljr^er-CD3y-CD28-CD3^ (. ITAMI . .ITAM2.. IT AM3 ..)) SEQ ID NO. 43 DGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQS GYYVCYPRGSKPE DAN FY LY L RARVGSADDAKKDAAKKDDAKKDDAKKDGSFKIPIEELEDRVFVNCNTSI TWVEGTVGTLLSDITRLDLGKRILDPRGIYRCNGTDIYKDKESTVQVHYRMPJYAAIEVMYPPPYLDNEKSN GTIIHVKGKHLCPSPLFPGPSKPFWVLVWGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPPRPG FTRKHyQPYAPFKDFAAYRSRVKFSRSADAPAYQQG^JQLYNELNLGRREEYDVWKRRGRDPEMGGKPRR KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQKLP P R (CD3s4mker-CD3d-CD28-CD3C (.. ITAMI . .ITAM2.. ITAM3 ..)) [000158] In this application, it is discovered that a CD3 chimeric chain as provided herein, wherein the CD3 chimeric chain is a fusion protein comprising a full or partial length of CD3s ectodomain, at least one of CD36 and CD3y full or partial length ectodomain, and a CD3(^ endodomain comprising at least one ITAM and optionally one or more signaling domain, is capable of presenting the chimeric CD3 ectodomain to cell surface when expressed in the cell that is TCRneg. Further the cell surface expression of CD3 ectodomains enables CD3 binding triggered signaling transduction through fused CD3(^ endodomain while having no peptide-MHC binding potential. [000159] As such, in view of Design 5, provided herein is a cell or a population thereof, wherein the cell is an iPSC, a clonal iPSC, a clonal iPS cell line cell, or a derivative cell obtained from differentiating the iPSC; and the cell comprises: a disruption of at least one of an endogenous TCRa constant region and an endogenous TCRP constant region, and at least an exogenous polynucleotide encoding a CD3 chimeric chain fusion protein (ccCD3), wherein the fusion protein comprises a full or partial length of ectodomain of CD3s, and a full or partial length ectodomain of either one of CD36 and CD3y, and a full or partial length of endodomain of CD3(^ having at least one ITAM and optionally one or more signaling domain, wherein the ectodomains of the CD3 chimeric chain are present at the cell surface (cs-CD3) when expressed. [000160] The cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) in a TCRneg cell (TCRneg cs-CD3) as disclosed herein in the various designs of FIGS. 1A-C can function as a CD3 related cell surface triggering receptor for binding with molecules including, not limited to, CD3 specific antibodies or functional variants thereof, CARs, and / or engagers, which are further described below. As provided further, the said TCRneg cs-CD3 cell, or a population thereof may further comprise one or more of: hnCD16 knock-in; a CAR; a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof; B2M knockout or knockdown; CIITA knockout or knockdown; an introduced expression of HLA-G or non-cleavable HLA-G; CD38 knockout, and additional engineered modalities described herein. Further provided in this application is a master cell bank comprising single cell sorted and expanded clonal engineered iPSCs having at least one phenotype as provided herein, including but not limited to, TCRneg cs-CD3, CD16, CAR, CD38 negative, IL15 (fusion protein with receptor or truncated variants), B2M'7' CIITA'7', and B2M'7' CIITA'7' HLA-G, wherein the cell bank provides a platform for additional iPSC engineering and a renewable source for manufacturing off-the-shelf, engineered, homogeneous cell therapy products, which are well-defined and uniform in composition, and can be mass produced at significant scale in a costeffective manner. 2. hnCD 16 knock-in [000161] CD16 has been identified as two isoforms, Fc receptors FcyRIIIa (CD16a; NM_000569.6) and FcyRIIIb (CD16b; NM_000570.4). CD16a is a transmembrane protein expressed by NK cells, which binds monomeric IgG attached to target cells to activate NK cells and facilitate antibody-dependent cell-mediated cytotoxicity (ADCC). CD 16b is exclusively expressed by human neutrophils. “High affinity CD 16,” “non-cleavable CD 16,” or “high affinity non-cleavable CD 16,” as used herein, refers to various CD 16 variants. The wildtype CD 16 has low affinity and is subject to down regulation including ectodomain shedding, a proteolytic cleavage process that regulates the cells surface density of various cell surface molecules on leukocytes upon NK cell activation. F176V (also called F158V in some publications) is an exemplary CD 16 polymorphic allele / variant having high affinity; whereas S197P variant is an example of genetically engineered non-cleavable version of CD 16. An engineered CD 16 variant comprising both Fl76V and S197P has high affinity and is non-cleavable, which was described in greater detail in WO2015 / 148926, and the complete disclosure of which is incorporated herein by reference. In addition, a chimeric CD 16 receptor with the ectodomain of CD 16 essentially replaced with at least a portion of CD64 ectodomain can also achieve the desired high affinity and non-cleavable features of a CD 16 receptor capable of carrying out ADCC. In some embodiments, the replacement ectodomain of a chimeric CD 16 comprises one or more of ECI, EC2, and EC3 exons of CD64 (UniPRotKB_P12314 or its isoform or polymorphic variant). [000162] As such, a high-affinity non-cleavable CD 16 receptor (hnCD16), in some embodiments, comprises both Fl76V and S197P; and in some embodiments, comprises Fl76V and with the cleavage region eliminated. In some other embodiments, a hnCD16 comprises a sequence having identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any percentage in-between, when compared to any of the exemplary sequences, SEQ ID NOs. 7, 8 and 9, each comprises at least a portion of CD64 ectodomain. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. SEQ ID NOs. 7, 8 and 9 are encoded respectively by exemplifying SEQ ID NOs. 10-12. As used herein and throughout the application, the percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions / total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm recognized in the art. SEQ ID NO. 7: MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYR ITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYYRNGK AFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTSPLLEGNLVTLSCE TKLLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQ LPTPVWFHYQVSFCL VMVLLFAVDTGLYFSVKTNTRSSTRDWKDHKFKWRKDPQDK (340 a.a. CD64 domain-based construction; CD16TM; CD16ICD} SEQ ID NO. 8 MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYR ITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYYRNGK AFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTSPLLEGNLVTLSCE TKLLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLF F P P G Y Q VSFCL VMVLLFAVDTGLYFSVKTNIRSSTRDWKDHKFKWRKDPQDK (336 a.a. CD64 exon-based construction; CD16TM; CD16ICD} SEQ ID NO. 9 MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGFFP PGYQVSFCL VMVLLF AVDTGLYFSVKTNTRSSTRDWKDHKFKWRKDPQDK (335 a.a. CD64 exon-based construction; CD16TM; CD16ICD} SEQ ID NO. 10 cttggagaca gtggacacca gaaaccgtaa tttctcaatg gtcaatgaca cagctggaaa ggagaacctc tactatcgaa aaaaccaaca acatcagcag tctgtgacat ctcttgcaga cgaggcagga ttatactggt gagcttcaag ttctgcttgg acaaacattc cctcaagaca acatgtggtt caaaggcagt ccttgcattg gcacagccac gtggtgaata tccacagagg tggccttgag atggcaaagc taagtcacaa gaatatctgt ccccactcct ggcctggttt acacatcctc gcgaggctgc tgcttggcct tgatggtact gaagctcaac aa cttgacaact gatcactttg tgaggtgctc tcagacctcg caggtgccag ctggctacta gtgtcatgcg ctttaagttt tggcacctac cactgtgaaa ggaggggaat gcagctttac tgaataccaa cacagaggat ccagttacca cctttttgca aagagactgg ctgctccttt cagcctccat catctgcctg acccccagct agaggtctct ctgcaggtct tggaaggata ttccactgga cattgctcag gagctatttc ctggtcaccc ttctccttct atactaactg ggaaatgtcc actcctgtct gtggacacag aaggaccata gggttccagt gggtcagcgt ggagcagctc acagaatcac cagggcgaag ccagcagagt agctggtgta attctaacct gcatgggaaa cagctccagt tgagctgtga acatgggcag ctagaagaga ttaagcgcag ggtttcatta gactatattt aatttaaatg tgatgggcaa gttccaagag tacacagtgg ctctgccagt tgaccccata cttcacggaa caatgtgctt caccattctg gcatcgctac gctgaatgca aacaaagttg caagaccctg agactctggg ccctgagttg ccaagtctct ctctgtgaag gagaaaggac SEQIDNO. 11 cttggagaca gtggacacca gaaaccgtaa tttctcaatg gtcaatgaca cagctggaaa ggagaacctc tactatcgaa si a. d a c a a d acatcagcag tctgtgacat ctcttgcaga cgaggcagga ttatactggt gagcttcaag atggtactcc agctcaacaa acatgtggtt caaaggcagt ccttgcattg gcacagccac gtggtgaata tccacagagg tggccttgag a ll ci q c a. a a of c taagtcacaa gaatatctgt ccccactcct ggcctggttt acacatcctc gcgaggctgc tgcttggttt tttttgcagt g a. g a c b g g a ci cttgacaact gatcactttg tgaggtgctc t Cdg d C C t CQ caggtgccag ctggctacta gtgtcatgcg ctttaagttt tggcacctac cactgtgaaa ggaggggaat gcagctttac tgaataccaa cacagaggat gttctttcca ggacacagga ggaccataaa ctgctccttt cagcctccat c a t c t g c c t g d C C C C C a. Q CL agaggtctct ctgcaggtct tggaaggata ttccactgga catrgctcaa gagctatttc ctggtcaccc ttctccttct atactaactg ggaaatgtcc cctgggtacc ctatatttct tttaaatgga gggttccagt gggtcagcgt ggagcagctc acagaatcac cagggcgaag ccagcagagt agctggtgta attctaacct gcatgggaaa cagctccagt tgagctgtga acatgggcag c r a g a a g a q a ttaagcgcag aagtctcttt ctgtgaagac gaaaggaccc t g a t g g g c a a gttccaagag tacacagtgg ctctgccagt tgaccccata cttcacggaa caatgtgctt caccattctg gcatcgctac gctgaatgca aacaaagttg caagaccctg agactctggg ccctgagttg ctgcttggtg aaacattcga tcaagacaaa SEQ ID NO. 12 atgtggttct aaggcagtga ttgcactgtg acagccactc ggtgaataca cacagaggct gccttgaggt ggcaaagcct agtcacaatg atatctgtca ccactcctgg cctggtttgc acatcctctg gaggctgcca cttggcttct gcagtggaca tggaaggacc igacaactci tcactttgca aggtgctcca a c? a c c t c g a. c ggtgccagag ggctactact gtcatgcgtg ttaagttttt cjcacctacca ctgtgaaaga aggggaatct agctttactt a a c a c c a a a c cagaggatgg ttccacctgg caggactata ataaatttaa gctcctttgg gcctccatgg tctgcctggg ccccagctac aggtctctca gcaggtctcc gaaggataag ccactggaac ttgctcaggc gctatttcca ggtcaccctg ctccttctac actaactgct aaatgtcctt gtaccaagtc tttctctgtg atggagaaag gttccagttg gtcagcgtgt agcagctcta a g a a c. c a c c c gggcgaagtg agcagagtct ctggtgtaca tctaacctca atgggaaagc gctccagtgc agctgtgaaa atgggcagca agaagagaag aagcgcagcc tctttctgct a a g a c a a a c a. gaccotcaag atgggcaagt tccaagagga cacagtggtt ctgccagtgt accccataca ggacaccaca aaccgtaacc tctcaatggc caatgacagt gctggaaatc agaacctctg c t a t c g a a a t aaccaacata atcagcagga tgtgacatcc cttgcagagg aggcaggaac atactggtgc gcttcaagtg actccttttt aacaagagac [000163] Accordingly, provided herein are clonal iPSCs genetically engineered to comprise, among other editing as contemplated and described herein, a high-affinity non-cleavable CD 16 receptor (hnCD16), wherein the genetically engineered iPSCs are capable of differentiating into effector cells comprising the hnCD16 introduced to the iPSCs. In some embodiments, the derived effector cells comprising hnCD16 are NK cells. In some embodiments, the derived effector cells comprising hnCD16 are T cells. The exogenous hnCD16 expressed in iPSC or derivative cells therefrom has high affinity in binding to not only ADCC antibodies or fragments thereof, but also to bi-, tri-, or multi- specific engagers or binders that recognize the CD 16 or CD64 extracellular binding domains of said hnCD16 and variants thereof. The bi-, tri-, or multispecific engagers or binders are further described below in this application (see section 1.7). As such, at least one of the aspects of the present application provides a derivative effector cell or a cell population thereof preloaded with one or more pre-selected ADCC antibody through high-affinity binding with the extracellular domain of the hnCD16 expressed on the derivative effector cell, in an amount sufficient for therapeutic use in a treatment of a condition, a disease, or an infection as further detailed in section V. below, wherein said hnCD16 comprises an extracellular binding domain of CD64, or of CD 16 having Fl76V and S197P. [000164] In some other embodiments, the native CD 16 transmembrane- and / or the intracellular- domain of a hnCD16 is further modified or replaced, such that a chimeric Fc receptor (CFcR) is produced to comprise a non-native transmembrane domain, a non-native stimulatory domain and / or a non-native signaling domain. The term “non-native” used herein means that the transmembrane, stimulatory or signaling domain are derived from a different receptor other than the receptor which provides the extracellular domain. In the illustration here, the CFcR based on CD 16 or variants thereof does not have a transmembrane, stimulatory or signaling domain that is derived from CD 16. In some embodiments, the exogenous hnCD16 based CFcR comprises a non-native transmembrane domain derived from CD3D, CD3E, CD3G, CD3^, CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, OX40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL12,1L15, KIR2DL4, KIR2DSL NKp30, NKp44. NKp46, NKG2C, NKG2D, T cell receptor polypeptide. In some embodiments, the exogenous hnCD16 based CFcR comprises a non-native stimulatory / inhibitory domain derived from CD27, CD28, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, orNKG2D polypeptide. In some embodiments, the exogenous hnCD16 based CFcR comprises a non-native signaling domain derived from CD3(^, 2B4, DAP 10, DAP 12, DNAM1, CD137 (41BB), 11.21, IL7, IL12, ILLS, \Kp30, NKp44, NKp46, NKG2C, or NKG2D polypeptide. In one embodiment of hnCD16, the provided chimeric receptor comprises a transmembrane domain and a signaling domain both derived from one of IL7, IL J 2, IL LS, NKp30, NKp44, NKp46, NKG2C, and NKG2D polypeptide. One particular embodiment of the hnCD16 based chimeric Fc receptor comprises a transmembrane domain of NKG2D, a stimulatory domain of 2B4, and a signaling domain of CD3(^; wherein the extracellular domain of the hnCD16 is derived from a full length or partial sequence of the extracellular domain of CD64 or CD 16, wherein the extracellular domain of CD 16 comprises Fl 76 V and S197P. Another embodiment of the hnCD16 based chimeric Fc receptor comprises a transmembrane domain and a signaling domain of CD3(^; wherein the extracellular domain of the hnCD16 is derived from a full length or partial sequence of the extracellular domain of CD64 or CD 16, wherein the extracellular domain of CD 16 comprises Fl76V and S197P. [000165] The various embodiments of hnCD16 based chimeric Fc receptor as described above are capable of binding, with high affinity, to the Fc region of an antibody or fragment thereof; or to the Fc region of a bi-, tri-, or multi- specific engager or binder. Upon binding, the stimulatory and / or signaling domains of the chimeric receptor enable the activation and cytokine secretion of the effector cells, and the killing of the tumor cells targeted by the antibody, or said bi-, tri-, or multi- specific engager or binder having a tumor antigen binding component as well as the Fc region. Without being limited by theory, through the non-native transmembrane, stimulatory and / or signaling domains, or through an engager binding to the ectodomain, of the hnCD16 based chimeric Fc receptor, the CFcR could contribute to effector cells’ killing ability while increasing the effector cells’ proliferation and / or expansion potential,. The antibody and the engager can bring tumor cells expressing the antigen and the effector cells expressing the CFcR into a close proximity, which also contributes to the enhanced killing of the tumor cells. Exemplary tumor antigen for bi-, tri-, multi- specific engager or binders include, but are not limited to, B7H3, BCMA, CD10, CD19, CD20, CD22, CD24, CD30, CD33, CD34, CD38, CD44, CD79a, CD79b, CD 123, CD 138, CD 179b, CEA, CLEC12A, CS-1, DLL3, EGFR, EGFRvIII, EPCAM, FLT-3, FOLRI, FOLR3, GD2, gpA33, HER2, HM1.24, LGR5, MSLN, MCSP, MICA / B, PSMA, PAMA, P-cadherin, and R0R1. Some non-limiting exemplary bi-, tri-, multi- specific engager or binders suitable for engaging effector cells expressing the hnCD16 based CFcR in attacking tumor cells include CD16 (or CD64)-CD30, CD16 (or CD64)-BCMA, CD16 (or CD64)-IL 15-EPCAM, and CD16 (or CD64)-IL15-CD33. [000166] Unlike the endogenous CD 16 receptor expressed by primary NK cells which gets cleaved from the cellular surface following NK cell activation, the various non-cleavable versions of CD 16 in derivative NK avoids CD 16 shedding and maintains constant expression. In derivative NK cell, non-cleavable CD16 increases expression of TNFa and CD107a indicative of improved cell functionality. Non-cleavable CD 16 also enhances the antibody-dependent cell-mediated cytotoxicity (ADCC), and the engagement of bi-, tri-, or multi- specific engagers. ADCC is a mechanism of NK cell mediated lysis through the binding of CD16 to antibody-coated target cells. The additional high affinity characteristics of the introduced hnCD16 in derived NK cell also enables in vitro loading of ADCC antibody to the NK cell through hnCD16 before administering the cell to a subject in need of a cell therapy. As provided, the hnCD16 may comprise Fl76V and S197P in some embodiments, or may comprise a full or partial ectodomain originated from CD64 as exemplified by SEQ ID NO: 7, 8 or 9, or may further comprises at least one of non-native transmembrane domain, stimulatory domain and signaling domain. As disclosed, the present application also provides a derivative NK cell or a cell population thereof, preloaded with one or more pre-selected ADCC antibody in an amount sufficient for therapeutic use in a treatment of a condition, a disease, or an infection as further detailed in section V. below. [000167] Unlike primary NK cells, mature T cells from a primary source (i.e., natural / native sources such as peripheral blood, umbilical cord blood, or other donor tissues) do not express CD 16. It was unexpected that iPSC comprising an expressed exogenous non-cleavable CD 16 did not impair the T cell developmental biology and was able to differentiate into functional derivative T cells that not only express the exogenous CD 16, but also are capable of carrying out function through an acquired ADCC mechanism. This acquired ADCC in the derivative T cell can additionally be used as an approach for dual targeting and / or to rescue antigen escape often occurred with CAR-T cell therapy, where the tumor relapses with reduced or lost CAR-T targeted antigen expression or expression of a mutated antigen to avoid recognition by the CAR (chimerical antigen receptor). When said derivative T cell comprises acquired ADCC through exogenous CD 16 expression, and when an antibody targets a different tumor antigen from the one targeted by the CAR, the antibody can be used to rescue CAR-T antigen escape and reduce or prevent relapse or recurrence of the targeted tumor often seen in CAR-T treatment. Such a strategy to reduce and / or prevent antigen escape while achieving dual targeting is equally applicable to NK cells expressing one or more CARs. The various CARs that can be used in this antigen escape reduction and prevention strategy is further delineated below. [000168] As such, the present invention provides a derivative T cell comprising an exogenous CD 16. In some embodiments, the hnCD16 comprised in the derivative T cell comprises Fl76V and S197P In some other embodiments, the hnCD16 comprised in the derivative T cell comprises a full or partial ectodomain originated from CD64 as exemplified by SEQ ID NO: 7, 8 or 9; or may further comprises at least one of non-native transmembrane domain, stimulatory domain and signaling domain. As explained, such derivative T cells have an acquired mechanism to target tumors with a monoclonal antibody meditated by ADCC to enhance the therapeutic effect of the antibody. As disclosed, the present application also provides a derivative T cell, or a cell population thereof, preloaded with one or more pre-selected ADCC antibody in an amount sufficient for therapeutic use in a treatment of a condition, a disease, or an infection as further detailed in section V. below. [000169] Additionally provided in this application is a master cell bank comprising single cell sorted and expanded clonal engineered iPSCs having at least one phenotype as provided herein, including but not limited to, CD 16, wherein the cell bank provides a platform for additional iPSC engineering and a renewable source for manufacturing off-the-shelf, engineered, homogeneous cell therapy products, including but not limited to derivative NK and T cells, which are well-defined and uniform in composition, and can be mass produced at significant scale in a cost-effective manner. 3. CAR expression [000170] Applicable to the genetically engineered iPSC and derivative effector cell thereof may be any CAR design known in the art. CAR, a chimerical antigen receptor, is a fusion protein generally including an ectodomain that comprises an antigen recognition region, a transmembrane domain, and an endo-domain. In some embodiments, the ectodomain can further include a signal peptide or leader sequence and / or a spacer. In some embodiments, the endodomain can further comprise a signaling peptide that activates the effector cell expressing the CAR. In some embodiments, the antigen recognition domain can specifically bind an antigen. In some embodiments, the antigen recognition domain can specifically bind an antigen associated with a disease or pathogen. In some embodiments, the disease-associated antigen is a tumor antigen, wherein the tumor may be a liquid or a solid tumor. In some embodiments, the CAR is suitable to activate either T or NK cells expressing said CAR. In some embodiments, the CAR is NK cell specific for comprising NK-specific signaling components. In certain embodiments, said T cells are derived from a CAR expressing iPSCs, and the derivative T cells may comprise T helper cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, aP T cells, y6 T cells, or a combination thereof. In certain embodiments, said NK cells are derived from a CAR expressing iPSCs. [000171] In certain embodiments, said antigen recognition region comprises a murine antibody, a human antibody, a humanized antibody, a camel Ig, a shark heavy-chain-only antibody (VNAR), Ig NAR, a chimeric antibody, a recombinant antibody, or antibody fragment thereof. Non-limiting examples of antibody fragment include Fab, Fab', F(ab)'2, F(ab)'3, Fv, single chain antigen binding fragment (scFv), (scFv)2, disulfide stabilized Fv (dsFv), minibody, diabody, triabody, tetrabody, single-domain antigen binding fragments (sdAb, Nanobody), recombinant heavy-chain-only antibody (VHH), and other antibody fragments that maintain the binding specificity of the whole antibody. Non-limiting examples of antigen that may be targeted by a CAR include ADGRE2, carbonic anhydrase IX (CAIX), CCRI, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CD269 (BCMA), CDS, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell (e.g., a cell surface antigen), epithelial glycoprotein2 (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine-protein kinases erb-B2,3,4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), ICAM-1, Integrin B7, Interleukin-13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A (CAI9.9), Lewis Y (LeY), LI cell adhesion molecule (LI-CAM), LILRB2, melanoma antigen family A 1 (MAGE-A1), MICA / B, Mucin 1 (Muc-1), Mucin 16 (Muc-16), Mesothelin (MSLN), NKCSI, NKG2D ligands, c-Met, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), PRAME, prostate stem cell antigen (PSCA), PRAME prostatespecific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), TIM-3, TRBCI, TRBC2, vascular endothelial growth factor R2 (VEGF- R2), Wilms tumor protein (WT-1), and various pathogen antigen known in the art. Non-limiting examples of pathogen includes virus, bacteria, fungi, parasite and protozoa capable of causing diseases. [000172]   In some embodiments, the transmembrane domain of a CAR comprises a full length or at least a portion of the native or modified transmembrane region of CD3D, CD3E, CD3G, CD3i; CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, OX40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL12, IL15, KIR2DL4, KIR2DS1, \Kp3". NKp44, NKp46, NKG2C, NKG2D, T cell receptor polypeptide. [000173] In some embodiments, the signaling peptide of the endo-domain (or intracellular domain) comprises a full length or at least a portion of a polypeptide of CD3(^, 2B4, DAP 10, DAP12, DNAM1, CD137 (41BB), IL21, IL7, IL12, IL15, NKp30, NKp44, NKp46, NKG2C, or NKG2D. In one embodiment, the signaling peptide of a CAR comprises an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to at least one ITAM (immunoreceptor tyrosine-based activation motif) of CD3(^. [000174] In certain embodiments, said endo-domain further comprises at least one costimulatory signaling region. Said costimulatory signaling region can comprise a full length or at least a portion of a polypeptide of CD27, CD28, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D, or any combination thereof. [000175] In one embodiment, the CAR applicable to the cells provided in this application comprises a co-stimulatory domain derived from CD28, and a signaling domain comprising the native or modified ITAMI of CD3^, represented by an amino acid sequence of at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to SEQ ID NO: 13. In a further embodiment, the CAR comprising a co-stimulatory domain derived from CD28, and a native or modified ITAMI of CD3(^ also comprises a hinge domain and trans membrane domain derived from CD28, wherein an scFv may be connected to the transmembrane domain through the hinge, and the CAR comprises an amino acid sequence of at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to SEQ ID NO: 14. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. SEQ ID NO: 13 RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQ LYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLFNELQKDKMAEAFSEIGMKGE RRRGKGHDGLFQGLSTATKDTFDALHMQALPPR (153 a.a. CD28 co-stim + CD3<ITAM) SEQ ID NO: 14 lEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVEVVVGGVEACYSEEVEVA fiifwvrskrsrllhsdymnmtprrpgptrkhyqpyapprdfaayrsrvkfsrsadapay QQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLFNELQKDKMAEAFSE IGMKGERRRGKGHDGLFQGLSTATKDTFDALHMQALPPR (219 a.a. CD28 hinge + CD28 TM + CD28 co-stim + CD3<ITAM) [000176] In another embodiment, the CAR applicable to the cells provided in this application comprises a transmembrane domain derived from NKG2D, a co-stimulatory domain derived from 2B4, and a signaling domain comprising the native or modified CD3(^, represented by an amino acid sequence of at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to SEQ ID NO: 15. Said CAR comprising a transmembrane domain derived from NKG2D, a co-stimulatory domain derived from 2B4, and a signaling domain comprising the native or modified CD3(^ may further comprise a CD8 hinge, wherein the amino acid sequence of such a structure is of at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to SEQ ID NO: 16. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. SEQ ID NO: 15 SNLFVASWIAVMIIFRIGMAVAIFCCFFFPSWRRKRKEKQ SET S PRE FLTIYE DVKDLKT RRNHEQEQTFPGGGSTIYSMIQSQSSAPTSQEPAYTLYSLIQPSRKSGSRKRNHSPSFNS TIYEVIGKSQPKAQNPARLSRKELENFDVYSRVKFSRSADAPAYKQGQNQLYNELNLGRR EEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL Y QGL S TAT KDTY DALHMQAL P P R (263 a.a NKG2D TM + 2B4 + CD3Q SEQ ID NO: 16 TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDSNEFVASWIAVMIIF RIGMAVAIFCCFFETSWRRKRKEKQSETSPKEFLTIYEDVKDLKTRRNHEQEQTFPGGGS TIYSMIQSQSSAPTSQEPAYTLYSLIQPSRKSGSRKRNHSPSFNSTIYEVIGKSQPKAQN PARLSRKELENFDVYSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPE MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL HMQALPPR (308 a.a CD8 hinge + NKG2D TM + 2B4 + CD3Q [000177] Non-limiting CAR strategies further include heterodimeric, conditionally activated CAR through dimerization of a pair of intracellular domain (see for example, U.S. Pat. No. 9587020); split CAR, where homologous recombination of antigen binding, hinge, and endodomains to generate a CAR (see for example, U.S. Pub. No. 20170183407); multi-chain CAR that allows non-covalent link between two transmembrane domains connected to an antigen binding domain and a signaling domain, respectively (see for example, U.S. Pub. No. 20140134142); CARs having bispecific antigen binding domain (see for example, U.S. Pat. No. 9447194), or having a pair of antigen binding domains recognizing same or different antigens or epitopes (see for example, U.S. Pat No. 8409577), or a tandem CAR (see for example, Hegde et al., J Clin Invest. 2016;126(8):3036-3052); inducible CAR (see for example, U.S. Pub. Nos. 20160046700, 20160058857, 20170166877); switchable CAR (see for example, U.S. Pub. No: 20140219975); and any other designs known in the art. [000178] Provided herein therefore include derivative cells obtained from differentiating genomically engineered iPSCs, wherein both the iPSCs and the derivative cells comprise one or more CARs along with additional modified modalities, including, but not limited to, TCRneg cs-CD3, and / or hnCD16. Additionally provided in this application is a master cell bank comprising single cell sorted and expanded clonal engineered iPSCs having at least one phenotype as provided herein, including but not limited to, CAR and one or both of TCRneg cs-CD3 and hnCD16, wherein the cell bank provides a platform for additional iPSC engineering and a renewable source for manufacturing off-the-shelf, engineered, homogeneous cell therapy products, which are well-defined and uniform in composition, and can be mass produced at significant scale in a cost-effective manner. In one particular embodiment, the iPSC and its derivative cells comprises TCRneg cs-CD3, hnCD16, and a CAR targeting a selected tumor or viral antigen, wherein the derivative cells are NK or T cells, and wherein the derivative cells may be used with, through hnCD16 binding, one or more ADCC antibodies or a bi-, tri- or multispecific engager that target a tumor antigen different from the one targeted by CAR to avoid or to reduce tumor antigen escape while achieving dual targeting of the same tumor. [000179] In a further embodiment, the iPSC and its derivative T cells comprising a CAR have the CAR inserted in a TCR constant region, leading to TCR knockout, and placing CAR expression under the control of the endogenous TCR promoter. Additional insertion sites include but are not limited to AAVS1, CCR5, ROSA26, collagen, HTRP, HU, GAPDH, RUNX1, B2M, 72 TAPI, TAP2, tapasin, NLRC5, CIITA, RFXANK, CIITA, RFX5, RFXAP, NKG2A, NKG2D, CD38, CD58, CD54, CD56, CIS, CBL-B, S0CS2, PD1, CTLA4, LAG3, TIM3, or TIGIT. In some embodiments, derivative TCR negative CAR-T cell derived from engineered iPSCs further comprise hnCD16 having an ectodomain native to CD 16 (Fl76V and / or S197P) or derived from CD64, and native or non-native transmembrane, stimulatory and signaling domains. In another embodiment, the iPSC and its derivative NK cells comprising a CAR have the CAR inserted in the NKG2 A locus or NKG2D locus, leading to NKG2A or NKG2D knock out, and placing CAR expression under the control of the endogenous NKG2A or NKG2D promoter. Additionally provided is a master cell bank comprising single cell sorted and expanded clonal engineered iPSCs having at least one phenotype as provided herein, including but not limited to, CAR, wherein the cell bank provides a platform for additional iPSC engineering and a renewable source for manufacturing off-the-shelf, engineered, homogeneous cell therapy products, which are well-defined and uniform in composition, and can be mass produced at significant scale in a cost-effective manner. 4. Exogenously introduced cytokine and / or cytokine signaling [000180] By avoiding systemic high-dose administration of clinically relevant cytokines, the risk of dose-limiting toxicities due to such a practice is reduced while cytokine mediated cell autonomy being established. To achieve lymphocyte autonomy without the need to additionally administer soluble cytokines, a partial or full length peptide of one or more of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and / or their respective receptor is introduced to the cell to enable cytokine signaling with or without the expression of the cytokine itself, thereby maintaining or improving cell growth, proliferation, expansion, and / or effector function with reduced risk of cytokine toxicities. In some embodiments, the introduced cytokine and / or its respective native or modified receptor for cytokine signaling are expressed on the cell surface. In some embodiments, the cytokine signaling is constitutively activated. In some embodiments, the activation of the cytokine signaling is inducible. In some embodiments, the activation of the cytokine signaling is transient and / or temporal. [000181] FIG. 2 presents several construct designs using IL 15 as an illustrative example. The transmembrane (TM) domain of any of the designs in FIG. 2 can be native to the IL15 receptor or may be modified or replaced with transmembrane domain of any other membrane bound proteins. [000182] FIG. 2 Design 1: IL15 and IL15Ra are co-expressed by using a self-cleaving peptide, mimicking trans-presentation of IL15, without eliminating cis-presentation of IL15. [000183] FIG. 2 Design 2: IL15Ra is fused to IL15 at the C-terminus through a linker, mimicking trans-presentation without eliminating cis-presentation of IL15 as well as ensuring IL15 membrane-bound. [000184] FIG. 2 Design 3: IL15Ra with truncated intracellular domain is fused to IL15 at the C-terminus through a linker, mimicking trans-presentation of IL15, maintaining IL15 membranebound, and additionally eliminating cis-presentation and / or any other potential signal transduction pathways mediated by a normal IL15R through its intracellular domain. The intracellular domain of IL15Ra has been deemed as critical for the receptor to express in the IL15 responding cells, and for the responding cells to expand and function. Such a truncated construct comprises an amino acid sequence of at least 75%, 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 17, which may be encoded by an exemplary nucleic acid sequence represented by SEQ ID NO: 18. In one embodiment of the truncated IL15 / IL15Ra, the construct does not comprise the last 4 amino acid “KSRQ” of SEQ ID NO: 17, and comprises an amino acid sequence of at least 75%, 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 21. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. SEQ ID NO: 17 MDWTWILFLVAAATRVHSGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDA TLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTES GCKECEELEEKNIKEFLQSFVHIVQMFINTSSGGGSGGGGSGGGGSGGGGSGGGSLQITC PPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKC IRDPALVHQRPAPPSTVTTAGVTPQPESLSPSGKEPAASSPSSNNTAATTAAIVPGSQLM PSKSPSTGTTEISSHESSHGTPSQTTAKNWELTASASHQPPGVYPQGHSDTTVAISTSTV LLCGLSAVSLLACYLKSRQ (379 a.a.; signal and linker peptides are underlined) SEQ ID NO: 18 ATGGACTGGACCTGGATTCTGTTCCTGGTCGCGGCTGCAACGCGAGTCCATAGCGGTATC CATGTTTTTATTCTTGGGTGTTTTTCTGCTGGGCTGCCTAAGACCGAGGCCAACTGGGTA AAT G T CAT GAG T GAG C T CAAGAAAATAGAAGAC C T TATACAAAG CAT G GAGAT T GAT G C T ACTCTCTACACTGAGTCAGATGTACATCCCTCATGCAAAGTGACGGCCATGAAATGTTTC CTCCTCGAACTTCAAGTCATATCTCTGGAAAGTGGCGACGCGTCCATCCACGACACGGTC GAAAACCTGATAATACTCGCTAATAATAGTCTCTCTTCAAATGGTAACGTAACCGAGTCA GGTTGCAAAGAGTGCGAAGAGTTGGAAGAAAAAAACATAAAGGAGTTCCTGCAAAGTTTC GTGCACATTGTGCAGATGTTCATTAATACCTCTAGCGGCGGAGGATCAGGTGGCGGTGGA AGCGGAGGTGGAGGCTCCGGTGGAGGAGGTAGTGGCGGAGGTTCTCTTCAAATAACTTGT CCTCCACCGATGTCCGTAGAACATGCGGATATTTGGGTAAAATCCTATAGCTTGTACAGC CGAGAGCGGTATATCTGCAACAGCGGCTTCAAGCGGAAGGCCGGCACAAGCAGCCTGACC GAGTGCGTGCTGAACAAGGCCACCAACGTGGCCCACTGGACCACCCCTAGCCTGAAGTGC ATCAGAGATCCCGCCCTGGTGCATCAGCGGCCTGCCCCTCCAAGCACAGTGACAACAGCT GGCGTGACCCCCCAGCCTGAGAGCCTGAGCCCTTCTGGAAAAGAGCCTGCCGCCAGCAGC CCCAGCAGCAACAATACTGCCGCCACCACAGCCGCCATCGTGCCTGGATCTCAGCTGATG CCCAGCAAGAGCCCTAGCACCGGCACCACCGAGATCAGCAGCCACGAGTCTAGCCACGGC ACCCCATCTCAGACCACCGCCAAGAACTGGGAGCTGACAGCCAGCGCCTCTCACCAGCCT CCAGGCGTGTACCCTCAGGGCCACAGCGATACCACAGTGGCCATCAGCACCTCCACCGTG CTGCTGTGTGGACTGAGCGCCGTGTCACTGCTGGCCTGCTACCTGAAGTCCAGACAGTGA (1140 n.a. ) SEQ ID NO: 21 MDWTWILFLVAAATRVHSGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDA TLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTES GCKECEELEEKNIKEFLQSFVHIVQMFINTSSGGGSGGGGSGGGGSGGGGSGGGSLQITC PPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKC IRDPALVHQRPAPPSTVTTAGVTPQPESLSPSGKEPAASSPSSNNTAATTAAIVPGSQLM PSKSPSTGTTEISSHESSHGTPSQTTAKNWELTASASHQPPGVYPQGHSDTTVAISTSTV LLCGLSAVSLLACYL (375 a.a.; signal and linker peptides are underlined) [000185] One having ordinary skill in the art would appreciate that the signal peptide and the linker sequences above are illustrative and in no way limit their variations suitable for use as a signal peptide or linker. There are many suitable signal peptide or linker sequences known and available to those in the art. The ordinary skilled in the art understands that the signal peptide and / or linker sequences may be substituted for another sequence without altering the activity of the functional peptide led by the signal peptide or linked by the linker. [000186] FIG. 2 Design 4: Since Design 3 construct was shown to be functional in promoting effector cell survival and expansion, demonstrating that the cytoplasmic domain of IL15Ra can be omitted without negatively impacting the autonomous feature of the effector cell equipped with IL15 in such a design, Design 4 is a construct providing another working alternative of Design 3, from which essentially the entire IL15Ra is removed except for the Sushi domain fused with IL15 at one end and a transmembrane domain on the other (mb-Sushi), optionally with a linker between the Sushi domain and the trans-membrane domain. The fused IL15 / mb-Sushi is expressed at cell surface through the transmembrane domain of any membrane bound protein. With a construct such as Design 4, unnecessary signaling through IL15Ra, including cis-presentation, is eliminated when only the desirable trans-presentation of IL15 is retained. In some embodiments, the component comprising IL 15 fused with Sushi domain comprises an amino acid sequence of at least 75%, 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 19, which may be encoded by an exemplary nucleic acid sequence represented by SEQ ID NO: 20. In embodiments, the sequence identity is at least 80%. In embodiments, the sequence identity is at least 90%. In embodiments, the sequence identity is at least 95%. In embodiments, the sequence identity is 100%. SEQIDNO: 19 MDWTWILFLVAAATRVHSGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDA TLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTES GCKECEELEEKNIKEFLQSFVHIVQMFINTSSGGGSGGGGSGGGGSGGGGSGGGSLQITC PPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKC IR (242 a.a.; signal and linker peptides are underlined) SEQ ID NO: 20 ATGGACTGGACCTGGATTCTGTTCCTGGTCGCGGCTGCAACGCGAGTCCATAGCGGTATC CATGTTTTTATTCTTGGGTGTTTTTCTGCTGGGCTGCCTAAGACCGAGGCCAACTGGGTA AAT G T CAT GAG T GAG C T CAAGAAAATAGAAGAC C T TATACAAAG CAT G GAGAT T GAT G C T ACTCTCTACACTGAGTCAGATGTACATCCCTCATGCAAAGTGACGGCCATGAAATGTTTC CTCCTCGAACTTCAAGTCATATCTCTGGAAAGTGGCGACGCGTCCATCCACGACACGGTC GAAAACCTGATAATACTCGCTAATAATAGTCTCTCTTCAAATGGTAACGTAACCGAGTCA GGTTGCAAAGAGTGCGAAGAGTTGGAAGAAAAAAACATAAAGGAGTTCCTGCAAAGTTTC GTGCACATTGTGCAGATGTTCATTAATACCTCTAGCGGCGGAGGATCAGGTGGCGGTGGA AGCGGAGGTGGAGGCTCCGGTGGAGGAGGTAGTGGCGGAGGTTCTCTTCAAATAACTTGT CCTCCACCGATGTCCGTAGAACATGCGGATATTTGGGTAAAATCCTATAGCTTGTACAGC CGAGAGCGGTATATCTGCAACAGCGGCTTCAAGCGGAAGGCCGGCACAAGCAGCCTGACC GAGTGCGTGCTGAACAAGGCCACCAACGTGGCCCACTGGACCACCCCTAGCCTGAAGTGC ATCAGA (726 n.a.) [000187] One having ordinary skill in the art would appreciate that the signal peptide and the linker sequences above are illustrative and in no way limit their variations suitable for use as a signal peptide or linker. There are many suitable signal peptide or linker sequences known and available to those in the art. The ordinary skilled in the art understands that the signal peptide and / or linker sequences may be substituted for another sequence without altering the activity of the functional peptide led by the signal peptide or linked by the linker. [000188] FIG. 2 Design 5: A native or modified IL15RP is fused to IL15 at the C-terminus through a linker, enabling constitutive signaling and maintaining IL15 membrane-bound and trans-representation. [000189] FIG. 2 Design 6: A native or modified common receptor yC is fused to IL15 at the C-terminus through a linker for constitutive signaling and membrane bound trans-presentation of the cytokine. The common receptor yC is also called the common gamma chain or CD 132, also known as IL2 receptor subunit gamma or IL2RG. yC is a cytokine receptor sub-unit that is common to the receptor complexes for many interleukin receptors, including, but not limited to, IL2, IL4, IL7, IL9, IL 15 and IL21 receptor. [000190] FIG. 2 Design 7: Engineered IL15RP that forms homodimer in absence of IL15 is useful for producing constitutive signaling of the cytokine. [000191] In some embodiments, one or more of cytokine IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18 and IL21, and / or receptors thereof, may be introduced to iPSC using one or more of the designs in FIG. 2, and to its derivative cells upon iPSC differentiation. In some embodiments, IL2 or IL15 cell surface expression and signaling is through the construct illustrated in any one of Designs 1-7. In some embodiments, IL4, IL7, IL9, or IL21 cell surface expression and signaling is through the construct illustrated in Design 5, 6, or 7, by using either a common receptor or a cytokine specific receptor. In some embodiments, IL7 surface expression and signaling is through the construct illustrated in Design 5, 6, or 7, by using either a common receptor or a cytokine specific receptor, such as an IL4 receptor. The transmembrane (TM) domain of any of the designs in FIG. 2 can be native to respective cytokine receptor or may be modified or replaced with transmembrane domain of any other membrane bound proteins. [000192] In addition to an induced pluripotent cell (iPSC), a clonal iPSC, a clonal iPS cell line cell, or iPSC derived cells, comprising at least one engineered modality as disclosed herein, also provided is a master cell bank comprising single cell sorted and expanded clonal engineered iPSCs having at least an exogenously introduced cytokine and / or cytokine receptor signaling as described in this section, wherein the cell bank provides a platform for additional iPSC engineering and a renewable source for manufacturing off-the-shelf, engineered, homogeneous cell therapy products, which are well-defined and uniform in composition, and can be mass produced at significant scale in a cost-effective manner. In iPSCs and derivative cells therefrom comprising both CAR and exogenous cytokine and / or cytokine receptor signaling, the CAR and IL may be expressed in separate construct, or may be co-expressed in a bi-cistronic construct comprising both CAR and IL. In some further embodiments, IL15 in a form represented by any of the construct designs in FIG. 2 can be linked to either the 5’ or the 3’ end of a CAR expression construct through a self-cleaving 2A coding sequence, illustrated as, for example, CAR-2A-IL15 or IL15-2A-CAR. As such, the IL15 and CAR are in a single open reading frame (ORF). In one embodiment, the CAR-2A-IL15 or IL15-2A-CAR construct comprises IL15 in Design 3 of FIG. 2. In another embodiment, the CAR-2A-IL15 or IL15-2A-CAR construct comprises IL15 in Design 3 of FIG. 2. In yet another embodiment, the CAR-2A-IL15 or IL15-2A-CAR construct comprises IL15 in Design 7 of FIG. 2. When CAR-2A-IL15 or IL15-2A-CAR is expressed, the self-cleaving 2A peptide allows the expressed CAR and IL15 dissociate, and the dissociated IL15 can then be presented at cell surface. The CAR-2A-IL15 or IL15-2A-CAR bi-cistronic design allows a coordinated CAR and IL15 expression both in timing and quantity, and under the same control mechanism that may be chosen to incorporate, for example, an inducible promoter for the expression of the single ORF. Self-cleaving peptides are found in members of the Picomaviridae virus family, including aphthoviruses such as foot-and-mouth disease virus (FMDV), equine rhinitis A virus (ERAV), Thosea asigna virus (TaV) and porcine tescho virus- 1 (PTV-I) (Donnelly, ML, et al, J. Gen. Virol, 82, 1027-101 (2001); Ryan, MD, et al., J. Gen. Virol., 72, 2727-2732 (2001)), and cardioviruses such as Theilovirus (e.g., Theiler's murine encephalomyelitis) and encephalomyocarditis viruses. The 2 A peptides derived from FMDV, ERAV, PTV-I, and TaV are sometimes also referred to as "F2A", "E2A", "P2A", and "T2A", respectively. [000193] The bi-cistronic CAR-2A-IL15 or IL15-2A-CAR embodiment as disclosed herein for IL15 is also contemplated for expression of any other cytokine provided herein, for example, IL2, IL4, IL6, IL7, IL9, IL 10, IL11, IL 12, IL 18, and IL2L In some embodiments, IL2 cell surface expression and signaling is through the construct illustrated in any of the Designs 1-7. In some other embodiments, IL4, IL7, IL9, or IL21 cell surface expression and signaling is through the construct illustrated in Design 5, 6, or 7, either using a common receptor and / or a cytokine specific receptor. [000194] In iPSCs and derivative cells therefrom comprising both CAR and exogenous cytokine and / or cytokine receptor signaling, including but not limited to IL15, the iPSCs and derivative cells may further comprise TCRneg cs-CD3, and / or CD16. 5. HLA-I- and HLA-II- deficiency [000195] Multiple HLA class I and class II proteins must be matched for histocompatibility in allogeneic recipients to avoid allogeneic rejection problems. Provided herein is an iPSC cell line and its derivative cells differentiated therefrom with eliminated or substantially reduced expression of both HLA class I and HLA class II proteins. HLA class I deficiency can be achieved by functional deletion of any region of the HLA class I locus (chromosome 6p21), or deletion or reducing the expression level of HLA class-I associated genes including, but not limited to, beta-2 microglobulin (B2M) gene, TAP 1 gene, TAP 2 gene and Tapasin. For example, the B2M gene encodes a common subunit essential for cell surface expression of all HLA class I heterodimers. B2M negative cells are HLA-I deficient. HLA class II deficiency can be achieved by functional deletion or reduction of HLA-II associated genes including, but not limited to, RFXANK, CIITA, RFX5 and RFXAP. CIITA is a transcriptional coactivator, functioning through activation of the transcription factor RFX5 required for class II protein expression. CIITA negative cells are HLA-II deficient. Provided herein is an iPSC line and its derivative cells with both HLA-I and HLA-II deficiency, for example for lacking both B2M and CIITA expression, wherein the obtained derivative effector cells enable allogeneic cell therapies by eliminating the need for MHC (major histocompatibility complex) matching, and avoid recognition and killing by host (allogeneic) T cells. [000196] For some cell types, a lack of class I expression leads to lysis by NK cells. To overcome this “missing self’ response, HLA-G may be optionally knocked in to avoid NK cell recognition and killing of the HLA-I deficient effector cells derived from an engineered iPSC. In one embodiment, the HLA-I deficient iPSC and its derivative cells further comprise HLA-G knock-in. In some embodiments, the provided HLA-I deficient iPSC and its derivative cells further comprise one or both of CD58 knockout and CD54 knockout. CD58 (or LFA-3) and CD54 (or ICAM-1) are adhesion proteins initiating signal-dependent cell interactions, and facilitating cell, including immune cell, migration. It was shown that CD58 knockout has a higher efficiency in reducing allogeneic NK cell activation than CD54 knockout; while double knockout of both CD58 and CD54 has the most enhanced reduction of NK cell activation. In some observation, the CD58 and CD54 double knockout is even more effective than HLA-G overexpression for HLA-I deficient cells in overcoming “missing-self’ effect. As provided herein is a master cell bank comprising single cell sorted and expanded clonal engineered iPSCs having TCRneg cs-CD3, HLA-I and HLA-II deficiency, and one or more of hnCD16, CAR and IL, without adversely impacting the differentiation potential of the iPSC and function of the derived effector cells including derivative T and NK cells. As provided above, in some embodiments, the HLA-I and HLA-II deficient iPSC and its derivative cells have an exogenous polynucleotide encoding HLA-G. In some embodiments, the HLA-I and HLA-II deficient iPSC and its derivative cells are CD58 null. In some other embodiments, the HLA-I and HLA-II deficient iPSC and its derivative cells are CD54 null. In yet some other embodiments, the HLA-I and HLA-II deficient iPSC and its derivative cells are CD58 null and CD54 null. Said cell bank provides a platform for additional iPSC engineering, and a renewable source for manufacturing off-the-shelf, engineered, homogeneous cell therapy products, which are well-defined and uniform in composition, and can be mass produced at significant scale in a cost-effective manner. 6. CD38 knockout [000197] Cell surface molecule CD38 is highly upregulated in multiple hematologic malignancies derived from both lymphoid and myeloid lineages, including multiple myeloma and a CD20 negative B-cell malignancy, which makes it an attractive target for antibody therapeutics to deplete cancer cell. Antibody mediated cancer cell depletion is usually attributable to a combination of direct cell apoptosis induction and activation of immune effector mechanisms such as ADCC (antibody-dependent cell-mediated cytotoxicity). In addition to ADCC, the immune effector mechanisms in concert with the therapeutic antibody may also include phagocytosis (ADCP) and / or complement-dependent cytotoxicity (CDC). [000198] Other than being highly expressed on malignant cells, CD38 is also expressed on plasma cells as well as on NK cells, and activated T and B cells. During hematopoiesis, CD38 is expressed on CD34+ stem cells and lineage-committed progenitors of lymphoid, erythroid, and myeloid, and during the final stages of maturation which continues through the plasma cell stage. As a type II transmembrane glycoprotein, CD38 carries out cell functions as both a receptor and a multifunctional enzyme involved in the production of nucleotide-metabolites. As an enzyme, CD38 catalyzes the synthesis and hydrolysis of the reaction from NAD+ to ADP-ribose, thereby producing secondary messengers CADPR and NAADP which stimulate release of calcium from the endoplasmic reticulum and lysosomes, critical for the process of cell adhesion which process is calcium dependent. As a receptor, CD38 recognizes CD31 and regulates cytokine release and cytotoxicity in activated NK cells. CD38 is also reported to associate with cell surface proteins in lipid rafts, to regulate cytoplasmic Ca2+flux, and to mediate signal transduction in lymphoid and myeloid cells. [000199] In malignancy treatment, systemic use of CD38 antigen binding receptor transduced T cells have been shown to lyse the CD38+ fractions of CD34+ hematopoietic progenitor cells, monocytes, NK cells, T cells and B cells, leading to incomplete treatment responses and reduced or eliminated efficacy because of the impaired recipient immune effector cell function. In addition, in multiple myeloma patients treated with daratumumab, a CD38 specific antibody, NK cell reduction in both bone marrow and peripheral blood was observed, although other immune cell types, such as T cells and B cells, were unaffected despite their CD38 expression (Casneuf et al., Blood Advances. 2017; 1(23):2105-2114). Without being limited by theories, the present application provides a strategy to leverage the full potential of CD38 targeted cancer treatment by overcoming CD38 specific antibody and / or CD38 antigen binding domain induced effector cell depletion or reduction through fratricide. In addition, since CD38 is upregulated on activated lymphocytes such as T or B cells, by suppressing activation of these recipient lymphocytes using CD38 specific antibody such as daratumumab in the recipient of allogeneic effector cells, the allorej ection against these effector cells would be reduced and / or prevented and thereby increasing effector cell survival and persistency. As such, the present application also provides a strategy to enhance effector cell persistency and / or survival through reducing or preventing allorej ection by using CD38 specific antibody, a secreted CD38 specific engager or a CD38 CAR (chimeric antigen receptor) against activation of recipient T and B cells, i.e., lymphodepletion of activated T and B cells, often prior to adoptive cell transferring. Specifically, the strategies as provided include generating a CD38 knockout iPSC line, a master cell bank comprising single cell sorted and expanded clonal CD38 negative iPSCs, and obtaining CD38 negative (CD38neg) derivative effector cells through directed differentiation of the engineered iPSC line, wherein the derivative effector cells are protected against fratricide and allorej ection among other advantages when CD38 targeted therapeutic moi eties are employed with the effector cells. In addition, anti-CD38 monoclonal antibody therapy significantly depletes a patient’s activated immune system without adversely affecting the patient’s hematopoietic stem cell compartment. CD38 negative derivative cell has the ability to resist CD38 antibody mediated depletion, and may be effectively administered in combination with anti-CD38 or CD38-CAR without the use of toxic conditioning agents and thus reduce and / or replace chemotherapy based lymphodepletion. The master cell bank comprising single cell sorted and expanded clonal CD38neg iPSCs provides a platform for additional iPSC engineering, including but not limited to one or more of TCRneg cs-CD3, hnCD16, CAR, IL and HLAI and II deficiency, and a renewable source for manufacturing off-the-shelf, engineered, homogeneous cell therapy products, which are well-defined and uniform in composition, and can be mass produced at significant scale in a cost-effective manner. [000200] In one embodiment as provided herein, the CD38 knockout in an iPSC line is a bi-allelic knockout. As disclosed herein, the provided CD38 negative iPSC line further comprises at least TCRneg and one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed; and said iPSC is capable of directed differentiation to produce functional derivative hematopoietic cells including, but not limited to, mesodermal cells with definitive hemogenic endothelium (HE) potential, definitive HE, CD34 hematopoietic cells, hematopoietic stem and progenitor cells, hematopoietic multipotent progenitors (MPP), T cell progenitors, NK cell progenitors, myeloid cells, neutrophil progenitors, T cells, NKT cells, NK cells, B cells, neutrophils, dendritic cells, and macrophages. In some embodiments, when an anti-CD38 antibody is used to induce ADCC or an anti-CD38 CAR is used for targeted cell killing, the CD38neg iPSC and / or its derivative effector cells thereof are not eliminated by the anti-CD38 antibody, the anti-CD38 CAR, or recipient activated T or B cells, thereby increasing the iPSC and its effector cell persistence and / or survival in the presence of, and / or after exposure to, such therapeutic moieties. In some embodiments, the effector cell has increased persistence and / or survival in vivo in the presence of, and / or after exposure to, such therapeutic moieties. 7. Additional modifications [000201] In some embodiments, the iPSC, and its derivative effector cells comprising TCRneg cs-CD3 and one or more of CD 16, CAR, IL, HLA I and II deficiency and CD38' / _ may additionally comprise deletion or reduced expression in at least one of TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; or introduced or increased expression in at least one of HLA-E, 41BBL, CD4, CD8, CD47, CD113, CD131, CD137, CD80, PDL1, A2AR, TCR, Fc receptor, an engager, and surface triggering receptor for coupling with bi-, multi- specific or universal engagers. [000202] Bi- or multi- specific engagers are fusion proteins consisting of two or more singlechain variable fragments (scFvs), or other functional variants, of different antibodies, with at least one scFv binds to an effector cell surface molecule or “surface triggering receptor”, and at least another to a tumor cell via a tumor specific surface molecule. As used herein the term “surface triggering receptor” refers to a receptor capable of triggering or initiating an immune response, e.g. a cytotoxic response, of the effector cell. Surface triggering receptors may be engineered, and may be an endogenous surface protein expressed on effector cells, e.g. a T cell, a NK cell, a NKT cell, a B cell, a macrophage, a neutrophil. In some embodiments, the surface triggering receptor facilitates bi- or multi- specific antibody engagement between the effector cells and specific target cell e.g. a tumor cell, independent of the effector cell’s natural receptors and cell types. In some other embodiments, one or more exogenous surface triggering receptors could be introduced to the effector cells using the methods and compositions provided herein, i.e., through engineering of an iPSC, optionally generating a master cell bank comprising single cell sorted and expanded clonal engineered iPSCs, and then directing the differentiation of the iPSC to T, NK or any other effector cells comprising the same genotype as the source iPSC. [000203] Using this approach, one may also generate iPSCs comprising a universal surface triggering receptor, and then differentiate such iPSCs into populations of various effector cell types that express the universal surface triggering receptor. By “universal”, it is meant that the surface triggering receptor can be expressed in, and activate, any effector cells irrespective of the cell type, and all effector cells expressing the universal receptor can be coupled or linked to the engagers having the same epitope recognizable by the surface triggering receptor, regardless of the engager’s tumor binding specificities. In some embodiments, engagers having the same tumor targeting specificity are used to couple with different universal surface triggering receptor. In some embodiments, engagers having different tumor targeting specificity are used to couple with the same universal surface triggering receptor. As such, one or multiple effector cell types can be engaged to kill one specific type of tumor cells in some case, and to kill two or more types of tumors in some other cases. A surface triggering receptor generally comprises a costimulatory domain for effector cell activation and an anti-epitope that is specific to the epitope of an engager, or vice versa, the surface triggering receptor comprises an epitope that is recognizable or specific to the anti-epitope of the engager. For example, a bi-specific engager is specific to the anti-epitope / epitope of a surface triggering receptor on one end and is specific to a tumor antigen on the other end. [000204] As provided herein, the various forms of cell surface presented CD3 molecule as disclosed are applicable, among other function, as a CD3 related cell surface triggering receptor for engager recognition, which is particular useful in a cell that is TCR negative such that expressed CD3 molecule does not present on cell surface despite its expression. In some embodiments, the CD3 related surface triggering receptor for engager recognition is comprised in a complete or partial CD3 molecule (i.e., subunits or subdomains of a CD3 complex) presented at the cell surface of an effector cell when expressed. In some embodiments, the complete or partial CD3 molecule presented at the effector cell surface comprises (1) at least a complete or partial length of at least one ectodomain from one or more CD3 subunits comprising CD3s, CD36, and / or CD3s; and optionally (2) a complete or partial length of an endodomain of CD3(^. In some embodiments, all subunits or subdomains of the complete or partial CD3 molecule comprising the CD3 related surface triggering receptor are endogenous. In some embodiments, at least one subunit or subdomain of the complete or partial CD3 molecule comprising the CD3 related surface triggering receptor is exogenous. In some embodiments, the bispecific antibody engaging CD3 related cell surface triggering receptor as disclosed herein is CD3-CD19. In still another embodiment, the bispecific antibody is CD3-CD33. In yet another embodiment, the bispecific antibody further comprises a linker between the effector cell and tumor cell antigen binding domains, for example, a modified IL15 as a linker for effector NK cells to facilitate effector cell expansion (called TriKE, or Tri-specific Killer Engager, in some publications). [000205] Other than CD3, additional effector cell surface molecules, or surface triggering receptor, that can be used for bi- or multi- specific engager recognition, or coupling, include, but are not limited to, CD28, CD5, CD 16, NKG2D, CD64, CD32, CD89, NKG2C, and a chimeric Fc receptor as disclosed herein. In some embodiments, the CD 16 expressed on the surface of effector cells for engager recognition is a hnCD16, comprising CD 16 (containing Fl76V and optionally S197P) or CD64 extracellular domain, and native or non-native transmembrane, stimulatory and / or signaling domains as described in section 1.2. In some embodiments, the CD 16 expressed on the surface of effector cells for engager recognition is a hnCD16 based chimeric Fc receptor (CFcR). In some embodiments, the hnCD16 based CFcR comprises a transmembrane domain of NKG2D, a stimulatory domain of 2B4, and a signaling domain of CD3(^; wherein the extracellular domain of the hnCD16 is derived from a full length or partial sequence of the extracellular domain of CD64 or CD 16; and wherein the extracellular domain of CD 16 comprises Fl76V and optionally S197P. [000206] The exemplary tumor cell surface molecules for bi- or multi- specific engager recognition include, but are not limited to, B7H3, BCMA, CD 10, CD 19, CD20, CD22, CD24, CD30, CD33, CD34, CD38, CD44, CD79a, CD79b, CD123, CD138, CD179b, CEA, CLEC12A, CS-1, DLL3, EGFR, EGFRvIII, EPC AM, FLT-3, FOLRI, FOLR3, GD2, gpA33, HER2, HM1.24, LGR5, MSLN, MCSP, MICA / B, PSMA, PAMA, P-cadherin, ROR1. [000207] In view of the above, for engaging CD3 on the effector cells, in one embodiment, the bispecific antibody is CD3-CD19; and in another embodiment, the bispecific antibody is CD3-CD33. For engaging CD16 on the effector cells the bispecific antibody is CD16-CD30 or CD64-CD30. In another embodiment, the bispecific antibody is CD16-BCMA or CD64-BCMA. In yet another embodiment, the bispecific antibody further comprises a linker between the effector cell and tumor cell antigen binding domains, for example, a modified IL15 as a linker for effector NK cells to facilitate effector cell expansion (called TriKE, or Tri-specific Killer Engager, in some publications). In one embodiment, the TriKE is CD16-IL15-EPCAM or CD64-IL15-EPCAM. In another embodiment, the TriKE is CD16-IL15-CD33 or CD64-IL15-CD33. In yet another embodiment, the TriKE is NKG2C-IL15-CD33. The linker may also originate from other cytokines including, but not limited to, IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL18, and IL21. 8. Genetically engineered iPSC line and iPSC-derived cells provided herein [000208] In light of the above, the present application provides a TCRneg cell, or a population thereof, comprising a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed (TCRneg cs-CD3), wherein the cell is an induced pluripotent cell (iPSC), a clonal iPSC, a clonal iPS cell line cell, or iPSC derived cells obtained from directed differentiation of TCRneg cs-CD3 iPSC. Also provided is a master cell bank comprising single cell sorted and expanded clonal engineered iPSCs having a phenotype as described herein, wherein the cell bank provides a renewable source for manufacturing off-the-shelf, engineered, homogeneous cell therapy products, which are well-defined and uniform in composition, and can be mass produced at significant scale in a cost-effective manner. [000209] In some embodiments, the iPSC derived cells are hematopoietic cells including, but not limited to, mesodermal cells with definitive hemogenic endothelium (HE) potential, definitive HE, CD34 hematopoietic cells, hematopoietic stem and progenitor cells, hematopoietic multipotent progenitors (MPP), T cell progenitors, NK cell progenitors, myeloid cells, neutrophil progenitors, T cells, NKT cells, NK cells, B cells, neutrophils, dendritic cells, and macrophages. In some embodiments, the iPSC derived hematopoietic cells comprise effector cells such as T, NK, and regulatory cells, which are TCRneg and comprise a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed. In a further embodiment, the present application provides an iPSC derived TCRneg T cell, or a population thereof, comprising a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) (TCRneg cs-CD3), wherein the T cell is obtained from directed differentiation of TCRneg cs-CD3 iPSC. [000210] As used herein, TCRneg is also referred to as TCR negative, TCR' / _, “TCR null”, or TCR knockout, which comprises cells without endogenous TCR expression either by nature (for example, NK cell or iPSC derived NK cell), by gene expression regulation, or by genomic editing of an iPSC cell (for example, iPSC, iPSC reprogrammed from T cell (TiPSC)) or a T cell to knock out an endogenous TCR or one or more subunits thereof, or by obtaining TCR negative derivative cells differentiated from iPSC having TCR knocked out. As such, the TCR that is knocked out in a cell as disclosed is an endogenous TCR complex. Disrupting the expression of the constant region of either TCRa or TCRP of TCR in a cell is one of many methods of knocking out the endogenous TCR complex of the cell. TCRneg cells are discovered as not being able to present CD3 complex to the cell surface despite of the expression of all CD3 subunits in the TCRneg cells, which adversely affect cell functions that requires cell surface CD3 recognition, binding and / or signaling. The cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) as disclosed herein in a TCRneg cell can function as a CD3 related cell surface triggering receptor for binding with molecules including, not limited to, antibodies or functional variants thereof, and / or engagers as described herein. [000211] Provided herein also is an iPSC or iPSC-derived cell comprising one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, wherein the cell is optionally TCR negative. When the cs-CD3 is expressed, it functions as a CD3 related cell surface triggering receptor. In some embodiments of the CD3 related surface triggering receptor as provided in a TCRneg cell, the receptor is comprised in a complete or partial endogenous CD3 molecule presented at effector cell surface when expressed, wherein the endogenous CD3 molecule presentation, otherwise does not take place in a TCRneg cell even when expressed, is enabled by its association with a recombinant TCR comprising one or more of a full or partial length of an exogenous TCRa, an exogenous TCRP, and any variants thereof as provided in this application. In some embodiments, the cell surface presentation of a complete or partial endogenous CD3 molecule in a TCRneg cell is enabled by additionally expressing in said cell at least a recombinant TCR comprising a non-binding recombinant TCR (nb-rTCR), a defined recombinant TCR (d-rTCR), and / or a recombinant pre-TCR. [000212] In some embodiments, the TCRneg cell comprising a CD3 related surface triggering receptor comprises a non-binding recombinant TCR (nb-rTCR), wherein the nb-rTCR comprises one or both of a tgTRAC (transgenic TCRa constant region) and a tgTRBC (transgenic TCRP constant region); as such the TCRneg iPSC or iPSC-derived cell comprises one or more polynucleotides encoding tgTRAC and / or tgTRBC. In some embodiments of the TCRneg cell comprising a polynucleotide encoding tgTRAC, said polynucleotide is inserted in a TRAC locus, wherein the inserted polynucleotide disrupts expression of endogenous TRAC thereby leading to endogenous TCR knockout, and optionally wherein the inserted polynucleotide is driven by an endogenous promoter of TRAC or a heterologous promoter. In some embodiments of the TCRneg cell comprising a polynucleotide encoding tgTRBC, said polynucleotide is inserted in a TRBC locus, wherein the inserted polynucleotide disrupts expression of endogenous TRBC thereby leading to endogenous TCR knockout, and optionally wherein the inserted polynucleotide is driven by an endogenous promoter of TRBC or a heterologous promoter. [000213] In some embodiments, the TCRneg cell comprising a CD3 related surface triggering receptor comprises a defined recombinant TCR (d-rTCR), wherein the d-rTCR comprises a tgTCRa (transgenic TCRa) and a tgTCRp (transgenic TCRP), wherein each of the tgTCRa and the tgTCRp comprises a respective defined variable region in addition to a respective constant region (i.e., TRAC and TRBC); as such the TCRneg iPSC or iPSC-derived cell comprises one or more polynucleotides encoding tgTCRa and / or tgTCRp. In some embodiments, the defined variable region is originated from TCR alpha and beta of T cell having known TCR specificity. In some embodiments, the defined variable region is originated from TCR alpha and beta of invariant NKT cells. In some embodiments of the TCRneg cell comprising a polynucleotide encoding tgTCRa, said polynucleotide is inserted in a TRAC locus, wherein the inserted polynucleotide disrupts expression of endogenous TRAC thereby leading to endogenous TCR knockout, and optionally wherein the inserted polynucleotide is driven by an endogenous promoter of TRAC or a heterologous promoter. In some embodiments of the TCRnegcell comprising a polynucleotide encoding tgTCRp, said polynucleotide is inserted in a TRBC locus, wherein the inserted polynucleotide disrupts expression of endogenous TRBC thereby leading to endogenous TCR knockout, and optionally wherein the inserted polynucleotide is driven by an endogenous promoter of TRBC or a heterologous promoter. [000214] In some embodiments, the TCRneg cell comprising a CD3 related surface triggering receptor comprises a recombinant pre-TCR (p-rTCR), wherein the p-rTCR comprises a tgpTCRa (transgenic pre-TCRa), and optionally a tgTRBC or a tgTCRP, wherein the tgTCRP comprises a defined variable region; as such the TCRneg iPSC or iPSC-derived cell comprises at least a polynucleotide encoding tgpTCRa. In some embodiments of the TCRneg cell comprising a polynucleotide encoding tgpTCRa, said polynucleotide is inserted in a TRAC locus, wherein the inserted polynucleotide disrupts expression of endogenous TRAC thereby leading to endogenous TCR knockout, and optionally wherein the inserted polynucleotide is driven by an endogenous promoter of TRAC or a heterologous promoter. In some embodiments of the TCRneg cell comprising a polynucleotide encoding tgTRBC or tgTCRP in addition to tgpTCRa, said tgTRBC or tgTCRP encoding polynucleotide is inserted in a TRBC locus, wherein the inserted polynucleotide disrupts expression of endogenous TRBC thereby leading to endogenous TCR knockout, and optionally wherein the inserted tgTRBC or tgTCRP encoding polynucleotide is driven by an endogenous promoter of TRBC or a heterologous promoter, respective defined variable region. [000215] In some embodiments of the CD3 related surface triggering receptor in a TCRneg cell, the receptor is comprised in a complete or partial CD3 molecule comprising at least one exogenous subunit or subdomain from one or more of CD3s, CD36, and CD3y. In one embodiment, the CD3 related surface triggering receptor for engager recognition in a TCRneg cell is comprised in a partial CD3 molecule comprising at least a full or partial length ectodomain of CD3s. In one embodiment, the CD3 related surface triggering receptor for engager recognition in a TCRneg cell is comprised in a partial CD3 molecule comprising at least a full or partial length ectodomain of CD3s, and additionally a full or partial length ectodomain of CD3y or CD36. In one embodiment, said CD3 molecule comprises at least a full or partial length of an ectodomain of CD3s, CD3y and / or CD36, wherein the full or partial length of ectodomain(s) is fused with a constant region of TCRa or TCRP, and wherein the partial fusion proteins each comprising TRAC or TRBC are capable of forming heterodimer with endogenous CD3(^. As such, in one embodiment of the TCRneg iPSC or iPSC-derived cell having a CD3 related surface triggering receptor, the cell comprises at least one of (i) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD36, and a TCRa constant region (tgCD3(s-6)-TRAC); (ii) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD3y, and a TCRP constant region (tgCD3(s-y)-TRBC); (iii) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD3y, and a TCRa constant region (tgCD3(s-y)-TRAC); and / or (iv) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD36, and a TCRP constant region (tgCD3(s-6)-TRBC). In some embodiments of the TCRneg cell having a CD3 related surface triggering receptor, the cell comprises a heterodimer comprising a transgenic fusion protein comprising a TCRa constant region fused with a full or partial length of ectodomain of at least CD3s and a transgenic fusion protein comprising a TCRP constant region fused with a full or partial length of ectodomain of at least CD3s. [000216] In some embodiments of the CD3 related surface triggering receptor in a TCRneg cell, the receptor is comprised in a complete or partial CD3 molecule comprising at least one exogenous subunit or subdomain from one or more of CD3s, CD36, CD3y, and / or CD3(^, and optionally one or more signaling domains of 2B4, 4-1BB, CD16, CD2, CD28, CD28H, CD3(^, DAP10, DAP12, DNAM1, FcERIy IL21R, IL-2Rp (IL-15Rp), IL-2Ry, IL-7R, KIR2DS2, NKG2D, NKp30, NKp44, NKp46, CD3(^1XX, CS1, or CD8 for signal transduction and / or costimulation, wherein all subunits or subdomains, including the signaling domains are fused to form a chimeric chain. In one embodiment, the CD3 related surface triggering receptor for engager recognition in a TCRneg cell is comprised in a CD3 chimeric chain comprising at least a full or partial length ectodomain of CD3s; a full or partial length ectodomain of one or both of CD36 and CD3y; and a full or partial length of endodomain of CD(^. In one embodiment, the CD3 related surface triggering receptor for engager recognition in a TCRneg cell is comprised in a CD3 chimeric chain comprising a full or partial length ectodomain of CD3s; a full or partial length ectodomain of one or both of CD36 and CD3y; a full or partial length of endodomain of CD(^, further comprises a cytoplasmic signaling domain of one or both of CD28 and 41BBL. As such, in one embodiment of the TCRneg iPSC or iPSC-derived cell having a CD3 related surface triggering receptor, the cell comprises at least one of: (i) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD3y, and a full or partial length of endodomain of CD3(^ [tgCD3(s-y)-Q; (ii) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD36, and a full or partial length of endodomain of CD3(^ [tgCD3(s-6)-Q; (iii) a transgenic fusion protein comprising a full or partial length of ectodomain of CD3s, a transgenic fusion protein comprising a full or partial length of ectodomain of CD3y or CD36, a full or partial length of endodomain of CD3(^, and a signaling domain of CD28 [tgCD3(s- y / 6)-28Q; (iv) a transgenic fusion protein comprising a full or partial length of ectodomain of CD3s, a transgenic fusion protein comprising a full or partial length of ectodomain of CD3y or CD36, a full or partial length of endodomain of CD3(^, and a signaling domain of 41BB [tgCD3(s- y / 6)-BBQ; and / or (v) a transgenic fusion protein comprising a full or partial length of ectodomain of CD3y or CD36, a full or partial length of endodomain of CD3(^, a signaling domain of CD28, and a signaling domain of 41BB [tgCD3(s- y / 6)-(28-BB)Q. [000217] Further provided herein is an iPSC comprising one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and a polynucleotide encoding a high affinity non-cleavable CD 16 (hnCD16), wherein the iPSC is capable of directed differentiation to produce functional derivative hematopoietic cells. In some embodiments, the effector cells comprise T cells. In some embodiments, the effector cells comprise NK cells. [000218] An iPSC comprising one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and a polynucleotide encoding a target specific chimeric antigen receptor (CAR) is provided herein, wherein the iPSC is capable of directed differentiation to produce functional derivative effector cells. [000219] Additionally provided is an iPSC comprising one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and a polynucleotide encoding at least one exogenous cytokine and / or its receptor (IL) to enable cytokine signaling contributing to cell survival, persistence and / or expansion, wherein the iPSC line is capable of directed differentiation to produce functional derivative hematopoietic cells having improved survival, persistency, expansion, and effector cell function. In some embodiments, the iPSC comprising cs-CD3 is TCR negative (TCRneg cs-CD3). The exogenously introduced cytokine signaling(s) comprise the signaling of any one, or two, or more of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, and IL21. In some embodiments, the introduced partial or full peptide of cytokine and / or its respective receptor for cytokine signaling are expressed on the cell surface. In some embodiments, the cytokine signaling is constitutively activated. In some embodiments, the activation of the cytokine signaling is inducible. In some embodiments, the activation of the cytokine signaling is transient and / or temporal. In some embodiments, the transient / temporal expression of a cell surface cytokine / cytokine receptor is through a retrovirus, Sendai virus, an adenovirus, an episome, mini-circle, or RNAs including mRNA. In some embodiments, the exogenous cell surface cytokine and / or receptor comprised in the TCRneg cs-CD3 iPSC or derivative cells therefrom enables IL7 signaling. In some embodiments, the exogenous cell surface cytokine and / or receptor comprised in the TCRneg cs-CD3 iPSC or derivative cells therefrom enables IL 10 signaling. In some embodiments, the exogenous cell surface cytokine and / or receptor comprised in the TCRneg cs-CD3 iPSC or derivative cells therefrom enables IL15 signaling. In some embodiments of said TCRneg cs-CD3 IL iPSC, the IL15 expression is through construct 3 of FIG. 2. In some embodiments of said TCRneg cs-CD3 IL iPSC, the IL15 expression is through construct 4 of FIG. 2. Said TCRneg cs-CD3 IL iPSC and its derivative cells of the above embodiments are capable of maintaining or improving cell growth, proliferation, expansion, and / or effector function autonomously without contacting additionally supplied soluble cytokines in vitro or in vivo. In some embodiments, TCRneg cs-CD3 IL iPSC and its derivative effector cells can be used with an anti-CD38 antibody to induce ADCC without causing effector cell elimination, thereby synergistically increasing the iPSC and its effector cell persistence and / or survival. [000220] Further provided is an iPSC comprising one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and a CD38 knockout, wherein the iPSC is capable of directed differentiation to produce functional derivative hematopoietic cells having improved survival, persistency, expansion, and effector cell function. In some embodiments, the iPSC comprising cs-CD3 is TCR negative (TCRneg cs-CD3). Cell surface molecule CD38 is highly upregulated in multiple hematologic malignancies derived from both lymphoid and myeloid lineages, including multiple myeloma and a CD20 negative B-cell malignancy, which makes it an attractive target for antibody therapeutics to deplete cancer cell. Other than being highly expressed on malignant cells, CD38 is also expressed on plasma cells as well as on NK cells, and activated T and B cells. In some embodiments, when an anti-CD38 antibody, a CD38 binding CAR, or an CD3 engager comprising anti-CD38 scFV is used to induce the ADCC and / or tumor cell targeting, the TCRneg cs-CD3 CD38' / _ iPSC and / or its derivative effector cells can target the CD38 expressing (tumor) cells without causing effector cell elimination, i.e., reduction or depletion of CD38 expressing effector cells, thereby increasing the iPSC and its effector cell persistence and / or survival. [000221] Also provided is an iPSC comprising one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, a B2M knockout and a CIITA knockout, and optionally, a polynucleotide encoding HLA-G, wherein the iPSC is capable of directed differentiation to produce functional derivative hematopoietic cells. In some embodiments, the iPSC comprising cs-CD3 is TCR negative (TCRneg cs-CD3). In some embodiments, said TCRneg cs-CD3 B2M' / _ CIITA'7' iPSC and its derivative effector cells are both HLA-I and HLA-II deficient. [000222] In view of the above, provided herein include an iPSC comprising one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex, or one or more subunits or subdomains thereof (cs-CD3) when expressed, and optionally one, two, three or all four of: hnCD16, CAR, an exogenous cytokine / receptor, and B2M / CIITA knockout; wherein when B2M is knocked out, a polynucleotide encoding HLA-G, or alternatively, one or both of CD58 and CD54 knockout, is optionally introduced, and wherein the iPSC is capable of directed differentiation to produce functional derivative hematopoietic cells. In some embodiments, the iPSC comprising cs-CD3 is TCR negative (TCRneg cs-CD3). Also included in this application are functional iPSC derivative hematopoietic cells comprising a TCRneg, cs-CD3, and optionally one, two, three or all four of: hnCD16, B2M / CIITA knockout, CAR, and an exogenous cytokine / receptor; wherein when B2M is knocked out, a polynucleotide encoding HLA-G, or alternatively, one or both of CD58 and CD54 knockout, is optionally introduced, and wherein the derivative hematopoietic cells include, but are not limited to, mesodermal cells with definitive hemogenic endothelium (HE) potential, definitive HE, CD34 hematopoietic cells, hematopoietic stem and progenitor cells, hematopoietic multipotent progenitors (MPP), T cell progenitors, NK cell progenitors, myeloid cells, neutrophil progenitors, T cells, NKT cells, NK cells, B cells, neutrophils, dendritic cells, and macrophages. [000223] Another aspect provided herein includes an iPSC or iPSC derived cells comprising TCRneg, cs-CD3, and a truncated fusion protein of IL15 and IL15Ra, wherein the fusion protein does not comprise an intracellular domain. Shown as “IL15Ra(AICD) fusion” and “IL5 / mb-Sushi” in FIG. 2, these embodiments are further collectively abbreviated as IL15 A throughout this application. In some embodiments, the truncated IL15 / IL15Ra fusion protein lacking intracellular domain comprises an amino acid sequence of at least 75%, 80%, 85%, 90%, 95% or 99% identity to SEQ ID NOs: 17, 19 or 21. In some embodiments, the truncated IL15 / IL15Ra fusion protein lacking intracellular domain comprises an amino acid sequence of SEQ ID NO: 17. In some embodiments, the truncated IL15 / IL15Ra fusion protein lacking intracellular domain comprises an amino acid sequence of SEQ ID NO: 19 . In some embodiments, the truncated IL15 / IL15Ra fusion protein lacking intracellular domain comprises an amino acid sequence of SEQ ID NO: 21. In yet some other embodiments, the iPSC or iPSC derived cells comprising TCRneg, cs-CD3, a truncated IL15 / IL15Ra fusion protein lacking intracellular domain (IL 15A) further comprise one or more of: CD38 knockout, hnCD16, CAR, an exogenous cytokine / receptor, and B2M / CIITA knockout; wherein when B2M is knocked out, a polynucleotide encoding HLA-G is optionally introduced, and wherein the iPSC is capable of directed differentiation to produce functional derivative hematopoietic cells, and wherein the derivative hematopoietic cells include, but are not limited to, mesodermal cells with definitive hemogenic endothelium (HE) potential, definitive HE, CD34 hematopoietic cells, hematopoietic stem and progenitor cells, hematopoietic multipotent progenitors (MPP), T cell progenitors, NK cell progenitors, myeloid cells, neutrophil progenitors, T cells, NKT cells, NK cells, B cells, neutrophils, dendritic cells, and macrophages. [000224] As such, the present application provides iPSCs and its functional derivative hematopoietic cells, which comprise any one of the following genotypes in Table 1. “IL”, as provided in Table 1 stands for one of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, and IL21, depending on which specific cytokine / receptor expression is selected; and when IL stands for IL15, it also comprises IL15A, which is detailed above as a truncated fusion protein of IL15 and IL15Ra but without an intracellular domain. Further, when iPSCs and its functional derivative hematopoietic cells have a genotype comprising both CAR and IL, the CAR and IL are optionally comprised in a bi-cistronic expression cassette comprising a 2A sequence. As comparison, in some other embodiments, CAR and IL are in separate expression cassettes comprised in iPSCs and its functional derivative hematopoietic cells. In one particular embodiment, comprised in the iPSCs and its functional derivative effector cells expressing both CAR and IL, IL is IL15 in a construct 3 or 4 of FIG. 2, wherein the IL15 construct is comprised in an expression cassette with, or separate from, the CAR. Table 1: Applicable Genotypes of the Cells Provided: cs- CD3 TCRneg hnCD16 CAR IL CD38- / - BZM^CIITA / - HLA-G or (CD58 7 w / orw / o CD547) Genotype V 1 cs-CD3 V V z cs-CD3 TCRneg V V 3 cs-CD3 hnCD16 V V 4 cs-CD3 CAR V V 5 cs-CD3 IL V V 6 cs-CD3 CD38- / - V V 7' cs-CD3 B2M7CIITA7’ V V V 8    cs-CD3 B2M' / 'CIITA' / 'CD58' / ' 9■   cs-CD3 B2M' / 'CIITA' / 'CD54' / ' 10■ cs-CD3 B2M / CIITA / CD58 / - CD547' 1L cs-CD3 B2M7CIITA7'HLA-G V V V 12 cs-CD3TCRneghnCD16 V V V 13' cs-CD3 TCRneg CAR V V V 14' cs-CD3TCRneg IL V V V 15 cs-CD3 TCRneg CD38- / - V V V 16' cs-CD3 TCRneg B2M7CHTA7' V V V V 17' cs-CD3 TCRneg B2M / CIITA / CD58 / - 18' cs-CD3 TCRneg B2M / CIITA / CD54 / - 19' cs-CD3 TCRneg B2M / CIITA / CD58 / - CD547' 20' cs-CD3 TCRneg B2M / CIITA a HLA-G V V V 21 cs-CD3 hnCD16 CAR V V V 22 cs-CD3 hnCD16 IL V V V 23 cs-CD3 hnCD16 CD38- / - V V V 24 cs-CD3 hnCD16 621^ 0ITA7’ V V V V 25 cs-CD3 hnCD16 B2M / CIITA / CD58 / - 26 cs-CD3 hnCD16 621^ 0ITA7’CD54 A 27 cs-CD3 hnCD16 B2M / CIITA / CD58 / - CD547' 28 cs-CD3 hnCD16 B2M / CIITA7’ HLA-G V V V 29 cs-CD3 CAR IL WO 2020 / 210398                                                 PCT / US2020 / 027327 00 m Q cj or < cj m Q cj CO (J d m < H o 1 rxl CD or < cj m Q cj CO (J rn 32 CS-CD3 CAR BZM / CIITA / CDSS7- 33 CS-CD3 CAR BZM / CIITA / CDSA7- 34' cs-CD3 CAR BZM / CIITA / CDSS7- CD54 / ' 35 cs-CD3 CAR B2M / CIITA / - HLA-G 00 m Q cj ________1 m Q cj CO (J cn < H o 1 rxl CD ________i m Q cj CO cj cn 38 CS-CD3 IL BZM / CIITA / CDSS7- 39' cs-CD3 IL B2M / -CIITA- / CD54- / - 40' cs-CD3 IL B2M- / CIITA- / -CD58- / - CD54 / ' 4L cs-CD3 IL B2M- / CIITA- / -HLA-G 42 cs-CD3 CD38- / - B2M / CIITA / - 't LD Q (J 00 it 00 S3 in in in <r Q Q Q _1 (J (J (J X <c <c <c <c H H H H o o o o rxl rxl rxl rxl CD CD CD CD 00 00 00 00 m m m m Q Q Q Q CJ CJ CJ CJ m m m m Q Q Q Q cj cj cj cj co co co co o o o o rn •si- lo co 47 cs-CD3 TCRneg hnCD16 CAR ________1 LO Q O C _c no QJ G or o 1m Q o co (J 00 49   cs-CD3 TCRneg hnCD16 CD38- / - 50- cs-CD3 TCRneg hnCD16 B2M / CIITA7- LT) Q O > > > (0 00      00   1 LT) LT) LT) < Q Q Q -I CJ CJ CJ X <c <c <c <c H H H H □ □ □ □ rxl rxl rxl rxl CD CD CD CD tlO tlO tlO tlO QJ QJ QJ QJ G  G  G  G or or or or o o o o H H H H m m m m Q Q Q Q CJ CJ CJ CJ co  co  co  co (J  (J  (J  (J LT) S S S ________1 or < CJ M QJ G or CJ 1m Q CJ co (J 00 m Q CJ or < CJ M QJ G or CJ 1m Q CJ co (J 57' CS-CD3 TCRneg CAR B2M / CIITA 7' 't LD Q (J 00 if 00 't3 LD LD LD <T Q Q Q -I (J (J (J X <c <c <c <c H H H H o o o o rxl rxl rxl rxl CD CD CD CD or or or or < < < < o o o o tlO tlO tlO tlO QJ QJ QJ QJ G  G  G  G or or or or o o o o H H H H m m m m Q Q Q Q CJ CJ CJ CJ co co co co (J (J (J (J oo d d vh 00 m Q CJ ________1 M QJ G or CJ 1m Q CJ co (J s 63' CS-CD3 TCRneg IL B2M / CIITA 7' > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > LD Q (J 00      00 't3 m m m < Q Q Q _1 (J (J (J X 1111 o o o o rxl rxl rxl rxl CD CD CD CD ________1 ________l ________l ________l no no no no <U QJ QJ QJ c c c c or or or or cj cj cj cj H H H H m m m m Q Q Q Q cj cj cj cj co co co co (J (J (J (J <c H o 1 r\l CD 00 m Q O no <U G or cj 1 m Q cj co cj oo LD Q (J 00      00  't3 m m m «± Q Q Q _1 (J (J (J X <c <c <c <c H H H H o o o o rxl rxl rxl rxl CD CD CD CD 00 00 00 00 m m m m Q Q Q Q CJ CJ CJ CJ no no no no <U QJ QJ QJ G  G  G  G or or or or u u u u H H H H m m m m Q Q Q Q cj cj cj cj co  co  co  co (J  (J  (J  (J g O T-i <N 73 cs-CD3 hnCD16 CAR IL 74 cs-CD3 hnCD16 CAR CD38- / - <c H o 1 rxl CD or < cj co Q CJ c _c m Q cj co cj 76 CS-CD3 hnCD16 CAR EZI^-CHTA7' CD587- 77 cs-CD3 hnCD16 CAR EZI^-CHTA7' CD547' 78 cs-CD3 hnCD16 CAR EZI^-CHTA7' CD587- CD547' 79 cs-CD3 hnCD16 CAR EZI^-CHTA7' HLA-G 80 cs-CD3 hnCD16 IL CD38- / - - / -V±ID- / -IAIZ9 11 9ldDuq EOJ-so T8 LH Q O > > > CO 00      00   1 LT) LT) LT) < Q Q Q -I CJ CJ CJ X < < < < H H H H u u u u rsi rsi rsi rsi CD CD CD CD m m m m Q Q Q Q u u u u co co co co (J (J (J (J <n rn          lo 00 00 00 00 - / -V1ID- / -IAIZ9 7-8E0D 9ldDuq EdJ-so 98 'S-LD Q (J 00      00 't3 in in in <r Q Q Q _1 (J (J (J X <r <c <c <c u u u u rsi rsi rsi rsi CD CD CD CD 00 00 00 00 m m m m Q Q Q Q u u u u ID IO IO ID Q Q Q Q u u u u c c c c _c _c _c _c m m m m Q Q Q Q u u u u co  co  co  co (J  (J  (J  (J od cri o 00   00   00 CH 91 cs-CD3 CAR ILCD38- / - <c H CJ rsl CD ________i or < o m Q CJ co (J LD Q (J > > > m 00      00 1 in in in <r Q Q Q _1 (J (J (J X <c <c <c <c H H H H u u u u rsi rsi rsi rsi CD CD CD CD ________1 ________1 ________1 ________1 or or or or < < < < u u u u m m m m Q Q Q Q u u u u co co co co (J (J (J (J rn          lo cd 97  CS-CD3 CAR CD38- / - B2M aCIITA a > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > LD Q (J > > > m 00      00   i m m m < Q Q Q _1 CJ CJ CJ X < < < < H H H H U U U U rsl rsl rsl rsl CO CO CO CO 00 00 00 00 m m m m Q Q Q Q (J (J (J (J cc cc cc cc < < < < (J (J (J (J m m m m Q Q Q Q u u u u vi vi vi vi <j <j <j <j .        . ¢5 <-i CC g O O < H o 1 r\l CD ob m Q O ________i m Q o CO (J <N o LD Q (J > > > m 00      00   1 m m m < Q Q Q _l CJ CJ CJ X < < < < H H H H o o o o rsi rsi rsi rsi CD CD CD CD ob ob ob ob m m m m Q Q Q Q o o o o _l —1 —1 —1 m m m m Q Q Q Q o o o o co  co  co  co o o o o rn 'si lo co o o o o ________1 or < o LO Q O C _c no <U G or o 1 m Q o co cj o 00 m Q o or < o LO Q O C _c M <U G or o 1m Q o co cj 00 o <c H □ 1 r\i CD or < o LO Q O C _c M <U G or o 1m Q o co cj o LO Q (J bo bo 't3 m m m «± Q Q Q _1 (J (J (J X <c <c <c <c H H H H □ □ □ □ rsl rsl rsl rsl □Q 00 00 00 uo uo uo uo Q Q Q Q (J (J (J (J c c c c -C -C -C -C M M M M <U     QJ     QJ     QJ G  G  G  G or or or or o o o o H H H H m m m m Q Q Q Q o o o o co  co  co  co (J  (J  (J  (J O T-i <N rn 00 m Q o ________1 or < o LO Q O C _c m Q o co (J <c H □ rsl CO ________i or < o LO Q O C _c m Q o co (J 'S' LO Q (J 00      00 't3 in in in <r Q Q Q _1 (J (J (J X <c <c <c <c H H H H □ □ □ □ rsl rsl rsl rsl □Q 00 00 00 ________1 ________1 ________1 ________1 or or or or < < < < o o o o LO LO LO LO Q Q Q Q O O O O C C C C _c _c _c _c m m m m Q Q Q Q o o o o co co co co (J (J (J (J CD pL od oS < H o rsi CD ob m Q O ________i LO Q O C _c m Q o co (J d Cxi 'S' LO Q (J > > > m 00 'S' 00   1 in in in <r Q Q Q -I (J (J (J X < < < < H H H H rsi rsi rsi rsi CD CD CD CD ob ob ob ob m m m m Q Q Q Q o o o o ________1 ________1 ________1 ________1 LO LO LO LO Q Q Q Q O O O O c c c c _c _c _c _c m m m m Q Q Q Q o o o o co co co co (J (J (J (J T-i <n rn «si <N <N <N <N < H o rsl CD ob m Q O ________i or < o m Q o co (J <N LO Q (J oo bo 't3 in in in <r Q Q Q _1 (J (J (J X < < < < H H H H O LJ LJ LJ rsi rsi rsi rsi CD CD CD CD ob ob ob ob m m m m Q Q Q Q o o o o ________1 ________1 ________1 ________1 or or or or < < < < o o o o m m m m Q Q Q Q o o o o co co co co (J (J (J (J cd pL od d <N <N <N <N 00 m Q o ________1 or < o LO Q O C _c M QJ G or o 1m Q o co (J d m <c H □ r\i CD ________i or < o LO Q O C _c M QJ G or o 1m Q o co (J rn > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > 132 CS-CD3 TCRneg hnCD16 CAR IL BZM / CHTA / CDSS / - 133 CS-CD3 TCRneg hnCD16 CAR IL B2M / CIITA / CD54 / - 134 cs-CD3 TCRneg hnCD16 CAR IL B2M / CIITA / CD58 / - CD547- 135 cs-CD3 TCRneg hnCD16 CAR IL B2M / CIITA / - HLA-G 136 cs-CD3 hnCD16 CAR IL CD38- / - B2M / CIITA / _ 137 cs-CD3 hnCD16 CAR IL CD38- / - B2M / CIITA / -CD58 / - 138 cs-CD3 hnCD16 CAR IL CD38- / - B2M / CIITA / -CD54 / - 139 cs-CD3 hnCD16 CAR IL CD38- / -B2M- / CIITA- / CD58- / - CD547- 140 cs-CD3 hnCD16 CAR IL CD38- / -B2M / CIITA / - HLA-G 141 cs-CD3 TCRneg hnCD16 CAR IL CD38- / - B2M / CIITA / _ ^i-LD Q , (J oo oo S5 LO £ LD < 8 6 8 i 1 i i rxl       rxl (N QQ “J QQ QQ 00 00 00 00 m m m m Q Q Q Q O O O O ________i         i         i ________i or or or or < < < < o o o o co co co co Q Q Q Q O O O O C C C C _c _c _c x: m no no no QJ QJ QJ QJ c c c c or or or or o o o o H H H H m m m m Q Q Q Q o o o o co  co  co  co (J  (J  (J  (J <n rn •si’ tri > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > 9.    Antibodies for immunotherapy [000225] In some embodiments, in addition to the genomically engineered effector cells as provided herein, additional therapeutic agent comprising an antibody, or an antibody fragment that targets an antigen associated with a condition, a disease, or an indication may be used with these effector cells in a combinational therapy. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a humanized antibody, a humanized monoclonal antibody, or a chimeric antibody. In some embodiments, the antibody, or antibody fragment, specifically binds to a viral antigen. In other embodiments, the antibody, or antibody fragment, specifically binds to a tumor antigen. In some embodiments, the tumor or viral specific antigen activates the administered iPSC derived effector cells to enhance their killing ability. In some embodiments, the antibodies suitable for combinational treatment as an additional therapeutic agent to the administered iPSC derived effector cells include, but are not limited to, anti-CD20 (rituximab, veltuzumab, ofatumumab, ublituximab, ocaratuzumab, obinutuzumab, ibritumomab, ocrelizumab), anti-CD22 (inotuzumab, moxetumomab, epratuzumab), anti-HER2 (trastuzumab, pertuzumab), anti-CD52 (alemtuzumab), anti-EGFR (certuximab), anti-GD2 (dinutuximab), anti-PDLl (avelumab), anti-CD38 (daratumumab, isatuximab, MOR202), anti-CD123 (7G3, CSL362), anti-SLAMF7 (elotuzumab), and their humanized or Fc modified variants or fragments or their functional equivalents and biosimilars. In some embodiments, the antibodies suitable for combinational treatment as an additional therapeutic agent to the administered iPSC derived effector cells further include bispecific or multi-specific antibodies that target more than one antigen or epitope on a target cell or recruit effector cells (T cell, NK cell, or macrophage cell) toward target cells while targeting the target cells. Such bispecific or multi-specific antibodies function as an engager capable of directing an effector cell, e.g. a T cell, a NK cell, an NKT cell, a B cell, a macrophage, and / or a neutrophil to a tumor cell and activating the immune effector cell, and have shown great potential to maximize the benefits of antibody therapy. An engager is specific to at least one tumor antigen and is specific to at least one surface triggering receptor of an immune effector cell. Examples of engagers include, but are not limited to, bi-specific T cell engagers (BiTEs), bi-specific killer cell engagers (BiKEs), tri-specific killer cell engagers (TriKEs), or multi- specific killer cell engagers, or universal engagers compatible with multiple immune cell types. [000226] In some embodiments, the iPSC derived effector cells comprise hematopoietic lineage cells comprising a genotype listed in Table 1. In some embodiments, the iPSC derived effector cells comprise NK cells comprising a genotype listed in Table 1. In some embodiments, the iPSC derived effector cells comprise T cells comprising a genotype listed in Table 1. In some embodiments of a combination useful for treating liquid or solid tumors, the combination comprises iPSC derived NK or T cells comprising at least TCRnegcs-CD3, and a bi-specific or multi-specific antibody that engages cells having cell surface CD3. The CD3 engager comprises at least a first variable segment that binds to a cs-CD3 and a second variable segment that binds to an antigen comprising at least one of ADGRE2, carbonic anhydrase IX (CAIX), CCRI, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CDS, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell, epithelial glycoprotein2 (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine-protein kinases erb- B2,3,4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), ICAM-1, Integrin B7, Interleukin-13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A(CA19.9), Lewis Y (LeY), LI cell adhesion molecule (Ll-CAM), LILRB2, melanoma antigen family A 1 (MAGE-A1), MICA / B, Mucin 1 (Muc-1), Mucin 16 (Muc-16), Mesothelin (MSLN), NKCSI, NKG2D ligands, c-Met, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), PRAME, prostate stem cell antigen (PSCA), PRAME prostate-specific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), TIM-3, TRBCI, TRBC2, vascular endothelial growth factor R2 (VEGF- R2), Wilms tumor protein (WT-1), and / or a pathogen antigen. [000227] In some embodiments of the CD3 engager, the engager comprises at least a first variable segment that binds to a cs-CD3 and a second variable segment that binds to an antigen comprising at least one of BCMA, CD19, CD20, CD33, CD38, CD52, CD123, CEA, EGFR, EpCAM, GD2, GPA33, HER2, MICA / B, PDL1, and / or PSMA. In yet some other embodiments of the CD3 engager, the engager comprises a second variable segment that binds to an antigen comprising at least one of CD19, CD33, CD123, CEA, EpCAM, GPA33, HER2, and / or PSMA. In still some other embodiments of the CD3 engager, the engager is at least one of: blinatumomab, catumaxomab, ertumaxomab, RO6958688, AFM11, MT110 / AMG 110, MT111 / AMG211 / MEDI-565, AMG330, MT112 / BAY2010112, MOR209 / ES414, MGD006 / S80880, MGD007, and / or FBTA05. In one embodiment, the combination comprises a CD3 engager and iPSC derived NK cells comprising TCRnegcs-CD3 and hnCD16. In one embodiment, the combination comprises a CD3 engager and iPSC derived NK cells comprising TCRnegcs-CD3 and hnCD16. In some further embodiments, the iPSC derived NK cells comprised in the combination with a CD3 engager comprise TCRnegcs-CD3, hnCD16, IL15, and a CAR targeting one of CD19, BCMA, CD20, CD22, CD38, CD123, HER2, CD52, EGFR, GD2, and PDL1; wherein the IL15 is co- or separately expressed with the CAR; and IL15 is in any one of the forms presented in constructs 1 to 7 of FIG. 2. In some particular embodiments, IL15 is in a form of construct 3, 4, or 7 when it is co- or separately expressed with the CAR. 10. Checkpoint inhibitors [000228] Checkpoints are cell molecules, often cell surface molecules, capable of suppressing or downregulating immune responses when not inhibited. It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Checkpoint inhibitors (CI) are antagonists capable of reducing checkpoint gene expression or gene products, or deceasing activity of checkpoint molecules, thereby block inhibitory checkpoints, restoring immune system function. The development of checkpoint inhibitors targeting PD1 / PDL1 or CTLA4 has transformed the oncology landscape, with these agents providing long term remissions in multiple indications. However, many tumor subtypes are resistant to checkpoint blockade therapy, and relapse remains a significant concern. One aspect of the present application provides a therapeutic approach to overcome CI resistance by including genomically engineered functional iPSC-derived cells as provided in a combination therapy with CI. In one embodiment of the combination therapy, the iPSC-derived cells are NK cells. In another embodiment of the combination therapy, the iPSC-derived cells are T cells. In addition to exhibiting direct antitumor capacity, the derivative NK cells provided herein have been shown to resist PDL1-PD1 mediated inhibition, and to have the ability to enhance T cell migration, to recruit T cells to the tumor microenvironment, and to augment T cell activation at the tumor site. Therefore, the tumor infiltration of T cell facilitated by the functionally potent genomically engineered derivative NK cells indicate that said NK cells are capable of synergizing with T cell targeted immunotherapies, including the checkpoint inhibitors, to relieve local immunosuppression and to reduce tumor burden. [000229] In one embodiment, the derived TCRnegNK cell for checkpoint inhibitor combination therapy comprises cs-CD3, and optionally one, two, three or all four of: hnCD16 expression, B2M / CIITA knockout, CAR expression, CD38 knockout, and an exogenous cell surface cytokine and / or receptor expression; wherein when B2M is knocked out, a polynucleotide encoding HLA-G or knockout of one or both of CD58 and CD54 is optionally included. In some embodiments, the derivative NK cell comprises any one of the genotypes listed in Table 1. In some embodiments, the above derivative NK cell additionally comprises deletion or reduced expression in at least one of TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; or introduced or increased expression in at least one of HLA-E, 41 BBL, CD3, CD4, CD8, CD47, CD113, CD131, CD137, CD80, PDL1, A2aR, CAR, Fc receptor, an engager, and surface triggering receptor for coupling with bi-, multi- specific or universal engagers. [000230] In another embodiment, the derived TCRneg T cell for checkpoint inhibitor combination therapy comprises cs-CD3, and optionally one, two, three or all four of: hnCD16 expression, B2M / CIITA knockout, CAR expression, a CD38 knockout, and an exogenous cell surface cytokine and / or receptor expression; wherein when B2M is knocked out, a polynucleotide encoding HLA-G or knockout of one or both of CD58 and CD54 is optionally included. In some embodiments, the derivative T cell comprises any one of the genotypes listed in Table 1. In some embodiments, the above derivative T cell additionally comprises deletion or reduced expression in at least one of TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; or introduced or increased expression in at least one of HLA-E, 41BBL, CD3, CD4, CD8, CD47, CD113, CD131, CD137, CD80, PDL1, A2aR, CAR, Fc receptor, an engager, and surface triggering receptor for coupling with bi-, multi- specific or universal engagers. [000231] Above said derivative NK or T cell is obtained from differentiating an iPSC clonal line comprising TCRnegcs-CD3, and optionally one, two, three or all four of: hnCD16 expression, B2M / CIITA knockout, CAR expression, CD38 knockout, and an exogenous cell surface cytokine expression; wherein when B2M is knocked out, a polynucleotide encoding HLA-G or knockout of one or both of CD58 and CD54 is optionally introduced. In some embodiments, above said iPSC clonal line further comprises deletion or reduced expression in at least one of TAPI, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; or introduced or increased expression in at least one of HLA-E, 41BBL, CD3, CD4, CD8, CD47, CD113, CD131, CD137, CD80, PDL1, A2AR, CAR, Fc receptor, an engager, and surface triggering receptor for coupling with bi-, multi- specific or universal engagers. [000232] Suitable checkpoint inhibitors for combination therapy with the derivative NK or T cells as provided herein include, but are not limited to, antagonists of PD-1 (Pdcdl, CD279), PDL-1 (CD274), TIM-3 (Havcr2), TIGIT (WUCAM and Vstm3), LAG-3 (Lag3, CD223), CTLA-4 (Ctla4, CD152), 2B4 (CD244), 4-1BB (CD137), 4-1BBL (CD137L), A2aR, BATE, BTLA, CD39 (Entpdl), CD47, CD73 (NT5E), CD94, CD96, CD 160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxpl, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2 (Pou2f2), retinoic acid receptor alpha (Rara), TLR3, VISTA, NKG2A / HLA-E, and inhibitory KIR (for example, 2DL1, 2DL2, 2DL3, 3DL1, and 3DL2). [000233] In some embodiments, the antagonist inhibiting any of the above checkpoint molecules is an antibody. In some embodiments, the checkpoint inhibitory antibodies may be murine antibodies, human antibodies, humanized antibodies, a camel Ig, a shark heavy-chain-only antibody (VNAR), Ig NAR, chimeric antibodies, recombinant antibodies, or antibody fragments thereof. Non-limiting examples of antibody fragments include Fab, Fab', F(ab)'2, F(ab)'3, Fv, single chain antigen binding fragments (scFv), (scFv)2, disulfide stabilized Fv (dsFv), minibody, diabody, triabody, tetrabody, single-domain antigen binding fragments (sdAb, Nanobody), recombinant heavy-chain-only antibody (VHH), and other antibody fragments that maintain the binding specificity of the whole antibody, which may be more cost-effective to produce, more easily used, or more sensitive than the whole antibody. In some embodiments, the one, or two, or three, or more checkpoint inhibitors comprise at least one of atezolizumab (anti-PDL1 mAb), avelumab (anti-PDLl mAb), durvalumab (anti-PDLl mAb), tremelimumab (anti-CTLA4 mAb), ipilimumab (anti-CTLA4 mAb), IPH4102 (anti-KIR), IPH43 (anti-MICA), IPH33 (anti-TLR3), lirimumab (anti-KIR), monalizumab (anti-NKG2A), nivolumab (anti-PDl mAb), pembrolizumab (anti-PDl mAb), and any derivatives, functional equivalents, or biosimilars thereof. [000234] In some embodiments, the antagonist inhibiting any of the above checkpoint molecules is microRNA-based, as many miRNAs are found as regulators that control the expression of immune checkpoints (Dragomir et al., Cancer Biol Med. 2018, 15(2):103-115). In some embodiments, the checkpoint antagonistic miRNAs include, but are not limited to, miR-28, miR-15 / 16, miR-138, miR-342, miR-20b, miR-21, miR-130b, miR-34a, miR-197, miR-200c, miR-200, miR-17-5p, miR-570, miR-424, miR-155, miR-574-3p, miR-513, and miR-29c. [000235] Some embodiments of the combination therapy with the provided iPSC-derived NK or T cells comprise at least one checkpoint inhibitor to target at least one checkpoint molecule; wherein the iPSC-derived cells have a genotype listed in Table 1. Some other embodiments of the combination therapy with the provided derivative NK or T cells comprise two, three or more checkpoint inhibitors such that two, three, or more checkpoint molecules are targeted. In some embodiments of the combination therapy comprising at least one checkpoint inhibitor and the iPSC-derived cells having a genotype listed in Table 1, said checkpoint inhibitor is an antibody, or a humanized or Fc modified variant or fragment, or a functional equivalent or biosimilar thereof, and said checkpoint inhibitor is produced by the iPSC-derived cells by expressing an exogenous polynucleotide sequence encoding said antibody, or a fragment or variant thereof. In some embodiments, the exogenous polynucleotide sequence encoding the antibody, or a fragment or a variant thereof that inhibits a checkpoint is co-expressed with a CAR, either in separate constructs or in a bi-cistronic construct comprising both CAR and the sequence encoding the antibody, or the fragment thereof. In some further embodiments, the sequence encoding the antibody or the fragment thereof can be linked to either the 5’ or the 3’ end of a CAR expression construct through a self-cleaving 2A coding sequence, illustrated as, for example, CAR-2A-CI or CI-2A-CAR. As such, the coding sequences of the checkpoint inhibitor and the CAR are in a single open reading frame (ORF). When the checkpoint inhibitor is delivered, expressed and secreted as a payload by the derivative effector cells capable of infiltrating the tumor microenvironment (TME), it counteracts the inhibitory checkpoint molecule upon engaging the TME, allowing activation of the effector cells by activating modalities such as CAR or activating receptors. In some embodiments, the checkpoint inhibitor co-expressed with CAR inhibits at least one of the checkpoint molecules: PD-1, PDL-1, TIM-3, TIGIT, LAG-3, CTLA-4, 2B4, 4-1BB, 4-1BBL, A2aR, BATE, BTLA, CD39 (Entpdl), CD47, CD73 (NT5E), CD94, CD96, CD160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxpl, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2 (Pou2f2), retinoic acid receptor alpha (Rara), TLR3, VISTA, NKG2A / HLA-E, and inhibitory KIR. In some embodiments, the checkpoint inhibitor co-expressed with CAR in a derivative cell having a genotype listed in Table 1 is selected from a group comprising atezolizumab, avelumab, durvalumab, tremelimumab, ipilimumab, IPH4102, IPH43, IPH33, lirimumab, monalizumab, nivolumab, pembrolizumab, and their humanized, or Fc modified variants, fragments and their functional equivalents or biosimilars. In some embodiments, the checkpoint inhibitor coexpressed with CAR is atezolizumab, or its humanized, or Fc modified variants, fragments or their functional equivalents or biosimilars. In some other embodiments, the checkpoint inhibitor co-expressed with CAR is nivolumab, or its humanized, or Fc modified variants, fragments or their functional equivalents or biosimilars. In some other embodiments, the checkpoint inhibitor co-expressed with CAR is pembrolizumab, or its humanized, or Fc modified variants, fragments or their functional equivalents or biosimilars. [000236]    In some other embodiments of the combination therapy comprising the iPSC- derived cells provided herein and at least one antibody inhibiting a checkpoint molecule, said antibody is not produced by, or in, the iPSC-derived cells and is additionally administered before, with, or after the administering of the iPSC-derived cells having a genotype listed in Table 1. In some embodiments, the administering of one, two, three or more checkpoint inhibitors in a combination therapy with the provided derivative NK or T cells are simultaneous or sequential. In one embodiment of the combination treatment comprising derived NK cells or T cells having a genotype listed in Table 1, the checkpoint inhibitor included in the treatment is one or more of atezolizumab, avelumab, durvalumab, tremelimumab, ipilimumab, IPH4102, IPH43, IPH33, lirimumab, monalizumab, nivolumab, pembrolizumab, and their humanized orFc modified variants, fragments and their functional equivalents or biosimilars. In some embodiments of the combination treatment comprising derived NK cells or T cells having a genotype listed in Table 1, the checkpoint inhibitor included in the treatment is atezolizumab, or its humanized or Fc modified variant, fragment and its functional equivalent or biosimilar. In some embodiments of the combination treatment comprising derived NK cells or T cells having a genotype listed in Table 1, the checkpoint inhibitor included in the treatment is nivolumab, or its humanized or Fc modified variant, fragment or its functional equivalent or biosimilar. In some embodiments of the combination treatment comprising derived NK cells or T cells having a genotype listed in Table 1, the checkpoint inhibitor included in the treatment is pembrolizumab, or its humanized or Fc modified variant, fragment or its functional equivalent or biosimilar. II. Methods for Targeted Genome Editing at Selected Locus in iPSCs [000237] Genome editing, or genomic editing, or genetic editing, as used interchangeably herein, is a type of genetic engineering in which DNA is inserted, deleted, and / or replaced in the genome of a targeted cell. Targeted genome editing (interchangeable with “targeted genomic editing” or “targeted genetic editing”) enables insertion, deletion, and / or substitution at preselected sites in the genome. When an endogenous sequence is deleted at the insertion site during targeted editing, an endogenous gene comprising the affected sequence may be knocked-out or knocked-down due to the sequence deletion. Therefore, targeted editing may also be used to disrupt endogenous gene expression with precision. Similarly used herein is the term “targeted integration,” referring to a process involving insertion of one or more exogenous sequences, with or without deletion of an endogenous sequence at the insertion site. In comparison, randomly integrated genes are subject to position effects and silencing, making their expression unreliable and unpredictable. For example, centromeres and sub-telomeric regions are particularly prone to transgene silencing. Reciprocally, newly integrated genes may affect the surrounding endogenous genes and chromatin, potentially altering cell behavior or favoring cellular transformation. Therefore, inserting exogenous DNA in a pre-selected locus such as a safe harbor locus, or genomic safe harbor (GSH) is important for safety, efficiency, copy number control, and for reliable gene response control. [000238] Targeted editing can be achieved either through a nuclease-independent approach, or through a nuclease-dependent approach. In the nuclease-independent targeted editing approach, homologous recombination is guided by homologous sequences flanking an exogenous polynucleotide to be inserted, through the enzymatic machinery of the host cell. [000239] Alternatively, targeted editing could be achieved with higher frequency through specific introduction of double strand breaks (DSBs) by specific rare-cutting endonucleases. Such nuclease-dependent targeted editing utilizes DNA repair mechanisms including non-homologous end joining (NHEJ), which occurs in response to DSBs. Without a donor vector containing exogenous genetic material, the NHEJ often leads to random insertions or deletions (in / dels) of a small number of endogenous nucleotides. In comparison, when a donor vector containing exogenous genetic material flanked by a pair of homology arms is present, the exogenous genetic material can be introduced into the genome during homology directed repair (HDR) by homologous recombination, resulting in a “targeted integration.” In some situations, the targeted integration site is intended to be within a coding region of a selected gene, and thus the targeted integration could disrupt the gene expression, resulting in simultaneous knock-in and knockout (KI / KO) in one single editing step. [000240] Inserting one or more transgenes at a selected position in a gene locus of interest (GOI) to knock out the gene at the same time can be achieved. Gene loci suitable for simultaneous knock-in and knockout (KI / KO) include, but are not limited to, B2M, TAPI, TAP2, tapasin, NLRC5, CIITA, RFXANK, CIITA, RFX5, RFXAP, TCR a or p constant region, NKG2A, NKG2D, CD38, CD58, CD54, CD56, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, and TIGIT. With respective site-specific targeting homology arms for position-selective insertion, it allows the transgene(s) to express either under an endogenous promoter at the site or under an exogenous promoter comprised in the construct. When two or more transgenes are to be inserted at a selected location (e.g., in a CD38 locus), a linker sequence, for example, a 2A linker or IRES, is placed between any two transgenes. The 2A linker encodes a self-cleaving peptide derived from FMDV, ERAV, PTV-I, or TaV (referred to as "F2A", "E2A", "P2A", and "T2A", respectively), allowing for separate proteins to be produced from a single translation. In some embodiments, insulators are included in the construct to reduce the risk of transgene and / or exogenous promoter silencing. The exogenous promoter may be CAG, or other constitutive, inducible, temporal-, tissue-, or cell type- specific promoters including, but not limited to CMV, EFla, PGK, and UBC. [000241] Available endonucleases capable of introducing specific and targeted DSBs include, but not limited to, zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN), RNA-guided CRISPR (Clustered Regular Interspaced Short Palindromic Repeats) systems. Additionally, DICE (dual integrase cassette exchange) system utilizing phiC31 and Bxbl integrases is also a promising tool for targeted integration. [000242] ZFNs are targeted nucleases comprising a nuclease fused to a zinc finger DNA binding domain. By a “zinc finger DNA binding domain” or “ZFBD” it is meant a polypeptide domain that binds DNA in a sequence-specific manner through one or more zinc fingers. A zinc finger is a domain of about 30 amino acids within the zinc finger binding domain whose structure is stabilized through coordination of a zinc ion. Examples of zinc fingers include, but not limited to, C2H2 zinc fingers, C3H zinc fingers, and C4 zinc fingers. A “designed” zinc finger domain is a domain not occurring in nature whose design / composition results principally from rational criteria, e.g., application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP designs and binding data. See, for example, U.S. Pat. Nos. 6,140,081; 6,453,242; and 6,534,261; see also WO 98 / 53058; WO 98 / 53059; WO 98 / 53060; WO 02 / 016536 and WO 03 / 016496. A “selected” zinc finger domain is a domain not found in nature whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. ZFNs are described in greater detail in U.S. Pat. No. 7,888,121 and U.S. Pat. No. 7,972,854, the complete disclosures of which are incorporated herein by reference. The most recognized example of a ZFN in the art is a fusion of the FokI nuclease with a zinc finger DNA binding domain. [000243] A TALEN is a targeted nuclease comprising a nuclease fused to a TAL effector DNA binding domain. By “transcription activator-like effector DNA binding domain”, “TAL effector DNA binding domain”, or “TALE DNA binding domain” it is meant the polypeptide domain of TAL effector proteins that is responsible for binding of the TAL effector protein to DNA. TAL effector proteins are secreted by plant pathogens of the genus Xanthomonas during infection. These proteins enter the nucleus of the plant cell, bind effector-specific DNA sequences via their DNA binding domain, and activate gene transcription at these sequences via their transactivation domains. TAL effector DNA binding domain specificity depends on an effector-variable number of imperfect 34 amino acid repeats, which comprise polymorphisms at select repeat positions called repeat variable-diresidues (RVD). TALENs are described in greater detail in US Patent Application No. 2011 / 0145940, which is herein incorporated by reference. The most recognized example of a TALEN in the art is a fusion polypeptide of the FokI nuclease to a TAL effector DNA binding domain. [000244] Another example of a targeted nuclease that finds use in the subject methods is a targeted Spoil nuclease, a polypeptide comprising a Spoil polypeptide having nuclease activity fused to a DNA binding domain, e.g. a zinc finger DNA binding domain, a TAL effector DNA binding domain, etc. that has specificity for a DNA sequence of interest. See, for example, U.S. Application No. 61 / 555,857, the disclosure of which is incorporated herein by reference. [000245] Additional examples of targeted nucleases suitable for the present invention include, but not limited to Bxbl, phiC31, R4, PhiBTl, and Wp / SPBc / TP901-l, whether used individually or in combination. [000246] Other non-limiting examples of targeted nucleases include naturally occurring and recombinant nucleases; CRISPR related nucleases from families including cas, cpf, cse, csy, csn, csd, cst, csh, csa, csm, and cmr; restriction endonucleases; meganucleases; homing endonucleases, and the like. [000247] As an exemplary example, CRISPR / Cas9 requires two major components: (1) a Cas9 endonuclease and (2) the crRNA-tracrRNA complex. When co-expressed, the two components form a complex that is recruited to a target DNA sequence comprising PAM and a seeding region near PAM. The crRNA and tracrRNA can be combined to form a chimeric guide RNA (gRNA) to guide Cas9 to target selected sequences. These two components can then be delivered to mammalian cells via transfection or transduction. When use the CRISPR / Cpf system, it requires a Cpf endonuclease (Cpfl, MAD7 and many more known in the art) and (...

Claims

1. A cell or a population thereof, wherein(i) the cell is an induced pluripotent stem cell (iPSC), a clonal iPSC, or a clonal iPS cell line cell, or a derivative cell obtained from differentiating said iPSC;(ii) the cell lacks expression of an endogenous TCR (TCRneg);(iii) the cell comprises one or more polynucleotide encoding one or more exogenous protein to provide a cell surface CD3 complex that lacks antigen recognition activity (cs-CD3) when expressed;(iv) expression of the one or more exogenous protein in the cell or a T cell derived therefrom induces formation of the cs-CD3 comprising (a) a CD3Z endodomain, and (b) one or more of a CD3s ectodomain, a CD35 ectodomain, or a CD3y ectodomain;(v) the one or more exogenous protein comprises:(a) a nb-rTCR, wherein the nb-rTCR comprises a non-binding recombinant TCR characterized by (1) a tgTRAC that is a transgenic TCRa constant region lacking a TCRa variable region, or (2) a tgTRBC that is a transgenic TCR0 constant region lacking a TCRP variable region;(b) a p-rTCR, wherein the p-rTCR is a recombinant pre-TCR; comprising extracellular and intracellular domains of a pre-TCRa;(c) a nb-rTCR-CD3, wherein the nb-rTCR-CD3 is a non-binding recombinant TCR comprising a fusion protein comprising: (1) a tgTRAC that is a transgenic TCRa constant region or a tgTRBC that is a transgenic TCR0 constant region; (2) the CD3a ectodomain; and (3) the CD33 ectodomain or the CD3y ectodomain; or(d) a ccCD3, wherein the ccCD3 is a CD3 chimeric chain comprising a fusion between (1) the CD3a ectodomain; (2) the CD38 ectodomain or the CD3y ectodomain; and (3) the CD3Z endodomain; and(vi) the derivative cell comprises a derivative T cell or a progenitor thereof.

2. The cell or population thereof of claim 1, wherein the one or more polynucleotide encodesexogenous protein comprising one or more of:(i) a transgenic fusion protein comprising full or partial length of ectodomains of CD3a and CD36, and a full or partial TCRa constant region (tgCD3(£-5)-TRAC);(ii) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD3y, and a full or partial TCR0 constant region (tgCD3(£-Y)-TRBC);2020271523   29 Jun 2026(iii) a transgenic fusion protein comprising full or partial length of ectodomains of CD3e and CD3y, and a full or partial TCRa constant region (tgCD3(s-Y)-TRAC);(iv) a transgenic fusion protein comprising full or partial length of ectodomains of CD3e and CD38, and a full or partial TCR0 constant region (tgCD3(s-3)-TRBC);(v) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD3y, and a full or partial length of endodomain of CD3Z (tgCD3(E-y)-Z);(vi) a transgenic fusion protein comprising full or partial length of ectodomains of CD3s and CD33, and a full or partial length of endodomain of CD3Z (tgCD3(s-3)-Z);(vii) a transgenic fusion protein comprising a full or partial length of ectodomain of CD3e, a transgenic fusion protein comprising a full or partial length of ectodomain of CD3y or CD33, a full or partial length of endodomain of CD3Z, and a signaling domain of CD28 (tgCD3(s- y / 3)-28Z);(viii) a transgenic fusion protein comprising a full or partial length of ectodomain of CD3s, a transgenic fusion protein comprising a full or partial length of ectodomain of CD3y or CD33, a full or partial length of endodomain of CD3Z, and a signaling domain of 41BB (tgCD3(s- y / 3)-BBZ); and / or(ix) a transgenic fusion protein comprising a full or partial length of ectodomain of CD3y or CD33, a full or partial length of endodomain of CD3Z, a signaling domain of CD28, and a signaling domain of 41BB (tgCD3(s- y / 3)-(28-BB)Z).

3. The cell or population thereof of claim 2,wherein the one or more polynucleotide encoding tgTRAC, tgTCRa, p-rTCR, tgCD3(s-3)-TRAC, tgCD3(s-Y)-TRAC, tgCD3(e-y)-Z, tgCD3(s-3)-£, tgCD3(s- y / 3)-28£, tgCD3(s- y / 3)-BBZ, or tgCD3(s- y / 3)-(28-BB)Z is inserted in a TRAC locus, and optionally upon insertion, is operatively linked to endogenous promoter of TRAC; orwherein the one or more polynucleotide encoding tgTRBC, tgTCRp, tgCD3(s-Y)-TRBC, tgCD3(s-3)-TRBC, tgCD3(e-y)-Z, tgCD3(s-3)-Z, tgCD3(s- y / 3)-28£, tgCD3(s- y / 3)-BBZ, and / or tgCD3(s- y / 3)-(28-BB)Z is inserted in a TRBC locus, and optionally upon insertion, is operatively linked to endogenous promoter of TRBC.

4. The cell or population thereof of claim 3,wherein the transgenic fusion protein comprises a constant region of TCRa, and optionally an N-terminal signal peptide; orwherein the transgenic fusion protein comprises a constant region of TCRa and a poly A tail at C-terminal, and optionally an N-terminal signal peptide; or2020271523   29 Jun 2026wherein the transgenic fusion protein comprises a a partial length of the constant region of TCRa, and optionally an N-terminal signal peptide; and wherein the insertion of the polynucleotide is in an exon of the constant region and is in frame; orwherein the transgenic fusion protein comprises a full or partial length of the constant region of TCRP, and optionally an N-terminal signal peptide; orwherein the transgenic fusion protein comprises a full length of the constant region of TCRP, and optionally an N-terminal signal peptide; orwherein the transgenic fusion protein comprises a partial length of the constant region of TCRP, and optionally an N-terminal signal peptide; and wherein the insertion of the polynucleotide is in an exon of the constant region and is in frame.

5. The cell or population thereof of claim 3, wherein the one or more polynucleotide insertedin TRAC and / or TRBC locus disrupts expression of TRAC and TRBC, respectively, leading to TCRneg cell.

6. The cell or population thereof of claim 5, wherein the one or more polynucleotide insertedin TRAC and / or TRBC locus is driven by (i) an endogenous promoter of TRAC and TRBC respectively, or (ii) a heterologous promoter.

7. The cell or population thereof of claim 1, wherein(i) the nb-rTCR comprises both of a tgTRAC and a tgTRBC;(ii) the p-rTCR comprises a tgpTCRa, and optionally a tgTRBC or a tgTCRP; or(iii) the ccCD3 comprises at least one of fusion proteins: tgCD3(a-Y)-Z, tgCD3(s-8)-£, tgCD3(a- y / 8)-28£, tgCD3(s- y / 8)-BBZ, and tgCD3(£-y / 8)-(28-BB)Z, wherein the fusion protein comprising full or partial length of ectodomains of CD3a, CD38 and / or CD3y protein, further comprises a cytoplasmic domain comprising a full or partial length endodomain of CDZ protein, and optionally one or both of a CD28 signaling domain and a 41BB signaling domain.

8. The cell or population thereof of claim 2, wherein the nb-rTCR-CD3 comprising fusionprotein tgCD3(s-8)-TRAC further comprises tgTRBC or tgTCRP; or wherein the nb-rTCR-CD3 comprising fusion protein tgCD3(s-y)-TRBC further comprises tgTRAC or tgTCRa.

9. The cell or population thereof of claim 7, wherein(i) the cell comprises one of the recombinant TCRs: nb-rTCR, or the p-rTCR, wherein the recombinant TCR complexes with endogenous CD3 subunits, thereby enabling cell surface presentation of endogenous CD3 subunits and signaling thereof; or2020271523   29 Jun 2026(ii) the cell comprises a nb-rTCR-CD3 or a ccCD3, thereby enabling cell surface presentation of exogenous CD3 subunits and signaling thereof.

10. The cell or population thereof of claim 1, wherein the cell further comprises one or more of:(i)    HLA-I deficiency;(ii)    HLA-II deficiency;(iii)   introduced expression of HLA-G or non-cleavable HLA-G;(iv)   an exogenous CD16 or a variant thereof;(v) a chimeric antigen receptor (CAR),(vi) a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof;(vii) deletion or reduced expression in at least one of B2M, CD38, TAP1, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, RFXAP, RAG1, and any gene in the chromosome 6p21 region; and(viii) introduced or increased expression in at least one of HLA-E, 41BBL, CD4, CD8, CD16, CD47, CD113, CD131, CD137, CD80, PDL1, A2AR, CAR, Fc receptor, an engager, and surface triggering receptor for coupling with bi- or multi- specific or universal engagers.

11. The cell or population thereof of claim 10, wherein the cell further comprises an exogenous CD16 or a variant thereof.

12. The cell or population thereof of claim 11, wherein the exogenous CD16 or a variant thereof comprises at least one of:(a)    F176V and S197P in ectodomain domain of CD16;(b) a full or partial ectodomain originated from CD64;(c)    a non-native (or non-CD16) transmembrane domain;(d)    a non-native (or non-CD16) intracellular domain;(e)    a non-native (or non-CD16) signaling domain;(f)    a non-native stimulatory domain; and(g) transmembrane, signaling, and stimulatory domains that are not originated from CD16, and are originated from a same or different polypeptide.

13. The cell or population thereof of claim 10, wherein the cell further comprises a chimeric antigen receptor (CAR), and wherein the CAR is:(i) T cell specific or NK cell specific;2020271523   29 Jun 2026(ii)    bi-specific antigen binding CAR;(iii)   a switchable CAR;(iv)   a dimerized CAR;(v)    a split CAR;(vi)   a multi-chain CAR;(vii)   an inducible CAR;(viii)  co-expressed with another CAR;(ix)    co-expressed with a partial or full length peptide of a cell surface expressedexogenous cytokine or a receptor thereof, optionally in separate constructs or in a bi-cistronic construct;(xi)    co-expressed with a checkpoint inhibitor, optionally in separate constructs or in abi-cistronic construct;(xii) specific to CD19 or BCMA; and / or(xiii) specific to any one of ADGRE2, carbonic anhydrase IX (CAIX), CCR1, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CDS, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell, epithelial glycoprotein2 (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine-protein kinases erb- B2,3,4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Growth Factor Receptor 2 (HER2), human telomerase reverse transcriptase (hTERT), ICAM-1, Integrin B7, Interleukin-13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9), Lewis Y (LeY), L1 cell adhesion molecule (L1-CAM), LILRB2, melanoma antigen family A 1 (MAGE-A1), MICA / B, Mucin 1 (Muc-1), Mucin 16 (Muc-16), Mesothelin (MSLN), NKCSI, NKG2D ligands, c-Met, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), PRAME, prostate stem cell antigen (PSCA), PRAME prostate-specific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), TIM-3, TRBC1, TRBC2, vascular endothelial growth factor R2 (VEGF- R2), Wilms tumor protein (WT-1), and a pathogen antigen;wherein the CAR of any one of (i) to (xiii) is optionally inserted at TRAC locus, and / or is driven by an endogenous promoter of TCR, and / or the TCR is knocked out by the CAR insertion.14 The cell or population thereof of claim 10, wherein the cell comprising a partial or full length peptide of a cell surface expressed exogenous cytokine or a receptor thereof, the exogenous cytokine or a receptor thereof2020271523   29 Jun 2026(a) comprises at least one of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and its respective receptor; or(b) comprises at least one of:(i)    co-expression of IL15 and IL15Ra by using a self-cleaving peptide;(ii) a fusion protein of IL15 and IL15Ra;(iii) an IL15 / IL15Ra fusion protein with intracellular domain of IL15Ra truncated;(iv)   a fusion protein of IL15 and membrane bound Sushi domain of IL15Ra;(v)    a fusion protein of IL15 and IL15RP;(vi)   a fusion protein of IL15 and common receptor yC, wherein the commonreceptor yC is native or modified; and(vii) a homodimer of IL15RP;wherein any one of (i)-(vii) can be co-expressed with a CAR in separate constructs or in a bi-cistronic construct;and optionally,(c) is transiently expressed.

15. The cell or population thereof of claim 1, wherein the derivative cell comprises a derivative CD34 cell, a derivative hematopoietic stem and progenitor cell, a derivative hematopoietic multipotent progenitor cell, a derivative T cell progenitor, a derivative NK cell progenitor, a derivative T cell, a derivative NKT cell, a derivative NK cell, or a derivative B cell.

16. The cell or population thereof of claim 1, wherein the cell comprises:(i)    one or more exogenous polynucleotides integrated in one safe harbor locus; or(ii)    more than two exogenous polynucleotides integrated in different safe harbor loci;or(iii) a polynucleotide encoding an IL15A comprising an amino acid sequence of at least 75%, 80%, 85%, 90%, 95% or 99% identity to SEQ ID NOs: 17, 19 or 21.

17. A clonal master cell bank comprising the clonal iPSC cell line cells as recited in any one of claims 1-16.

18. A composition comprising the cell or population thereof of any one of claims 1-16.

19. A composition for therapeutic use comprising the derivative cell of any one of claims 116, and one or more therapeutic agents.

Images